<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="systematic-review">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">J Health Econ Outcomes Res</journal-id><journal-id journal-id-type="iso-abbrev">J Health Econ Outcomes Res</journal-id><journal-id journal-id-type="publisher-id">1694</journal-id><journal-title-group><journal-title>Journal of Health Economics and Outcomes Research</journal-title></journal-title-group><issn pub-type="ppub">2326-697X</issn><issn pub-type="epub">2327-2236</issn><publisher><publisher-name>Columbia Data Analytics, LLC</publisher-name></publisher><self-uri xlink:href="https://jheor.org/">Website: Journal of Health Economics and Outcomes Research</self-uri></journal-meta>
<article-meta><article-id pub-id-type="pmid">38500521</article-id><article-id pub-id-type="pmc">10948140</article-id>
<article-id pub-id-type="publisher-id">91396</article-id><article-id pub-id-type="doi">10.36469/001c.91396</article-id><article-categories><subj-group subj-group-type="heading"><subject>General Indications</subject></subj-group></article-categories><title-group><article-title>Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Paoli</surname><given-names>Carly J.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing &#x2013; review &amp; editing</role><xref rid="author-note-1" ref-type="corresp"/><xref rid="author-aff-1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Linder</surname><given-names>J&#xF6;rg</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing &#x2013; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><xref rid="author-aff-2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gurjar</surname><given-names>Khushboo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing &#x2013; review &amp; editing</role><xref rid="author-aff-3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Thakur</surname><given-names>Deepika</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing &#x2013; review &amp; editing</role><xref rid="author-aff-3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wyckmans</surname><given-names>Julie</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing &#x2013; review &amp; editing</role><xref rid="author-aff-4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Grieve</surname><given-names>Stacy</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing &#x2013; review &amp; editing</role><xref rid="author-aff-3" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="author-aff-1">
<label>1</label>
<institution-wrap><institution content-type="edu">Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Titusville, New Jersey, USA</institution></institution-wrap>
</aff><aff id="author-aff-2">
<label>2</label>
<institution-wrap><institution content-type="edu">Janssen-Cliag of Johnson &amp; Johnson, Neuss, Germany</institution></institution-wrap>
</aff><aff id="author-aff-3">
<label>3</label>
<institution-wrap><institution content-type="edu">Cytel Inc., Waltham, Massachusetts, USA</institution></institution-wrap>
</aff><aff id="author-aff-4">
<label>4</label>
<institution-wrap><institution content-type="edu">Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Basel, Switzerland</institution></institution-wrap>
</aff><author-notes><corresp id="author-note-1"><bold>Corresponding author:</bold><bold>Email:</bold> CWorden@its.jnj.com</corresp></author-notes><pub-date publication-format="electronic" date-type="pub" iso-8601-date="2024-01-23"><day>23</day><month>1</month><year>2024</year></pub-date><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-01-02"><year>2024</year></pub-date><volume>11</volume><issue seq="1">1</issue><issue-title>Vol. 11, Issue 1, 2024</issue-title><fpage>8</fpage><lpage>22</lpage><history><date date-type="received" iso-8601-date="2023-12-06"><day>6</day><month>12</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-12-19"><day>19</day><month>12</month><year>2023</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>
This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (4.0)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
</license-p></license></permissions><self-uri content-type="pdf" xlink:href="https://jheor.org/article/91396.pdf"/><self-uri content-type="xml" xlink:href="https://jheor.org/article/91396.xml"/><self-uri content-type="json" xlink:href="https://jheor.org/article/91396.json"/><self-uri content-type="html" xlink:href="https://jheor.org/article/91396"/><abstract><p><bold>Background:</bold> Single-tablet combination therapies (STCTs) combine multiple drugs into one formulation, making drug administration more convenient for patients. STCTs were developed to address concerns with treatment adherence and persistence, but the impact of STCT use is not fully understood across indications.</p><p><bold>Objectives:</bold> We conducted a systematic literature review (SLR) to examine STCT-associated outcomes across 4 evidence domains: clinical trials, real-world evidence (RWE), health-related quality of life (HRQoL) studies, and economic evaluations.</p><p><bold>Methods:</bold> Four SLRs were conducted across the aforementioned domains. Included studies compared STCTs as well as fixed-dose combinations ([FDCs] of non-tablet formulations) with the equivalent active compounds and doses in loose-dose combinations (LDCs). Original research articles were included; case reports, case series, and non-English-language sources were excluded. Databases searched included EconLit, Embase, and Ovid MEDLINE&#xAE; ALL. Two independent reviewers assessed relevant studies and extracted data. Conflicts were resolved with a third reviewer or consensus-based discussion.</p><p><bold>Results:</bold> In all, 109 studies were identified; 27 studies were identified in more than one SLR. Treatment adherence was significantly higher in patients receiving FDCs vs LDCs in 12 of 13 RWE studies and 3 of 13 clinical trials. All 18 RWE studies reported higher persistence with FDCs. In RWE studies examining clinical outcomes (n&#x2009;=&#x2009;17), 14 reported positive findings with FDCs, including a reduced need for add-on medication, blood pressure control, and improved hemoglobin A1C. HRQoL studies generally reported numerical improvements with STCTs or similarities between STCTs and LDCs. Economic outcomes favored STCT use. All 6 cost-effectiveness or cost-utility analyses found FDCs were less expensive and more efficacious than LDCs. Four budget impact models found that STCTs were associated with cost savings. Medical costs and healthcare resource use were generally lower with FDCs than with LDCs.</p><p><bold>Discussion:</bold> Evidence from RWE and economic studies strongly favored STCT use, while clinical trials and HRQoL studies primarily reported similarity between STCTs and LDCs. This may be due to clinical trial procedures aimed at maximizing adherence and HRQoL measures that are not designed to evaluate drug administration.</p><p><bold>Conclusions:</bold> Our findings highlight the value of STCTs for improving patient adherence, persistence, and clinical outcomes while also offering economic advantages.</p></abstract><kwd-group><kwd>single-tablet combination therapy</kwd><kwd>fixed-dose combination</kwd><kwd>loose-dose combination</kwd><kwd>cost-effectiveness</kwd><kwd>real-world outcomes</kwd></kwd-group><funding-group><funding-statement>This study and its reporting were funded by Janssen Pharmaceuticals.</funding-statement></funding-group></article-meta></front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Chronic diseases result in high healthcare resource utilization (HCRU) and substantial costs for healthcare systems. Patients with chronic diseases frequently have low treatment adherence and persistence rates, which can result in poor clinical outcomes and contribute to higher HCRU and costs.<xref rid="ref-274971" ref-type="bibr"><sup>1&#x2013;6</sup></xref> Poor adherence can be driven by various factors, including a lack of health literacy, comorbidities and polypharmacy, inadequate access to medical care, and the high cost of treatments.<xref rid="ref-274977" ref-type="bibr"><sup>7</sup></xref> Mechanisms to improve patient adherence and persistence are increasingly sought after to advance the efficiency of healthcare systems and produce better health outcomes for patients,<xref rid="ref-274977" ref-type="bibr"><sup>7&#x2013;9</sup></xref> particularly patients with chronic diseases where combination therapy is recommended by clinical guidelines.<xref rid="ref-274980" ref-type="bibr"><sup>10&#x2013;12</sup></xref> Single-tablet combination therapies (STCT) that combine multiple drugs into one formulation may address some of the reasons for poor adherence by reducing the pill burden for patients with chronic diseases. Previous work has shown that across multiple indications, STCTs can encourage treatment adherence<xref rid="ref-274983" ref-type="bibr"><sup>13</sup></xref> and persistence,<xref rid="ref-274984" ref-type="bibr"><sup>14,15</sup></xref> and provide economic evidence supporting the use of STCTs for reducing costs and HCRU.<xref rid="ref-274986" ref-type="bibr"><sup>16,17</sup></xref></p>
      <p>The number of STCTs that have received regulatory approval in the United States (US) and Europe has increased in recent years. In the US, STCT approvals rose from 12 approvals in the 1980s to 59 approvals in the 2000s,<xref rid="ref-274988" ref-type="bibr"><sup>18</sup></xref> while in Europe, 7 STCTs were approved in 2016, compared with just 1 in 2010.<xref rid="ref-274989" ref-type="bibr"><sup>19</sup></xref> STCTs are now available for hypertension, HIV, asthma, diabetes, and other chronic diseases. The evaluation of STCT use is relevant to multiple stakeholders, including patients, clinicians, caregivers, and payers. To accurately assess the value provided by STCTs, a comprehensive picture of their impact is needed across indications, countries, and types of evidence. The goal of this systematic literature review (SLR) was to characterize the effects of STCTs and loose-dose combination products (LDC) on treatment adherence, compliance, persistence, clinical outcomes, economic outcomes, and health-related quality of life (HRQoL) across 4 evidence domains: clinical trials, real-world evidence (RWE), HRQoL studies, and economic evaluations.</p>
    </sec>
    <sec>
      <title>METHODS</title>
      <p>Four SLRs were conducted with unique search strategies to identify the most relevant records under the aforementioned research domains (<bold>Supplemental Table 1</bold>). Database and registry records published between January 2001 and December 2021 that compared fixed-dose combinations and LDCs were searched according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<xref rid="ref-274990" ref-type="bibr"><sup>20</sup></xref> Only comparisons of fixed-dose combinations and LDCs with the same active compounds and doses were considered. The databases searched included Cochrane, American College of Physicians Journal Club, National Health Service Economic Evaluation Database, EconLit, Embase, and Ovid MEDLINE&#xAE; ALL. Case reports, case series, and non-English language records were excluded according to the population, intervention, comparator, outcomes and study design criteria (<bold>Supplemental Table 2</bold>). Two independent reviewers identified relevant studies at the title and abstract level, assessed the full text of included studies, and extracted relevant study data. A third reviewer or consensus-based discussion was used to resolve any conflicts that arose during the screening and data extraction process. Data were extracted to Microsoft Excel&#xAE; [v.2301]. Figures and tables were created using Microsoft Excel&#xAE; [v.2301] and PowerPoint<sup>&#xAE;</sup> [v.2301].</p>
      <p>Real-world and clinical trial evidence are associated with different limitations and advantages for assessing treatment adherence and its effect on clinical outcomes. Clinical trials occur in a controlled setting with protocols to ensure that a direct comparison can be made between study arms. Patient behavior is closely monitored to ensure that patients take medication as prescribed, resulting in higher adherence than would be observed outside of the clinical trial environment. Additionally, patient populations in clinical trials are often more homogenous than in real-world settings.<xref rid="ref-274991" ref-type="bibr"><sup>21</sup></xref> In contrast, RWE is based on real-world data, often collected as part of routine healthcare administration and billing. Patients are not randomized and may be assigned to treatments based on physician bias, patient request, or insurance coverage.<xref rid="ref-274992" ref-type="bibr"><sup>22</sup></xref> Patient behaviors are typically captured more accurately by RWE. We chose to seek out both clinical trial data and RWE, since information from these sources is often complementary to one another.</p>
      <p>The SLRs of RWE and clinical trial data identified treatment adherence, compliance, and persistence outcomes. The terms, while similar, denote different aspects of patient behavior as it relates to clinical recommendations and prescriptions. Adherence is defined as the proportion of prescribed pills taken over a specific interval of time.<xref rid="ref-274993" ref-type="bibr"><sup>23</sup></xref> While the adherence threshold can vary across medications, a patient is generally considered adherent if they align with their prescribed dosing schedule 80% of the time.<xref rid="ref-274994" ref-type="bibr"><sup>24</sup></xref> Commonly used measures of adherence report the proportion of prescribed medication that a patient acquired at the pharmacy; these include the medication possession ratio (MPR) and the proportion of days covered.<xref rid="ref-274995" ref-type="bibr"><sup>25</sup></xref> In contrast to adherence, compliance encompasses a broader definition, referring to the extent to which patients align their medication usage with the recommended dosage, timing, and frequency provided by healthcare professionals in their day-to-day clinical management.<xref rid="ref-274996" ref-type="bibr"><sup>26</sup></xref> Treatment persistence refers to the act of continuing to take clinically recommended medication.<xref rid="ref-274996" ref-type="bibr"><sup>26</sup></xref> In the literature, some research studies use the terms <italic toggle="yes">treatment adherence</italic> and <italic toggle="yes">treatment compliance</italic> interchangeably. No subjective decisions were made to recategorize the data in identified studies; instead, the measures were reported as they were originally described. The number of studies as reported in the results are not mutually exclusive as some studies report multiple outcomes.</p>
      <p>When possible, comparable studies that reported the same outcome measures were placed in context with one another for data visualization and reporting, but no data transformations or meta-analyses were conducted. Outcome measures were included when the same metrics were reported across fixed-dose combination and LDC versions of equivalent formulations and doses, either from clinical trials, cohort studies, retrospective database studies, or switching studies, in which patients on LDCs with baseline measurements were switched to treatment with equivalent fixed-dose combinations. Statistically significant and numerical findings were reported as described in each study; no post-hoc statistical tests were performed.</p>
    </sec>
    <sec>
      <title>RESULTS</title>
      <p>After accounting for duplicate records, 109 original studies were included in our findings (<bold><xref rid="attachment-192286" ref-type="fig">Figure 1</xref></bold>).<xref rid="ref-274997" ref-type="bibr"><sup>27&#x2013;134</sup></xref> Twenty-seven of these studies were identified in more than 1 SLR.<xref rid="ref-275003" ref-type="bibr"><sup>33,34,37,40,42,44,47,48,51&#x2013;53,55,65&#x2013;68,75,87,98,100,106&#x2013;108,116,119,128,133</sup></xref> A list of the identified studies by SLR, along with study type and the indications included, is presented in <bold>Supplemental Table 3</bold>. North American, European, and Asian countries were well represented in studies relating to clinical evidence, HRQoL, and economic outcomes, while RWE was reported only from some North American and European countries.</p>
      <fig position="float" id="attachment-192286">
        <object-id pub-id-type="publisher-id">192286</object-id>
        <label>Figure 1.</label>
        <caption>
          <title>Preferred Reporting Items for Systematic Reviews and Meta-Analyses Diagrams</title>
          <p>Our findings included evidence relating to treatment adherence, treatment persistence, and clinical outcomes in RWE (<bold>A</bold>, n = 40) and clinical trials (<bold>B</bold>, n =48), along with HRQoL (<bold>C</bold>, n = 23) and economic outcomes (<bold>D</bold>, n = 25).</p>
          <p>Abbreviations: BIA, budget impact analysis; CEA, cost-effectiveness analysis; CMA, cost-minimization analysis; CUA, cost-utility analysis; HRQoL, health-related quality of life; HCRU, healthcare resource utilization.</p>
        </caption>
        <graphic xlink:href="jheor_2024_11_1_91396_192286" position="float"/>
      </fig>
      <p>STCTs were the most common fixed-dose formulation (n = 72), followed by inhaled suspensions (n = 18), eye-drop solutions (n = 16), and injected solution and nasal spray (n = 1 each).</p>
      <sec>
        <title>Treatment Adherence, Compliance, Persistence, and Clinical Outcomes in RWE</title>
        <p>Forty RWE studies (n = 34 retrospective observational<xref rid="ref-275001" ref-type="bibr"><sup>31,33,36,38,40,42,47,54&#x2013;56,58,59,74,76,85&#x2013;88,94,96,97,99,100,110&#x2013;115,121,122,126,127,129</sup></xref> and n = 6 prospective observational)<xref rid="ref-275019" ref-type="bibr"><sup>49,63,65,71,103,104</sup></xref> reported information on adherence rates, persistence rates, compliance, or clinical outcomes. The included clinical indications were frequently those treated with multiple drugs, and/ or with common comorbidities that added to the pill burden, such as cardiovascular disease (n = 23, including 19 hypertension),<xref rid="ref-275010" ref-type="bibr"><sup>40,42,49,54,59,63,71,74,76,86&#x2013;88,94,96,97,99,100,110&#x2013;115</sup></xref> type 2 diabetes mellitus (n = 10),<xref rid="ref-275001" ref-type="bibr"><sup>31,36,38,47,55,58,103,104,126,127</sup></xref> HIV (n = 3),<xref rid="ref-275003" ref-type="bibr"><sup>33,85,129</sup></xref> asthma (n = 2),<xref rid="ref-275091" ref-type="bibr"><sup>121,122</sup></xref> and 1 study each for chronic obstructive pulmonary disease (COPD)<xref rid="ref-275035" ref-type="bibr"><sup>65</sup></xref> and Parkinson&#x2019;s disease.<xref rid="ref-275026" ref-type="bibr"><sup>56</sup></xref></p>
        <p>Thirteen studies reported treatment adherence in patients taking STCTs vs LDCs, using MPR (n = 11), proportion of days covered (n = 7), or mean adherence (n = 3). In 12 of those studies, treatment adherence was significantly higher in patients who received fixed-dose combinations compared with LDCs<xref rid="ref-275006" ref-type="bibr"><sup>36,40,42,55,56,76,85&#x2013;87,96,97,122</sup></xref>; in the remaining study, patients taking STCTs had a numerically higher adherence.<xref rid="ref-275019" ref-type="bibr"><sup>49</sup></xref> An additional 8 studies described treatment adherence in patients who switched from LDCs or monotherapy to fixed-dose combinations,<xref rid="ref-275001" ref-type="bibr"><sup>31,38,47,54,58,71,126,127</sup></xref> with reported follow-up times ranging from 3 months<xref rid="ref-275033" ref-type="bibr"><sup>63</sup></xref> to 36 months.<xref rid="ref-275008" ref-type="bibr"><sup>38</sup></xref> Patients who switched to STCTs had higher treatment adherence in all studies except for one, in which patients switched from sulfonylureas (including glyburide) plus metformin to glyburide/ metformin for type 2 diabetes.<xref rid="ref-275028" ref-type="bibr"><sup>58</sup></xref> Even in this study, the STCT had better clinical outcomes (improvement of glycemic control, A1C reduction of 0.6% (<italic toggle="yes">p</italic> = .002), and the difference in adherence was not statistically significant (92.4% vs 90.9% after the switch to STCT). Of the studies that reported improved adherence with STCTs, 8 were of patients with hypertension<xref rid="ref-275010" ref-type="bibr"><sup>40,42,49,54,86,87,96,97</sup></xref> and 6 were of patients with type 2 diabetes mellitus.<xref rid="ref-275001" ref-type="bibr"><sup>31,36,38,47,55,126</sup></xref></p>
        <p>Four studies reported treatment compliance with STCTs or fixed-dose inhalers compared with LDCs.<xref rid="ref-275035" ref-type="bibr"><sup>65,103,104,110</sup></xref> Treatment compliance was significantly lower in patients taking LDCs in 2 of the 4 studies.<xref rid="ref-275073" ref-type="bibr"><sup>103,104</sup></xref> In the remaining 2 studies, compliance was numerically high with both fixed-dose combinations and LDCs (70.0%-80.0%),<xref rid="ref-275080" ref-type="bibr"><sup>110</sup></xref> and similar in 1 study using a fixed-dose inhaler (compliance defined as residual doses in the inhalation device returned by the patient 97.1% in the fixed dose inhaler group vs 98.4% in the 2-inhaler group).<xref rid="ref-275035" ref-type="bibr"><sup>65</sup></xref></p>
        <p>Of the 18 studies that examined treatment persistence, all studies reported higher persistence in patients taking STCTs or fixed-dose inhalers compared with LDCs. Among these 18 studies, 16 reported significantly higher persistence in patients taking STCTs or fixed-dose inhalers compared with LDCs in 1 or more treatment arms<xref rid="ref-275010" ref-type="bibr"><sup>40,42,56,59,74,87,96,97,100,110,112&#x2013;115,121,122</sup></xref>; while the remaining 2 studies did not report statistical significance, only a numerically higher treatment persistence with STCTs.<xref rid="ref-275058" ref-type="bibr"><sup>88,111</sup></xref> Thirteen studies reported mean 1-year persistence in STCTs vs LDCs (<bold><xref rid="attachment-192287" ref-type="table">Table 1</xref></bold>)<xref rid="ref-275010" ref-type="bibr"><sup>40,42,59,74,87,88,96,110&#x2013;115</sup></xref>; of these, 9 studies reported &#x2265;20% higher persistence in patients taking STCT.<xref rid="ref-275012" ref-type="bibr"><sup>42,59,74,87,96,111&#x2013;113,115</sup></xref> When summarized across studies, mean 1-year persistence was 51.9% for STCTs and 31.5% for LDCs. In a large retrospective study that included 81&#x202F;958 patients with hypertension, treatment persistence ranged from 16% to 42% greater in patients on STCTs compared with LDCs.<xref rid="ref-275010" ref-type="bibr"><sup>40</sup></xref></p>
        <table-wrap position="float" id="attachment-192287">
          <object-id pub-id-type="publisher-id">192287</object-id>
          <label>Table 1.</label>
          <caption>
            <title>Summary of RWE Findings for Persistence, Compliance, and Adherence, Where Comparable</title>
          </caption>
          <table frame="hsides" rules="groups">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<bold>Source</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Indication</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Population</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Intervention</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>STCT</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>LDC</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>&#x394;STCT&#x2013;&#x2060;LDC</bold>
</td>
              </tr>
              <tr>
                <td colspan="7" rowspan="1">
<bold>Mean 1-year persistence (%)</bold>
</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">Bramlage et al, 2018<xref rid="ref-275010" ref-type="bibr"><sup>40</sup></xref></td>
                <td rowspan="2" colspan="1">HTN</td>
                <td rowspan="2" colspan="1">Patients with HTN</td>
                <td rowspan="1" colspan="1">Ramipril/amlodipine</td>
                <td rowspan="1" colspan="1">65.7</td>
                <td rowspan="1" colspan="1">48.6</td>
                <td rowspan="1" colspan="1">17.10</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Candesartan/amlodipine</td>
                <td rowspan="1" colspan="1">55.5</td>
                <td rowspan="1" colspan="1">43.1</td>
                <td rowspan="1" colspan="1">12.40</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Brixner et al, 2008<xref rid="ref-275012" ref-type="bibr"><sup>42</sup></xref></td>
                <td rowspan="1" colspan="1">HTN</td>
                <td rowspan="1" colspan="1">Adults with HTN</td>
                <td rowspan="1" colspan="1">Valsartan/<break/>hydrochlorothiazide</td>
                <td rowspan="1" colspan="1">44.0</td>
                <td rowspan="1" colspan="1">16.0</td>
                <td rowspan="1" colspan="1">28.00</td>
              </tr>
              <tr>
                <td rowspan="4" colspan="1">Ehlken et al, 2011<xref rid="ref-275029" ref-type="bibr"><sup>59</sup></xref></td>
                <td rowspan="4" colspan="1">HTN</td>
                <td rowspan="4" colspan="1">Patients with HTN</td>
                <td rowspan="1" colspan="1">Olmesartan/<break/>hydrochlorothiazide</td>
                <td rowspan="1" colspan="1">44.6</td>
                <td rowspan="1" colspan="1">25.0</td>
                <td rowspan="1" colspan="1">19.60</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Olmesartan/amlodipine</td>
                <td rowspan="1" colspan="1">47.3</td>
                <td rowspan="1" colspan="1">27.4</td>
                <td rowspan="1" colspan="1">19.90</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Valsartan/<break/>hydrochlorothiazide</td>
                <td rowspan="1" colspan="1">39.6</td>
                <td rowspan="1" colspan="1">13.7</td>
                <td rowspan="1" colspan="1">25.90</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Valsartan/amlodipine</td>
                <td rowspan="1" colspan="1">44.6</td>
                <td rowspan="1" colspan="1">25.2</td>
                <td rowspan="1" colspan="1">19.40</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Jackson et al, 2006<xref rid="ref-275044" ref-type="bibr"><sup>74</sup></xref></td>
                <td rowspan="1" colspan="1">HTN</td>
                <td rowspan="1" colspan="1">Adults with HTN</td>
                <td rowspan="1" colspan="1">Valsartan/<break/>hydrochlorothiazide</td>
                <td rowspan="1" colspan="1">44.0</td>
                <td rowspan="1" colspan="1">16.0</td>
                <td rowspan="1" colspan="1">28.00</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Machnicki et al, 2015<xref rid="ref-275057" ref-type="bibr"><sup>87</sup></xref></td>
                <td rowspan="1" colspan="1">HTN</td>
                <td rowspan="1" colspan="1">Adults with HTN</td>
                <td rowspan="1" colspan="1">Amlodipine/valsartan/<break/>hydrochlorothiazide</td>
                <td rowspan="1" colspan="1">46.8</td>
                <td rowspan="1" colspan="1">23.6</td>
                <td rowspan="1" colspan="1">23.20</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Maggioni et al, 2019<xref rid="ref-275058" ref-type="bibr"><sup>88</sup></xref></td>
                <td rowspan="1" colspan="1">ACS</td>
                <td rowspan="1" colspan="1">Patients with ACS</td>
                <td rowspan="1" colspan="1">Aspirin/clopidogrel</td>
                <td rowspan="1" colspan="1">81.5</td>
                <td rowspan="1" colspan="1">72.9</td>
                <td rowspan="1" colspan="1">8.60</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ong et al, 2014<xref rid="ref-275066" ref-type="bibr"><sup>96</sup></xref></td>
                <td rowspan="1" colspan="1">HTN</td>
                <td rowspan="1" colspan="1">Patients with HTN</td>
                <td rowspan="1" colspan="1">Amlodipine/valsartan/<break/>hydrochlorothiazide<break/>(Exforge) HCT)</td>
                <td rowspan="1" colspan="1">47.2</td>
                <td rowspan="1" colspan="1">23.6</td>
                <td rowspan="1" colspan="1">23.60</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">Sandberg et al, 2011<xref rid="ref-275080" ref-type="bibr"><sup>110</sup></xref></td>
                <td rowspan="2" colspan="1">HTN</td>
                <td rowspan="2" colspan="1">Patients with HTN</td>
                <td rowspan="1" colspan="1">Olmesartan/<break/>hydrochlorothiazide</td>
                <td rowspan="1" colspan="1">44.6</td>
                <td rowspan="1" colspan="1">25.0</td>
                <td rowspan="1" colspan="1">-19.6</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Olmesartan/amlodipine</td>
                <td rowspan="1" colspan="1">47.3</td>
                <td rowspan="1" colspan="1">27.4</td>
                <td rowspan="1" colspan="1">19.9</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Simons et al, 2011<xref rid="ref-275082" ref-type="bibr"><sup>112</sup></xref></td>
                <td rowspan="1" colspan="1">HTN</td>
                <td rowspan="1" colspan="1">Patients with HTN</td>
                <td rowspan="1" colspan="1">Amlodipine/atorvastatin</td>
                <td rowspan="1" colspan="1">67.0</td>
                <td rowspan="1" colspan="1">41.0</td>
                <td rowspan="1" colspan="1">26.00</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Simons et al, 2017<xref rid="ref-275081" ref-type="bibr"><sup>111</sup></xref></td>
                <td rowspan="1" colspan="1">HTN</td>
                <td rowspan="1" colspan="1">Patients with HTN</td>
                <td rowspan="1" colspan="1">Amlodipine/atorvastatin</td>
                <td rowspan="1" colspan="1">66.0</td>
                <td rowspan="1" colspan="1">43.0</td>
                <td rowspan="1" colspan="1">23.00</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Simonyi et al, 2015<xref rid="ref-275083" ref-type="bibr"><sup>113</sup></xref></td>
                <td rowspan="1" colspan="1">HTN</td>
                <td rowspan="1" colspan="1">Patients with HTN</td>
                <td rowspan="1" colspan="1">Ramipril/amlodipine</td>
                <td rowspan="1" colspan="1">54.0</td>
                <td rowspan="1" colspan="1">34.0</td>
                <td rowspan="1" colspan="1">20.00</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Simonyi et al, 2016<xref rid="ref-275084" ref-type="bibr"><sup>114</sup></xref></td>
                <td rowspan="1" colspan="1">HTN</td>
                <td rowspan="1" colspan="1">Patients with HTN</td>
                <td rowspan="1" colspan="1">Perindopril/amlodipine</td>
                <td rowspan="1" colspan="1">40.0</td>
                <td rowspan="1" colspan="1">27.0</td>
                <td rowspan="1" colspan="1">13.00</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Simonyi et al, 2017<xref rid="ref-275085" ref-type="bibr"><sup>115</sup></xref></td>
                <td rowspan="1" colspan="1">HTN</td>
                <td rowspan="1" colspan="1">Patients with HTN</td>
                <td rowspan="1" colspan="1">Ramipril/amlodipine</td>
                <td rowspan="1" colspan="1">54.0</td>
                <td rowspan="1" colspan="1">34.0</td>
                <td rowspan="1" colspan="1">20.00</td>
              </tr>
              <tr>
                <td colspan="7" rowspan="1">
<bold>Mean compliance (%)</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Hagedorn et al, 2013<xref rid="ref-275035" ref-type="bibr"><sup>65</sup></xref></td>
                <td rowspan="1" colspan="1">COPD</td>
                <td rowspan="1" colspan="1">Adults&#xA0;with&#xA0;stage&#xA0;3&#xA0;or&#xA0;4<break/>COPD</td>
                <td rowspan="1" colspan="1">Fluticasone/salmeterol</td>
                <td rowspan="1" colspan="1">97.1</td>
                <td rowspan="1" colspan="1">98.4</td>
                <td rowspan="1" colspan="1">-1.30<sup>a</sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Rombopoulos et al, 2012<xref rid="ref-275074" ref-type="bibr"><sup>104</sup></xref></td>
                <td rowspan="1" colspan="1">T2DM</td>
                <td rowspan="1" colspan="1">Adults with T2DM</td>
                <td rowspan="1" colspan="1">Vildagliptin/metformin</td>
                <td rowspan="1" colspan="1">68.0</td>
                <td rowspan="1" colspan="1">56.0</td>
                <td rowspan="1" colspan="1">12.00</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Rombopoulos et al, 2015<xref rid="ref-275073" ref-type="bibr"><sup>103</sup></xref></td>
                <td rowspan="1" colspan="1">T2DM</td>
                <td rowspan="1" colspan="1">Adults with T2DM</td>
                <td rowspan="1" colspan="1">Vildagliptin/metformin</td>
                <td rowspan="1" colspan="1">98.9</td>
                <td rowspan="1" colspan="1">84.6</td>
                <td rowspan="1" colspan="1">14.30</td>
              </tr>
              <tr>
                <td colspan="7" rowspan="1">
<bold>Mean adherence (%)</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Degli et al, 2018<xref rid="ref-275024" ref-type="bibr"><sup>54</sup></xref></td>
                <td rowspan="1" colspan="1">HTN</td>
                <td rowspan="1" colspan="1">Adult with HTN</td>
                <td rowspan="1" colspan="1">Perindopril&#xA0;+&#xA0;amlodipine&#xA0;to<break/>perindopril/amlodipine</td>
                <td rowspan="1" colspan="1">79.8</td>
                <td rowspan="1" colspan="1">70.9</td>
                <td rowspan="1" colspan="1">8.90</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Duckworth, 2003<xref rid="ref-275028" ref-type="bibr"><sup>58</sup></xref></td>
                <td rowspan="1" colspan="1">T2DM</td>
                <td rowspan="1" colspan="1">Adults with T2DM who<break/>had been treated with<break/>glipizide or glyburide<break/>plus metformin 6 mo<break/>prior to switching to<break/>glyburide/ metformin</td>
                <td rowspan="1" colspan="1">Glyburide&#xA0;+&#xA0;metformin&#xA0;or<break/>glipizide + metformin to<break/>glyburide/metformin</td>
                <td rowspan="1" colspan="1">90.9</td>
                <td rowspan="1" colspan="1">92.4</td>
                <td rowspan="1" colspan="1">-1.50<sup>b</sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Legorreta et al, 2005<xref rid="ref-275055" ref-type="bibr"><sup>85</sup></xref></td>
                <td rowspan="1" colspan="1">HIV</td>
                <td rowspan="1" colspan="1">Adults with HIV who<break/>initiated therapy on or<break/>after September 1997</td>
                <td rowspan="1" colspan="1">Lamivudine/zidovudine</td>
                <td rowspan="1" colspan="1">85.0</td>
                <td rowspan="1" colspan="1">75.0</td>
                <td rowspan="1" colspan="1">10.00</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p><sup>a</sup>Statistical significance not measured.</p>
            <p><sup>b</sup>No statistically significant difference.</p>
            <p>Abbreviations: ACS, acute coronary syndrome; COPD, chronic obstructive pulmonary disease; HTN, hypertension; LDC, loose-dose combination; STCT, single-tablet combination therapy; T2DM, type 2 diabetes mellitus.</p>
          </table-wrap-foot>
        </table-wrap>
        <p>Clinical outcomes were reported by 17 studies, across indications of asthma, COPD, hypertension, and type 2 diabetes mellitus (<bold><xref rid="attachment-192288" ref-type="table">Table 2</xref></bold>).<xref rid="ref-275006" ref-type="bibr"><sup>36,40,42,49,58,63,65,71,94,99,100,103,104,111,121,122,126</sup></xref> Positive findings with STCTs or fixed-dose inhalers were reported in all but 3 studies that described similar outcomes with STCTs/fixed-dose inhalers and LDCs.<xref rid="ref-275035" ref-type="bibr"><sup>65,104,121</sup></xref> Of the studies that reported improved clinical outcomes with STCTs, 3 contained caveats that may weaken the finding, such as the likelihood of residual confounders,<xref rid="ref-275006" ref-type="bibr"><sup>36,94,111</sup></xref> and 2 reported improvements in subgroups of adherent or persistent patients only.<xref rid="ref-275012" ref-type="bibr"><sup>42,94</sup></xref> Significantly improved clinical outcomes included hemoglobin A1C (n = 3),<xref rid="ref-275006" ref-type="bibr"><sup>36,58,126</sup></xref> the need for add-on medication (n = 3),<xref rid="ref-275010" ref-type="bibr"><sup>40,42,122</sup></xref> all-cause hospitalization (n = 2),<xref rid="ref-275069" ref-type="bibr"><sup>99,100</sup></xref> blood pressure control (n = 1),<xref rid="ref-275033" ref-type="bibr"><sup>63</sup></xref> and all-cause mortality (n = 1).<xref rid="ref-275069" ref-type="bibr"><sup>99</sup></xref> Six studies reported statistical significance in both clinical outcome improvement and adherence, compliance, or persistence improvement.<xref rid="ref-275010" ref-type="bibr"><sup>40,42,100,103,122,126</sup></xref></p>
        <table-wrap position="float" id="attachment-192288">
          <object-id pub-id-type="publisher-id">192288</object-id>
          <label>Table 2.</label>
          <caption>
            <title>Reported Clinical Outcomes With STCTs</title>
          </caption>
          <table frame="hsides" rules="groups">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<bold>Source</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Intervention</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Clinical&#xA0;Outcome&#xA0;Compared&#xA0;With&#xA0;LDC</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Adherence, Compliance, and/or
Persistence&#xA0;Compared&#xA0;With&#xA0;LDC</bold>
</td>
              </tr>
              <tr>
                <td colspan="4" rowspan="1">
<bold>Asthma studies</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Stempel et al, 2005<xref rid="ref-275091" ref-type="bibr"><sup>121</sup></xref></td>
                <td rowspan="1" colspan="1">Ramipril/amlodipine</td>
                <td rowspan="1" colspan="1">No difference in the need for add-on SABA medication</td>
                <td rowspan="1" colspan="1">Persistence improvement<sup>a</sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Stoloff et al, 2004<xref rid="ref-275092" ref-type="bibr"><sup>122</sup></xref></td>
                <td rowspan="1" colspan="1">Fluticasone/salmeterol</td>
                <td rowspan="1" colspan="1">Reduced need for add-on SABA medication<sup>a</sup>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Adherence improvement<sup>a</sup></p></list-item><list-item><p>Persistence improvement<sup>a</sup></p></list-item></list>
</td>
              </tr>
              <tr>
                <td colspan="4" rowspan="1">
<bold>Cardiovascular disease studies</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ofili et al, 2017<xref rid="ref-275064" ref-type="bibr"><sup>94</sup></xref></td>
                <td rowspan="1" colspan="1">Isosorbide dinitrate/<break/>hydralazine<break/>hydrochloride<sup>c</sup>
</td>
                <td rowspan="1" colspan="1">Among adherent Black American patients, improved 1-year overall survival<sup>a</sup>
</td>
                <td rowspan="1" colspan="1">Worsened adherence</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Predel et al, 2020<xref rid="ref-275070" ref-type="bibr"><sup>100</sup></xref></td>
                <td rowspan="1" colspan="1">Aspirin/ramipril/<break/>atorvastatin</td>
                <td rowspan="1" colspan="1">
<p>Reduced incidence rate ratios for:</p>
<list list-type="bullet"><list-item><p>All-cause hospitalization<sup>a</sup></p></list-item><list-item><p>All-cause mortality</p></list-item><list-item><p>Coronary artery disease</p></list-item><list-item><p>Myocardial infarction</p></list-item><list-item><p>Stroke</p></list-item><list-item><p>Transitory ischemic attack</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">Persistence improvement<sup>a</sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Predel et al, 2021<xref rid="ref-275069" ref-type="bibr"><sup>99</sup></xref></td>
                <td rowspan="1" colspan="1">Ramipril/amlodipine</td>
                <td rowspan="1" colspan="1">
<p>Reduced incidence rate ratios for:</p>
<list list-type="bullet"><list-item><p>All cause hospitalization<sup>a</sup></p></list-item><list-item><p>Cardiovascular hospitalization<sup>a</sup></p></list-item><list-item><p>All-cause mortality<sup>a</sup></p></list-item><list-item><p>Coronary artery disease<sup>a</sup></p></list-item><list-item><p>Heart failure<sup>a</sup></p></list-item><list-item><p>Myocardial infarction<sup>a</sup></p></list-item><list-item><p>Stroke<sup>a</sup></p></list-item><list-item><p>Transitory ischemic attack<sup>a</sup></p></list-item></list>
</td>
                <td rowspan="1" colspan="1">Not measured</td>
              </tr>
              <tr>
                <td colspan="4" rowspan="1">
<bold>COPD</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Hagerdorn et al, 2013<xref rid="ref-275035" ref-type="bibr"><sup>65</sup></xref></td>
                <td rowspan="1" colspan="1">Fluticasone/salmeterol</td>
                <td rowspan="1" colspan="1">
<p>No difference in:</p>
<list list-type="bullet"><list-item><p>FEV<sub>1</sub></p></list-item><list-item><p>IVC</p></list-item><list-item><p>Tiffeneau index</p></list-item><list-item><p>Number of exacerbations</p></list-item><list-item><p>Use of rescue medication</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">No difference in compliance</td>
              </tr>
              <tr>
                <td colspan="4" rowspan="1">
<bold>Hypertension studies</bold>
</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">Bramlage et al, 2018<xref rid="ref-275010" ref-type="bibr"><sup>40</sup></xref></td>
                <td rowspan="1" colspan="1">Ramipril/amlodipine</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Smaller improvement in SBP compared with LDC</p></list-item><list-item><p>No difference in DBP</p></list-item><list-item><p>Reduced need for add-on medication<sup>a</sup></p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Adherence improvement<sup>a</sup></p></list-item><list-item><p>Persistence improvement<sup>a</sup></p></list-item></list>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Candesartan/<break/>amlodipine</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>SBP improvement</p></list-item><list-item><p>DBP improvement</p></list-item><list-item><p>Reduced need for add-on medication<sup>a</sup></p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Adherence improvement<sup>a</sup></p></list-item><list-item><p>Persistence improvement<sup>a</sup></p></list-item></list>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Brixner et al, 2008<xref rid="ref-275012" ref-type="bibr"><sup>42</sup></xref></td>
                <td rowspan="1" colspan="1">Valsartan/<break/>hydrochlorothiazide</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Among persistent patients, those receiving an STCT had a reduced need for add-on medication<sup>a</sup></p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Adherence improvement<sup>a</sup></p></list-item><list-item><p>Persistence improvement<sup>a</sup></p></list-item></list>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Czarnecka et al, 2015<xref rid="ref-275019" ref-type="bibr"><sup>49</sup></xref></td>
                <td rowspan="1" colspan="1">Bisoprolol/amlodipine</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>SBP improvement</p></list-item><list-item><p>DBP improvement</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">Adherence improvement</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Gaciong et al, 2017<xref rid="ref-275033" ref-type="bibr"><sup>63</sup></xref></td>
                <td rowspan="1" colspan="1">Bisoprolol/<break/>acetylsalicylic acid</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>SBP improvement<sup>a</sup></p></list-item><list-item><p>DBP improvement<sup>a</sup></p></list-item><list-item><p>Heart rate improvement<sup>a</sup></p></list-item></list>
</td>
                <td rowspan="1" colspan="1">Not measured</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Hostalek et al, 2015<xref rid="ref-275041" ref-type="bibr"><sup>71</sup></xref></td>
                <td rowspan="1" colspan="1">Bisoprolol/amlodipine</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>SBP improvement</p></list-item><list-item><p>DBP improvement</p></list-item><list-item><p>Heart rate improvement</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">Not measured</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Simons 2017<xref rid="ref-275081" ref-type="bibr"><sup>111</sup></xref></td>
                <td rowspan="1" colspan="1">Amlodipine/<break/>perindopril</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Reduced risk of mortality<sup>a,d</sup></p></list-item></list>
</td>
                <td rowspan="1" colspan="1">Persistence improvement</td>
              </tr>
              <tr>
                <td colspan="4" rowspan="1">
<bold>T2DM studies</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Blonde et al, 2003<xref rid="ref-275006" ref-type="bibr"><sup>36</sup></xref></td>
                <td rowspan="1" colspan="1">Glyburide/metformin</td>
                <td rowspan="1" colspan="1">A1C improvement<sup>a</sup>
</td>
                <td rowspan="1" colspan="1">Adherence improvement<sup>b</sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Duckworth 2003<xref rid="ref-275028" ref-type="bibr"><sup>58</sup></xref></td>
                <td rowspan="1" colspan="1">Glyburide/metformin</td>
                <td rowspan="1" colspan="1">A1C improvement<sup>a</sup>
</td>
                <td rowspan="1" colspan="1">Worsened persistence</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Rombopoulos et al, 2012<xref rid="ref-275074" ref-type="bibr"><sup>104</sup></xref></td>
                <td rowspan="1" colspan="1">Vildagliptin/<break/>metformin</td>
                <td rowspan="1" colspan="1">No difference in A1C</td>
                <td rowspan="1" colspan="1">Compliance improvement<sup>a</sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Rombopoulos et al, 2015<xref rid="ref-275073" ref-type="bibr"><sup>103</sup></xref></td>
                <td rowspan="1" colspan="1">Vildagliptin/<break/>metformin</td>
                <td rowspan="1" colspan="1">A1C improvement</td>
                <td rowspan="1" colspan="1">Compliance improvement<sup>a</sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Thayer et al, 2010<xref rid="ref-275096" ref-type="bibr"><sup>126</sup></xref></td>
                <td rowspan="1" colspan="1">Rosiglitazone/<break/>sulfonylurea</td>
                <td rowspan="1" colspan="1">A1C improvement<sup>a</sup>
</td>
                <td rowspan="1" colspan="1">Adherence improvement<sup>a</sup>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p><sup>a</sup>Statistically significant result.</p>
            <p><sup>b</sup>Linear regression did not find a relationship between adherence and improved A1C.</p>
            <p><sup>c</sup>STCT may not be bioequivalent to its LDC comparator.<xref rid="ref-274984" ref-type="bibr"><sup>14</sup></xref></p>
            <p><sup>d</sup>Study authors attributed result to residual confounders.</p>
            <p>Abbreviations: A1C, hemoglobin A1C; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; FEV<sub>1</sub>, forced expiratory volume in 1 second; IVC, inspiratory vital capacity; LDC, loose-dose combination therapy; SABA, short- acting &#x3B2;-agonist; SBP, systolic blood pressure; STCT, single-tablet combination therapy; T2DM, type 2 diabetes mellitus.</p>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec>
        <title>Treatment Adherence, Compliance, Persistence, and Clinical Outcomes in Clinical Trials</title>
        <p>The SLR for clinical trial evidence identified 48 records from 42 studies across the indications of glaucoma/ocular hypertension (n = 10),<xref rid="ref-275000" ref-type="bibr"><sup>30,35,57,61,66&#x2013;69,81,134</sup></xref> hypertension (n = 6),<xref rid="ref-275011" ref-type="bibr"><sup>41,60,83,92,124,131</sup></xref> asthma (n = 7),<xref rid="ref-275007" ref-type="bibr"><sup>37,72,75,98,106,107,133</sup></xref> tuberculosis (n = 6),<xref rid="ref-274998" ref-type="bibr"><sup>28,32,79,91,123,125,132</sup></xref> HIV (n = 3),<xref rid="ref-275018" ref-type="bibr"><sup>48,108,128</sup></xref> and others. Twenty-six studies did not identify the study phase,<xref rid="ref-274998" ref-type="bibr"><sup>28,29,32,34,44,50,57,60,61,75,80,81,83,92,93,98,106&#x2013;108,123&#x2013;125,128,131&#x2013;133</sup></xref> 14 were Phase 3 studies,<xref rid="ref-274997" ref-type="bibr"><sup>27,30,35,37,39,41,48,51&#x2013;53,66&#x2013;69,72,82,89,116,134</sup></xref> 1 was Phase 2,<xref rid="ref-275015" ref-type="bibr"><sup>45</sup></xref> and 1 was Phase 2/3.<xref rid="ref-275049" ref-type="bibr"><sup>79,91</sup></xref> Clinical trials were geographically diverse, with more studies including participants from Africa and Asia compared with the other study types. Thirteen studies reported adherence outcomes with fixed-dose combinations and LDCs: 9 reported similar outcomes with fixed-dose combinations and LDCs,<xref rid="ref-274998" ref-type="bibr"><sup>28,48,75,80,89,92,98,108,133</sup></xref> 3 reported a statistically significant improvement in adherence with STCTs,<xref rid="ref-275015" ref-type="bibr"><sup>45,83,124</sup></xref> and 1 reported a numerical improvement with fixed-dose eye drops.<xref rid="ref-275000" ref-type="bibr"><sup>30</sup></xref> Among the studies that reported a significant improvement in adherence with STCTs, 2 also reported improvements in blood pressure control.<xref rid="ref-275053" ref-type="bibr"><sup>83,124</sup></xref> All 4 studies that described compliance outcomes reported similar findings with STCTs/fixed-dose inhalers and LDCs.<xref rid="ref-274997" ref-type="bibr"><sup>27,28,37,123</sup></xref></p>
      </sec>
      <sec>
        <title>Health-Related Quality of Life Findings</title>
        <p>HRQoL findings were reported in 23 records of 19 studies,<xref rid="ref-275004" ref-type="bibr"><sup>34,37,44,48,51&#x2013;53,64&#x2013;68,73,75,95,98,106&#x2013;108,116,119,128,133</sup></xref> which included 14 clinical trials<xref rid="ref-275004" ref-type="bibr"><sup>34,37,44,48,51&#x2013;53,66&#x2013;68,75,98,106&#x2013;108,116,128,133</sup></xref> and 5 observational studies<xref rid="ref-275034" ref-type="bibr"><sup>64,65,73,95,119</sup></xref> primarily from North American and European countries. The studies included indications consisting of asthma (n = 7),<xref rid="ref-275007" ref-type="bibr"><sup>37,75,98,106,107,119,133</sup></xref> HIV (n = 3),<xref rid="ref-275018" ref-type="bibr"><sup>48,108,128</sup></xref> COPD (n = 2),<xref rid="ref-275021" ref-type="bibr"><sup>51&#x2013;53,65</sup></xref> and glaucoma (n = 2),<xref rid="ref-275036" ref-type="bibr"><sup>66&#x2013;68,73</sup></xref> among others. The study findings were largely noncomparable due to the heterogeneous methods used to assess HRQoL, which included generic and disease-specific scales, patient-reported outcome measures, and symptom reporting. Findings from the studies were mixed, with 5 of 8 treatment arms in the observational studies reporting a numerical (n = 4)<xref rid="ref-275034" ref-type="bibr"><sup>64,65,73,95</sup></xref> or significant (n = 1)<xref rid="ref-275034" ref-type="bibr"><sup>64</sup></xref> improvement in HRQoL with STCTs, and the remaining 3 treatment arms describing similar outcomes with fixed-dose combinations and LDCs.<xref rid="ref-275035" ref-type="bibr"><sup>65,73,119</sup></xref> Results were similar between fixed-dose combinations and LDCs in the majority (n = 9)<xref rid="ref-275004" ref-type="bibr"><sup>34,44,48,53,68,98,107,128,133</sup></xref> of the interventional HRQoL studies, but numerical improvements with fixed-dose combinations (n = 3)<xref rid="ref-275007" ref-type="bibr"><sup>37,108,116</sup></xref> and LDCs (n = 1)<xref rid="ref-275045" ref-type="bibr"><sup>75</sup></xref> were also reported.</p>
      </sec>
      <sec>
        <title>Economic Outcomes</title>
        <p>Economic outcomes were evaluated in 25 studies from 11 countries in North and South America, Europe, and Asia, and reported on indications of hypertension (n = 10),<xref rid="ref-275010" ref-type="bibr"><sup>40,42,46,62,70,77,78,87,102,120</sup></xref> asthma (n = 4),<xref rid="ref-275013" ref-type="bibr"><sup>43,90,105,119</sup></xref> diabetes (n = 3),<xref rid="ref-275017" ref-type="bibr"><sup>47,55,109</sup></xref> cardiovascular disease (n = 3),<xref rid="ref-275070" ref-type="bibr"><sup>100,117,118</sup></xref> COPD (n = 2),<xref rid="ref-275035" ref-type="bibr"><sup>65,101</sup></xref> glaucoma/ocular hypertension (n = 2),<xref rid="ref-275054" ref-type="bibr"><sup>84,130</sup></xref> and HIV (n = 1).<xref rid="ref-275003" ref-type="bibr"><sup>33</sup></xref> Six cost-effectiveness or cost-utility analyses compared STCT or fixed-dose inhalers with LDCs (n = 6, <bold><xref rid="attachment-192289" ref-type="table">Table 3</xref></bold>),<xref rid="ref-275013" ref-type="bibr"><sup>43,62,77,101,102,120</sup></xref> including 3 branded STCTs<xref rid="ref-275032" ref-type="bibr"><sup>62,77,101</sup></xref> and 1 branded fixed-dose inhaler.<xref rid="ref-275013" ref-type="bibr"><sup>43</sup></xref> All 6 analyses found that fixed-dose combinations were both less expensive and more efficacious than LDCs (in economic terminology, fixed-dose products dominated LDCs). Several budget impact analyses evaluated the use of STCTs and LDCs for patients with cardiovascular diseases, including hypertension and hyperlipidemia (n = 4, <bold><xref rid="attachment-192291" ref-type="table">Table 4</xref></bold>).<xref rid="ref-275032" ref-type="bibr"><sup>62,78,117,118</sup></xref> The scope of the analyses varied, with some studies estimating the cost savings from public payer<xref rid="ref-275032" ref-type="bibr"><sup>62,78</sup></xref> and patient perspectives<xref rid="ref-275048" ref-type="bibr"><sup>78</sup></xref> and others calculating the costs of medication<xref rid="ref-275087" ref-type="bibr"><sup>117</sup></xref> or treatment.<xref rid="ref-275088" ref-type="bibr"><sup>118</sup></xref> In all 4 studies, STCTs were associated with savings compared with LDCs.</p>
        <table-wrap position="float" id="attachment-192289">
          <object-id pub-id-type="publisher-id">192289</object-id>
          <label>Table 3.</label>
          <caption>
            <title>Findings from Cost-Effectiveness Models and Cost-Utility Analyses</title>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th rowspan="1" colspan="1">
<bold>Reference</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Study&#xA0;Design</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Country</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Population</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Intervention&#xA0;(STCT&#xA0;Brand)</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Main Message</bold>
</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Kawalec et al, 2015<xref rid="ref-275047" ref-type="bibr"><sup>77</sup></xref></td>
                <td rowspan="1" colspan="1">CEA + CUA</td>
                <td rowspan="1" colspan="1">Poland</td>
                <td rowspan="1" colspan="1">Patients&#xA0;with&#xA0;arterial<break/>hypertension</td>
                <td rowspan="1" colspan="1">Indapamide + amlodipine<break/>(Tertens-AM)</td>
                <td rowspan="1" colspan="1">STCT was less expensive than treatment with LDCs</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Subgroup: STCT<break/>patients with higher<break/>adherence</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">STCT&#xA0;dominates&#xA0;LDCs,&#xA0;in&#xA0;both<break/>NHF&#xA0;and&#xA0;patient&#x2019;s&#xA0;perspective</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ren et al, 2020<xref rid="ref-275072" ref-type="bibr"><sup>102</sup></xref></td>
                <td rowspan="1" colspan="1">CEA + CUA</td>
                <td rowspan="1" colspan="1">China</td>
                <td rowspan="1" colspan="1">Hypertensive adults</td>
                <td rowspan="1" colspan="1">Olmesartan + amlodipine<break/>(Sevikar)</td>
                <td rowspan="1" colspan="1">STCT dominates LDCs</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Fujii et al, 2015<xref rid="ref-275032" ref-type="bibr"><sup>62</sup></xref></td>
                <td rowspan="1" colspan="1">CEA, BIA</td>
                <td rowspan="1" colspan="1">Brazil</td>
                <td rowspan="1" colspan="1">Systemic arterial<break/>hypertension</td>
                <td rowspan="1" colspan="1">Bisoprolol + amlodipine<break/>(Concor AM)</td>
                <td rowspan="1" colspan="1">STCT dominates LDCs</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Stawowczyk et al, 2014<xref rid="ref-275090" ref-type="bibr"><sup>120</sup></xref></td>
                <td rowspan="1" colspan="1">CUA</td>
                <td rowspan="1" colspan="1">Poland</td>
                <td rowspan="1" colspan="1">Hypertensive&#xA0;patients</td>
                <td rowspan="1" colspan="1">Indapamide + amlodipine<break/>(Natrixam)</td>
                <td rowspan="1" colspan="1"><bold>Public&#xA0;payer&#xA0;perspective:</bold>&#xA0;STCT<break/>dominates LDCs<break/><bold>Patient&#x2019;s perspective:</bold> Net<break/>monetary&#xA0;benefit&#xA0;was&#xA0;higher&#xA0;with<break/>STCT</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Price et al, 2014<xref rid="ref-275071" ref-type="bibr"><sup>101</sup></xref></td>
                <td rowspan="1" colspan="1">CMA</td>
                <td rowspan="1" colspan="1">Sweden</td>
                <td rowspan="1" colspan="1">Moderate-to-severe<break/>COPD patients</td>
                <td rowspan="1" colspan="1">Indacaterol&#xA0;+&#xA0;glycopyrronium<break/>(Utibron)</td>
                <td rowspan="1" colspan="1">STCT dominates LDCs in all<break/>horizons, and in PSA iterations</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Br&#xFC;ggenj&#xFC;rgen et al, 2010<xref rid="ref-275013" ref-type="bibr"><sup>43</sup></xref></td>
                <td rowspan="1" colspan="1">CMA</td>
                <td rowspan="1" colspan="1">Germany</td>
                <td rowspan="1" colspan="1">Asthma</td>
                <td rowspan="1" colspan="1">Beclomethasone&#xA0;dipropionate&#xA0;+<break/>formoterol fumarate<break/>(CHF 1535)</td>
                <td rowspan="1" colspan="1">STCT dominates LDCs</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>Note: The result of the CEA from Fujii et al (2015) is shown here; findings from the BIA from Fujii et al (2015) is reported in <bold><xref rid="attachment-192291" ref-type="table">Table 4</xref></bold>.</p>
            <p>Abbreviations: BIA, budget impact analysis; CEA, cost-effectiveness analysis; CMA, cost-minimization analysis; COPD, chronic obstructive pulmonary disease; CUA, cost-utility analysis; LDC, loose-dose combination; NHF, National Health Fund; PSA, probabilistic sensitivity analysis; STCT, single-tablet combination therapy.</p>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap position="float" id="attachment-192291">
          <object-id pub-id-type="publisher-id">192291</object-id>
          <label>Table 4.</label>
          <caption>
            <title>Findings from Budget Impact Analyses</title>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th rowspan="1" colspan="1">
<bold>Short
Reference</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Country;
Currency</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Time
Horizon</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Population</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Intervention (STCT</bold>
<break/>
<bold>Brand)</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Savings</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Budget&#xA0;Impact</bold>
</th>
                <th rowspan="1" colspan="1">
<bold>Main&#xA0;Message</bold>
</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Fujii et al, 2015<xref rid="ref-275032" ref-type="bibr"><sup>62</sup></xref></td>
                <td rowspan="1" colspan="1">Brazil; Brazilian real (BRL)</td>
                <td rowspan="1" colspan="1">10 y</td>
                <td rowspan="1" colspan="1">Systemic arterial hypertension</td>
                <td rowspan="1" colspan="1">Bisoprolol + amlodipine (Concor AM)</td>
                <td rowspan="1" colspan="1">NR</td>
                <td rowspan="1" colspan="1">-300&#x202F;321&#x202F;412</td>
                <td rowspan="1" colspan="1">There were financial resource savings with Concor AM, in 2014- 2025</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Kawalec et al, 2014<xref rid="ref-275048" ref-type="bibr"><sup>78</sup></xref></td>
                <td rowspan="1" colspan="1">Poland; Polish zloty (PLN)</td>
                <td rowspan="1" colspan="1">3 y</td>
                <td rowspan="1" colspan="1">Hypertensive patients</td>
                <td rowspan="1" colspan="1">Indapamide + amlodipine (Natrixam)</td>
                <td rowspan="1" colspan="1">Cost savings at year 3:<break/><bold>NHF</bold><break/><bold>perspective:</bold><break/>-725&#x202F;965<break/><bold>Patient perspective:</bold><break/>-8&#x202F;328&#x202F;480</td>
                <td rowspan="1" colspan="1">NR</td>
                <td rowspan="1" colspan="1">Treatment with indapamide/amlodipine STCTs vs LDCs generates significant savings both from the public payer and patient perspectives</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Stafylas et al, 2018<xref rid="ref-275087" ref-type="bibr"><sup>117</sup></xref></td>
                <td rowspan="1" colspan="1">Greece; euros (&#x20AC;)</td>
                <td rowspan="1" colspan="1">5 y</td>
                <td rowspan="1" colspan="1">Essential hypertension and/or stable coronary artery disease in association with primary hypercholesterolemia or mixed hyperlipidemia</td>
                <td rowspan="1" colspan="1">Atorvastatin + perindopril + amlodipine</td>
                <td rowspan="1" colspan="1">Year 5:<break/>-1&#x202F;903&#x202F;639</td>
                <td rowspan="1" colspan="1">Cumulative over 5 y:<break/>-6&#x202F;107&#x202F;965</td>
                <td rowspan="1" colspan="1">Introduction of STCTs at a price lower than that of the LDCs of the same agents will reduce medication costs</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Stafylas et al, 2019<xref rid="ref-275088" ref-type="bibr"><sup>118</sup></xref></td>
                <td rowspan="1" colspan="1">Greece; euros (&#x20AC;)</td>
                <td rowspan="1" colspan="1">5 y</td>
                <td rowspan="1" colspan="1">Hyperlipidemia patients</td>
                <td rowspan="1" colspan="1">Rosuvastatin<break/>+ ezetimibe</td>
                <td rowspan="1" colspan="1">Year 5:<break/>-395&#x202F;447</td>
                <td rowspan="1" colspan="1">Cumulative over 5 y:<break/>-2&#x202F;351&#x202F;952</td>
                <td rowspan="1" colspan="1">The introduction of STCTs of ezetimibe/ rosuvastatin is expected to reduce treatment costs</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>Note: The result of the BIA from Fujii et al (2015) is shown here; findings from the CEA from Fujii et al (2015) is reported in <bold><xref rid="attachment-192289" ref-type="table">Table 3</xref></bold>.</p>
            <p>Abbreviations: BIA, budget impact analysis; CEA, cost-effectiveness analysis; COPD, chronic obstructive pulmonary disease; CUA, cost-utility analysis; LDC, loose-dose combination; NHF, National Health Fund; NR, not reported; PSA, probabilistic sensitivity analysis; STCT, single-tablet combination therapy</p>
          </table-wrap-foot>
        </table-wrap>
        <p>Among the 16 studies that examined medical costs and HCRU, findings were largely favorable toward fixed-dose combinations.<xref rid="ref-275003" ref-type="bibr"><sup>33,40,42,46,47,55,65,70,84,87,90,100,105,109,119,130</sup></xref> Medication costs over time were generally lower for fixed-dose combinations compared with LDCs (n = 6,<xref rid="ref-275012" ref-type="bibr"><sup>42,46,87,90,105,119</sup></xref>
<bold><xref rid="attachment-192292" ref-type="fig">Figure 2A</xref></bold>). Several studies reported lower overall medical costs with STCTs,<xref rid="ref-275012" ref-type="bibr"><sup>42,46,87</sup></xref> including a retrospective cohort study that included 8711 US patients with hypertension.<xref rid="ref-275012" ref-type="bibr"><sup>42</sup></xref> Patients received valsartan plus hydrochlorothiazide as an STCT or LDC and HCRU costs were compared after 12 months.<xref rid="ref-275012" ref-type="bibr"><sup>42</sup></xref> The average annual medical costs for patients receiving an STCT were $474 lower than for patients who received an LDC during the study period of 1996 to 2004. When patients were both persistent and adherent to medication, medical costs were $608 lower. There was also evidence of STCTs and fixed-dose inhalers reducing HCRU, with 3 studies reporting lower hospitalization rates over time (n = 3).<xref rid="ref-275057" ref-type="bibr"><sup>87,90,105</sup></xref> STCTs were also associated with reductions in emergency department costs<xref rid="ref-275057" ref-type="bibr"><sup>87</sup></xref> and utilization rates.<xref rid="ref-275016" ref-type="bibr"><sup>46,87,100</sup></xref></p>
        <fig position="float" id="attachment-192292">
          <object-id pub-id-type="publisher-id">192292</object-id>
          <label>Figure 2.</label>
          <caption>
            <title>Medication Costs for STCTs and LDCs</title>
            <p>Several of the identified economic studies reported the cost of medication over time for STCTs vs LDCs. Of these, 3 studies also reported hospitalization rates for STCTs vs LDCs.</p>
            <p>*Patients in this comparison received budesonide + formoterol in a single inhaler or 2 inhalers</p>
            <p>&#x2020;Patients in this comparison received budesonide + formoterol + terbutaline PRN in 2 or 3 inhalers Abbreviations: LDC, loose-dose combination product; NR, not reported; SEK, Swedish krona; STCT, single-tablet combination therapy; USD, US dollar.</p>
            <p>Sources: References 42, 46, 87, 90, 105, 119.</p>
          </caption>
          <graphic xlink:href="jheor_2024_11_1_91396_192292" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec>
      <title>DISCUSSION</title>
      <p>The results of this study reflect the growing body of evidence that link STCTs to increased treatment adherence and persistence, along with positive clinical and economic outcomes. The strongest evidence supporting STCT use came from the RWE and economic studies. Improved adherence and persistence with STCTs were seen consistently across RWE studies, including studies where patients switched from an LDC to an STCT. The majority of the studies that reported clinical outcomes with STCTs described improvements, particularly in glycemic control and the reduced need for add-on medication. Several studies linked improved adherence or persistence outcomes with improved clinical efficacy. Studies that did not find a link between adherence/persistence and clinical outcomes included patients with complex, chronic diseases, such as asthma, COPD, and cardiovascular disease. It is possible that unmeasured confounders, such as disease severity, time since diagnosis, or symptom presentation affected the measurement of clinical outcomes, and more work is needed to better describe the impact of STCTs for patients with these indications. Only 4 studies were identified that described compliance outcomes, perhaps due to evolving terminology that increasingly favors &#x201C;adherence&#x201D; over &#x201C;compliance,&#x201D; and retrospective studies that often include adherence and persistence measures based on patient records. The economic findings in favor of STCTs were robust and suggested that the improved clinical outcomes associated with STCTs can lead to reduced medication costs, hospitalizations, and overall medical costs over time. All the identified cost-effectiveness, cost-utility, and budget impact analyses demonstrated savings with STCTs compared with LDCs.</p>
      <p>While some clinical and HRQoL studies reported improvement in adherence and clinical outcomes with STCTs, the results were more heterogeneous. This may be a result of data collection methodology that is not optimized to compare outcomes with STCTs and LDCs. The controlled environment of clinical trials is designed to facilitate high treatment adherence, which may increase the adherence and persistence outcomes for LDCs and affect LDC-STCT comparisons in ways unrelated to pill burden. In studies that reported HRQoL outcomes, there was some evidence of improved outcomes among patients who received STCTs compared with those who received LDCs. However, most studies focused primarily on patient symptoms and general measures of HRQoL, rather than pill burden or drug administration processes. There is a need for future studies to compare STCTs and LDCs with HRQoL measures that more closely reflect the aspects of drug administration. Since there is evidence linking poor treatment satisfaction to poor adherence in patients with chronic diseases,<xref rid="ref-275105" ref-type="bibr"><sup>135,136</sup></xref> validated tools to measure treatment satisfaction, such as the Treatment Satisfaction Questionnaire for Medication<xref rid="ref-275107" ref-type="bibr"><sup>137</sup></xref> and the Diabetes Medication System Rating Questionnaire,<xref rid="ref-275108" ref-type="bibr"><sup>138</sup></xref> may be useful in understanding how STCTs can affect HRQoL.</p>
      <p>Our results, which included studies from countries on 6 continents, indicated that STCTs can boost adherence, clinical outcomes, and economic savings in most countries, but some considerations may be especially important in local markets. Much of the identified RWE and economic studies were based in the US and Europe. As a general recommendation, future research should include patients in other regions to shed light on global variation and common themes across STCT use and outcomes.</p>
      <p>While this article may be especially useful for payers, the benefits of STCT use are relevant to multiple stakeholders, including patients, clinicians, and caregivers. For patients, improved treatment adherence with STCTs can result in positive clinical outcomes, reduced medical costs, and improved treatment satisfaction. STCT use helps to align patient actions with the recommendations of clinicians, contributing to positive clinical outcomes. Caregivers benefit from STCTs through reduced medication costs, co-pay costs, and drug administration burden. Finally, payers benefit from the reduced economic burden and HCRU that is accompanied by improved clinical outcomes.</p>
      <sec>
        <title>Strengths</title>
        <p>The substantial amount of literature reporting outcomes of STCTs vs LDCs, spanning the last 2 decades and various countries, greatly contributed to the value of this study. The use of common measures in RWE studies and cost- effectiveness and budget impact analyses resulted in comparability across many studies. Furthermore, in contrast to previously published SLRs that primarily focused on the effects of STCTs in single indications including hypertension,<xref rid="ref-275109" ref-type="bibr"><sup>139,140</sup></xref> diabetes,<xref rid="ref-274986" ref-type="bibr"><sup>16</sup></xref> or HIV,<xref rid="ref-275111" ref-type="bibr"><sup>141</sup></xref> our searches were not limited by indication or intervention, which allowed for broad commonalities to emerge in the comparison of STCTs and LDCs. Not only do the results of our SLR support the observations that use of STCTs may improve adherence and clinical effectiveness while also lowering costs as presented in previously published SLRs,<xref rid="ref-274986" ref-type="bibr"><sup>16,139&#x2013;142</sup></xref> our study further provides analysis among patients with Parkinson&#x2019;s,<xref rid="ref-275113" ref-type="bibr"><sup>143</sup></xref> asthma,<xref rid="ref-275013" ref-type="bibr"><sup>43</sup></xref> and more general cardiovascular disease,<xref rid="ref-275064" ref-type="bibr"><sup>94,99,100</sup></xref> which have previously not been reported.</p>
      </sec>
      <sec>
        <title>Limitations</title>
        <p>Comparability in this study was limited by the variation in the outcomes that were measured and reported by the included studies. Additionally, in some cases, studies that did not report favorable results for the use of STCTs by one metric reported broadly favorable results for STCT use when considering other metrics. One example is a study that reported the results of switching from LDCs to STCTs in patients with type 2 diabetes mellitus.<xref rid="ref-275028" ref-type="bibr"><sup>58</sup></xref> Although treatment adherence was high before and after switching, adherence slightly declined after patients switched to STCTs (92.4% to 90.9%).<xref rid="ref-275028" ref-type="bibr"><sup>58</sup></xref> Despite this, hemoglobin A1C values were significantly improved with STCTs.<xref rid="ref-275028" ref-type="bibr"><sup>58</sup></xref> The context of the original study, though largely favorable to STCT use, is lost when reporting aggregated adherence results.</p>
        <p>The RWE findings clearly showed that STCT use is associated with improved outcomes but do not provide a mechanistic explanation for this within the context of drug administration. Since STCTs affect several distinct administration processes by reducing the number of medications to be prescribed, filled at the pharmacy, and consumed, studies that examine these processes directly could differentiate between benefits provided by STCTs and other administration options, like bundling prescriptions to be filled simultaneously at the pharmacy.<xref rid="ref-275114" ref-type="bibr"><sup>144</sup></xref></p>
        <p>Lastly, some heterogeneity in our results may be due to the inherent nature of different diseases that vary in patient population demographics, drug administration protocols, symptom severity, and perceived mortality risk&#x2014;factors that can influence patient behavior and treatment adherence.</p>
      </sec>
    </sec>
    <sec>
      <title>CONCLUSIONS</title>
      <p>The use of STCTs resulted in positive outcomes compared with LDCs across clinical studies, RWE, HRQoL studies, and economic evaluations. In RWE studies, STCTs were associated with consistent improvements in treatment adherence, persistence, and compliance, with evidence for greater adherence and persistence resulting in positive clinical outcomes. STCTs consistently dominated LDCs in cost-effectiveness and cost-utility analyses, and all identified budget impact analyses found cost savings with STCTs. This study provides a solid foundation for understanding the benefits of STCTs across clinical indications and the need for these to be thoughtfully considered in formulary decision-making. The findings highlight opportunities for future research to contribute by reporting STCT outcomes in additional countries and measuring drug administration&#x2013;related HRQoL.</p>
      <sec sec-type="author-contributions" id="contrib">
        <title>Author Contributions</title>
        <p>C.P. contributed to the planning, critical review of the manuscript, and approved the final manuscript; J.L. contributed to the planning, critical review of the manuscript, and approved the final manuscript; J.W. contributed to the planning, critical review of the manuscript, and approved the final manuscript; K.G. performed the systematic literature review, data extraction, and approved the final manuscript; D.T. performed the systematic literature review and data extraction, and approved the final manuscript; and S.G. performed the systematic literature review, data extraction, and approved the final manuscript.</p>
      </sec>
      <sec sec-type="COI-statement" id="coi">
        <title>Disclosures</title>
        <p>C.P. is an employee of Janssen Pharmaceutical Companies of Johnson &amp; Johnson and J.L. is an employee of Janssen-Cliag of Johnson &amp; Johnson, both with stock or stock options at Johnson &amp; Johnson. J.W. was an employee of Janssen Pharmaceutical Companies of Johnson &amp; Johnson at the time of the study. D.T. and S.G. are employees of Cytel, Inc.&#xA0;K.G. was an employee of Cytel, Inc.&#xA0;at the time of the study.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material id="attachment-193089" position="float" content-type="local-data">
        <caption>
          <title>Online Supplementary Material</title>
        </caption>
        <media xlink:href="jheor_2024_11_1_91396_193089.pdf"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <sec id="ack">
        <title>Acknowledgments</title>
        <p>Writing support was provided by Allison Brackley, PhD, and Elizabeth Hubscher, PhD of Cytel, Inc.</p>
      </sec>
    </ack>
    <ref-list>
      <ref id="ref-274971">
        <element-citation publication-type="book"><article-title>Economic impact of medication non-adherence by disease groups: a systematic review</article-title><source>BMJ Open</source><person-group person-group-type="author">
<name><surname>Cutler</surname><given-names>Rachelle Louise</given-names></name>
<name><surname>Fernandez-Llimos</surname><given-names>Fernando</given-names></name>
<name><surname>Frommer</surname><given-names>Michael</given-names></name>
<name><surname>Benrimoj</surname><given-names>Charlie</given-names></name>
<name><surname>Garcia-Cardenas</surname><given-names>Victoria</given-names></name>
</person-group><publisher-name>BMJ</publisher-name><date><month>1</month><year>2018</year></date><volume>8</volume><issue>1</issue><fpage>e016982</fpage><issn>2044-6055</issn><pub-id pub-id-type="doi">10.1136/bmjopen-2017-016982</pub-id><!--<pub-id pub-id-type="pmcid">PMC5780689</pub-id>--><pub-id pub-id-type="doi">10.1136/bmjopen-2017-016982</pub-id><pub-id pub-id-type="pmid">29358417</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274972">
        <element-citation publication-type="journal"><article-title>Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional study</article-title><source>BMC Family Practice</source><person-group person-group-type="author">
<name><surname>Fernandez-Lazaro</surname><given-names>Cesar I.</given-names></name>
<name><surname>Garc&#xED;a-Gonz&#xE1;lez</surname><given-names>Juan M.</given-names></name>
<name><surname>Adams</surname><given-names>David P.</given-names></name>
<name><surname>Fernandez-Lazaro</surname><given-names>Diego</given-names></name>
<name><surname>Mielgo-Ayuso</surname><given-names>Juan</given-names></name>
<name><surname>Caballero-Garcia</surname><given-names>Alberto</given-names></name>
<name><surname>Moreno Racionero</surname><given-names>Francisca</given-names></name>
<name><surname>C&#xF3;rdova</surname><given-names>Alfredo</given-names></name>
<name><surname>Miron-Canelo</surname><given-names>Jose A.</given-names></name>
</person-group><date><day>14</day><month>9</month><year>2019</year></date><volume>20</volume><issue>1</issue><fpage>132</fpage><issn>1471-2296</issn><pub-id pub-id-type="doi">10.1186/s12875-019-1019-3</pub-id><!--<pub-id pub-id-type="pmcid">PMC6744672</pub-id>--><pub-id pub-id-type="doi">10.1186/s12875-019-1019-3</pub-id><pub-id pub-id-type="pmid">31521114</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274973">
        <element-citation publication-type="journal"><article-title>Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5&#xA0;inhibitors</article-title><source>Pulmonary Circulation</source><person-group person-group-type="author">
<name><surname>Frantz</surname><given-names>Robert P.</given-names></name>
<name><surname>Hill</surname><given-names>Jerrold W.</given-names></name>
<name><surname>Lickert</surname><given-names>Cassandra A.</given-names></name>
<name><surname>Wade</surname><given-names>Rolin L.</given-names></name>
<name><surname>Cole</surname><given-names>Michele R.</given-names></name>
<name><surname>Tsang</surname><given-names>Yuen</given-names></name>
<name><surname>Drake</surname><given-names>William III</given-names></name>
</person-group><date><month>1</month><year>2020</year></date><volume>10</volume><issue>1</issue><fpage>2045894019880086</fpage><issn>2045-8940</issn><pub-id pub-id-type="doi">10.1177/2045894019880086</pub-id><!--<pub-id pub-id-type="pmcid">PMC7114296</pub-id>--><pub-id pub-id-type="doi">10.1177/2045894019880086</pub-id><pub-id pub-id-type="pmid">32274010</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274974">
        <element-citation publication-type="journal"><article-title>Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension</article-title><source>ERJ Open Research</source><person-group person-group-type="author">
<name><surname>Kjellstr&#xF6;m</surname><given-names>Barbro</given-names></name>
<name><surname>Sandqvist</surname><given-names>Anna</given-names></name>
<name><surname>Hjalmarsson</surname><given-names>Clara</given-names></name>
<name><surname>Nisell</surname><given-names>Magnus</given-names></name>
<name><surname>N&#xE4;sman</surname><given-names>Per</given-names></name>
<name><surname>Ivarsson</surname><given-names>Bodil</given-names></name>
</person-group><date><month>10</month><year>2020</year></date><volume>6</volume><issue>4</issue><issn>2312-0541</issn><pub-id pub-id-type="doi">10.1183/23120541.00299-2020</pub-id><!--<pub-id pub-id-type="pmcid">PMC7720683</pub-id>--><pub-id pub-id-type="doi">10.1183/23120541.00299-2020</pub-id><pub-id pub-id-type="pmid">33313301</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274975">
        <element-citation publication-type="journal"><article-title>Primary nonadherence to chronic disease medications: a meta-analysis</article-title><source>Patient Preference and Adherence</source><person-group person-group-type="author">
<name><surname>Lemstra</surname><given-names>Mark</given-names></name>
<name><surname>Nwankwo</surname><given-names>Chijioke</given-names></name>
<name><surname>Bird</surname><given-names>Yelena</given-names></name>
<name><surname>Moraros</surname><given-names>John</given-names></name>
</person-group><date><month>5</month><year>2018</year></date><volume>12</volume><fpage>721</fpage><lpage>731</lpage><issn>1177-889X</issn><pub-id pub-id-type="doi">10.2147/ppa.s161151</pub-id><!--<pub-id pub-id-type="pmcid">PMC5944464</pub-id>--><pub-id pub-id-type="doi">10.2147/ppa.s161151</pub-id><pub-id pub-id-type="pmid">29765208</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274976">
        <element-citation publication-type="journal"><article-title>Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database</article-title><source>Pulmonary Circulation</source><person-group person-group-type="author">
<name><surname>Studer</surname><given-names>Sean</given-names></name>
<name><surname>Hull</surname><given-names>Michael</given-names></name>
<name><surname>Pruett</surname><given-names>Janis</given-names></name>
<name><surname>Koep</surname><given-names>Eleena</given-names></name>
<name><surname>Tsang</surname><given-names>Yuen</given-names></name>
<name><surname>Drake</surname><given-names>William, III</given-names></name>
</person-group><date><year>2019</year></date><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><issn>2045-8940</issn><pub-id pub-id-type="doi">10.1177/2045894018816294</pub-id><!--<pub-id pub-id-type="pmcid">PMC6432690</pub-id>--><pub-id pub-id-type="doi">10.1177/2045894018816294</pub-id><pub-id pub-id-type="pmid">30421652</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274977">
        <element-citation publication-type="book">
          <article-title>Polypharmacy and medication adherence</article-title>
          <source>Aging</source>
          <person-group person-group-type="author">
<name><surname>Lavrador</surname><given-names>Marta</given-names></name>
<name><surname>Cabral</surname><given-names>Ana Cristina</given-names></name>
<name><surname>Castel-Branco</surname><given-names>Margarida</given-names></name>
<name><surname>Figueiredo</surname><given-names>Isabel Vitoria</given-names></name>
<name><surname>Fernandez-Llimos</surname><given-names>Fernando</given-names></name>
</person-group>
          <publisher-name>Elsevier</publisher-name>
          <date>
            <year>2023</year>
          </date>
          <volume>2023</volume>
          <fpage>435</fpage>
          <lpage>453</lpage>
          <isbn>9780128237618</isbn>
          <pub-id pub-id-type="doi">10.1016/b978-0-12-823761-8.00014-8</pub-id>
          <pub-id pub-id-type="doi">10.1016/b978-0-12-823761-8.00014-8</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-274978">
        <element-citation publication-type="journal">
          <article-title>Interventions to improve medication adherence: a review</article-title>
          <source>JAMA</source>
          <person-group person-group-type="author">
<name><surname>Kini</surname><given-names>Vinay</given-names></name>
<name><surname>Ho</surname><given-names>P. Michael</given-names></name>
</person-group>
          <date>
            <day>18</day>
            <month>12</month>
            <year>2018</year>
          </date>
          <volume>320</volume>
          <issue>23</issue>
          <fpage>2461</fpage>
          <lpage>2473</lpage>
          <issn>0098-7484</issn>
          <pub-id pub-id-type="doi">10.1001/jama.2018.19271</pub-id>
          <pub-id pub-id-type="doi">10.1001/jama.2018.19271</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-274979">
        <element-citation publication-type="journal"><article-title>Medication adherence interventions and outcomes: an overview of systematic reviews</article-title><source>European Journal of Hospital Pharmacy</source><person-group person-group-type="author">
<name><surname>Wilhelmsen</surname><given-names>Nina C</given-names></name>
<name><surname>Eriksson</surname><given-names>Tommy</given-names></name>
</person-group><date><year>2019</year></date><volume>26</volume><issue>4</issue><fpage>187</fpage><lpage>192</lpage><issn>2047-9956</issn><pub-id pub-id-type="doi">10.1136/ejhpharm-2018-001725</pub-id><!--<pub-id pub-id-type="pmcid">PMC6613929</pub-id>--><pub-id pub-id-type="doi">10.1136/ejhpharm-2018-001725</pub-id><pub-id pub-id-type="pmid">31338165</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274980">
        <element-citation publication-type="journal"><article-title>9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes&#x2014;2023</article-title><source>Diabetes Care</source><person-group person-group-type="author">
<name><surname>ElSayed</surname><given-names>Nuha A.</given-names></name>
<name><surname>Aleppo</surname><given-names>Grazia</given-names></name>
<name><surname>Aroda</surname><given-names>Vanita R.</given-names></name>
<name><surname>Bannuru</surname><given-names>Raveendhara R.</given-names></name>
<name><surname>Brown</surname><given-names>Florence M.</given-names></name>
<name><surname>Bruemmer</surname><given-names>Dennis</given-names></name>
<name><surname>Collins</surname><given-names>Billy S.</given-names></name>
<name><surname>Hilliard</surname><given-names>Marisa E.</given-names></name>
<name><surname>Isaacs</surname><given-names>Diana</given-names></name>
<name><surname>Johnson</surname><given-names>Eric L.</given-names></name>
<name><surname>Kahan</surname><given-names>Scott</given-names></name>
<name><surname>Khunti</surname><given-names>Kamlesh</given-names></name>
<name><surname>Leon</surname><given-names>Jose</given-names></name>
<name><surname>Lyons</surname><given-names>Sarah K.</given-names></name>
<name><surname>Perry</surname><given-names>Mary Lou</given-names></name>
<name><surname>Prahalad</surname><given-names>Priya</given-names></name>
<name><surname>Pratley</surname><given-names>Richard E.</given-names></name>
<name><surname>Seley</surname><given-names>Jane Jeffrie</given-names></name>
<name><surname>Stanton</surname><given-names>Robert C.</given-names></name>
<name><surname>Gabbay</surname><given-names>Robert A.</given-names></name>
</person-group><date><day>12</day><month>12</month><year>2022</year></date><volume>46</volume><issue>suppl 1</issue><fpage>S140</fpage><lpage>S157</lpage><issn>0149-5992</issn><pub-id pub-id-type="doi">10.2337/dc23-s009</pub-id><!--<pub-id pub-id-type="pmcid">PMC9810476</pub-id>--><pub-id pub-id-type="doi">10.2337/dc23-s009</pub-id><pub-id pub-id-type="pmid">36507650</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274981">
        <element-citation publication-type="webpage">
          <source>Global Strategy for Asthma Management and Prevention, 2023 Update</source>
          <person-group person-group-type="author">
<collab>Global Initiative for Asthma (GINA)</collab>
</person-group>
          <date>
            <year>2023</year>
          </date>
          <ext-link xlink:href="https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf" ext-link-type="uri">https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf</ext-link>
        </element-citation>
      </ref>
      <ref id="ref-274982">
        <element-citation publication-type="journal"><article-title>2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and European Renal Association (ERA)</article-title><source>J Hypertens</source><person-group person-group-type="author">
<name><surname>Mancia</surname><given-names>G.</given-names></name>
<name><surname>Kreutz</surname><given-names>R.</given-names></name>
<name><surname>Brunstr&#xF6;m</surname><given-names>M..</given-names></name>
<etal/>
</person-group><date><year>2023</year></date><volume>41</volume><issue>12</issue><fpage>1874</fpage><lpage>2071</lpage><pub-id pub-id-type="pmid">37345492</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274983">
        <element-citation publication-type="journal"><article-title>Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial</article-title><source>JAMA</source><person-group person-group-type="author">
<name><surname>Thom</surname><given-names>Simon</given-names></name>
<name><surname>Poulter</surname><given-names>N</given-names></name>
<name><surname>Field</surname><given-names>J</given-names></name>
<etal/>
</person-group><date><day>4</day><month>9</month><year>2013</year></date><volume>310</volume><issue>9</issue><fpage>918</fpage><lpage>929</lpage><issn>0098-7484</issn><pub-id pub-id-type="doi">10.1001/jama.2013.277064</pub-id><pub-id pub-id-type="doi">10.1001/jama.2013.277064</pub-id><pub-id pub-id-type="pmid">24002278</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274984">
        <element-citation publication-type="journal"><article-title>The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis</article-title><source>The Journal of Clinical Hypertension</source><person-group person-group-type="author">
<name><surname>Du</surname><given-names>Li-Ping</given-names></name>
<name><surname>Cheng</surname><given-names>Zhong-Wei</given-names></name>
<name><surname>Zhang</surname><given-names>Yu-Xuan</given-names></name>
<name><surname>Li</surname><given-names>Ying</given-names></name>
<name><surname>Mei</surname><given-names>Dan</given-names></name>
</person-group><date><day>27</day><month>4</month><year>2018</year></date><volume>20</volume><issue>5</issue><fpage>902</fpage><lpage>907</lpage><issn>1524-6175</issn><pub-id pub-id-type="doi">10.1111/jch.13272</pub-id><!--<pub-id pub-id-type="pmcid">PMC8030969</pub-id>--><pub-id pub-id-type="doi">10.1111/jch.13272</pub-id><pub-id pub-id-type="pmid">29700923</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274985">
        <element-citation publication-type="journal"><article-title>Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis</article-title><source>Archives of Medical Science</source><person-group person-group-type="author">
<name><surname>Kawalec</surname><given-names>Pawe&#x142;</given-names></name>
<name><surname>Holko</surname><given-names>Przemys&#x142;aw</given-names></name>
<name><surname>Gawin</surname><given-names>Ma&#x142;gorzata</given-names></name>
<name><surname>Pilc</surname><given-names>Andrzej</given-names></name>
</person-group><date><year>2018</year></date><volume>14</volume><issue>5</issue><fpage>1125</fpage><lpage>1136</lpage><issn>1734-1922</issn><pub-id pub-id-type="doi">10.5114/aoms.2018.77561</pub-id><!--<pub-id pub-id-type="pmcid">PMC6111352</pub-id>--><pub-id pub-id-type="doi">10.5114/aoms.2018.77561</pub-id><pub-id pub-id-type="pmid">30154897</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274986">
        <element-citation publication-type="journal"><article-title>A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes</article-title><source>Current Medical Research and Opinion</source><person-group person-group-type="author">
<name><surname>Hutchins</surname><given-names>Valerie</given-names></name>
<name><surname>Zhang</surname><given-names>Bin</given-names></name>
<name><surname>Fleurence</surname><given-names>Rachael L.</given-names></name>
<name><surname>Krishnarajah</surname><given-names>Girishanthy</given-names></name>
<name><surname>Graham</surname><given-names>John</given-names></name>
</person-group><date><day>5</day><month>4</month><year>2011</year></date><volume>27</volume><issue>6</issue><fpage>1157</fpage><lpage>1168</lpage><issn>0300-7995</issn><pub-id pub-id-type="doi">10.1185/03007995.2011.570745</pub-id><pub-id pub-id-type="doi">10.1185/03007995.2011.570745</pub-id><pub-id pub-id-type="pmid">21466277</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274987">
        <element-citation publication-type="journal"><article-title>Fixed-dose and fixed-ratio combination therapies in type 2 diabetes</article-title><source>Canadian Journal of Diabetes</source><person-group person-group-type="author">
<name><surname>Schlosser</surname><given-names>Robert</given-names></name>
</person-group><date><month>8</month><year>2019</year></date><volume>43</volume><issue>6</issue><fpage>440</fpage><lpage>444</lpage><issn>1499-2671</issn><pub-id pub-id-type="doi">10.1016/j.jcjd.2019.05.005</pub-id><pub-id pub-id-type="doi">10.1016/j.jcjd.2019.05.005</pub-id><pub-id pub-id-type="pmid">31375179</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274988">
        <element-citation publication-type="journal"><article-title>Fixed-dose combination drug approvals, patents and market exclusivities compared to single active ingredient pharmaceuticals</article-title><source>PLoS One</source><person-group person-group-type="author">
<name><surname>Hao</surname><given-names>Jing</given-names></name>
<name><surname>Rodriguez-Monguio</surname><given-names>Rosa</given-names></name>
<name><surname>Seoane-Vazquez</surname><given-names>Enrique</given-names></name>
</person-group><date><day>15</day><month>10</month><year>2015</year></date><volume>10</volume><issue>10</issue><fpage>e0140708</fpage><issn>1932-6203</issn><pub-id pub-id-type="doi">10.1371/journal.pone.0140708</pub-id><!--<pub-id pub-id-type="pmcid">PMC4607470</pub-id>--><pub-id pub-id-type="doi">10.1371/journal.pone.0140708</pub-id><pub-id pub-id-type="pmid">26469277</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274989">
        <element-citation publication-type="journal"><article-title>Body of evidence and approaches applied in the clinical development programme of fixed-dose combinations in the European Union from 2010 to 2016</article-title><source>British Journal of Clinical Pharmacology</source><person-group person-group-type="author">
<name><surname>N&#xF8;hr-Nielsen</surname><given-names>Asbj&#xF8;rn</given-names></name>
<name><surname>De Bruin</surname><given-names>Marie Louise</given-names></name>
<name><surname>Thomsen</surname><given-names>Mikael</given-names></name>
<name><surname>Pipper</surname><given-names>Christian Bressen</given-names></name>
<name><surname>Lange</surname><given-names>Theis</given-names></name>
<name><surname>Bjerrum</surname><given-names>Ole Jannik</given-names></name>
<name><surname>Lund</surname><given-names>Trine Meldgaard</given-names></name>
</person-group><date><day>17</day><month>6</month><year>2019</year></date><volume>85</volume><issue>8</issue><fpage>1829</fpage><lpage>1840</lpage><issn>0306-5251</issn><pub-id pub-id-type="doi">10.1111/bcp.13986</pub-id><!--<pub-id pub-id-type="pmcid">PMC6624404</pub-id>--><pub-id pub-id-type="doi">10.1111/bcp.13986</pub-id><pub-id pub-id-type="pmid">31077427</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274990">
        <element-citation publication-type="journal"><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><person-group person-group-type="author">
<name><surname>Page</surname><given-names>Matthew J</given-names></name>
<name><surname>McKenzie</surname><given-names>Joanne E</given-names></name>
<name><surname>Bossuyt</surname><given-names>Patrick M</given-names></name>
<name><surname>Boutron</surname><given-names>Isabelle</given-names></name>
<name><surname>Hoffmann</surname><given-names>Tammy C</given-names></name>
<name><surname>Mulrow</surname><given-names>Cynthia D</given-names></name>
<name><surname>Shamseer</surname><given-names>Larissa</given-names></name>
<name><surname>Tetzlaff</surname><given-names>Jennifer M</given-names></name>
<name><surname>Akl</surname><given-names>Elie A</given-names></name>
<name><surname>Brennan</surname><given-names>Sue E</given-names></name>
<name><surname>Chou</surname><given-names>Roger</given-names></name>
<name><surname>Glanville</surname><given-names>Julie</given-names></name>
<name><surname>Grimshaw</surname><given-names>Jeremy M</given-names></name>
<name><surname>Hr&#xF3;bjartsson</surname><given-names>Asbj&#xF8;rn</given-names></name>
<name><surname>Lalu</surname><given-names>Manoj M</given-names></name>
<name><surname>Li</surname><given-names>Tianjing</given-names></name>
<name><surname>Loder</surname><given-names>Elizabeth W</given-names></name>
<name><surname>Mayo-Wilson</surname><given-names>Evan</given-names></name>
<name><surname>McDonald</surname><given-names>Steve</given-names></name>
<name><surname>McGuinness</surname><given-names>Luke A</given-names></name>
<name><surname>Stewart</surname><given-names>Lesley A</given-names></name>
<name><surname>Thomas</surname><given-names>James</given-names></name>
<name><surname>Tricco</surname><given-names>Andrea C</given-names></name>
<name><surname>Welch</surname><given-names>Vivian A</given-names></name>
<name><surname>Whiting</surname><given-names>Penny</given-names></name>
<name><surname>Moher</surname><given-names>David</given-names></name>
</person-group><date><day>29</day><month>3</month><year>2021</year></date><volume>372</volume><fpage>n71</fpage><issn>1756-1833</issn><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><!--<pub-id pub-id-type="pmcid">PMC8005924</pub-id>--><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274991">
        <element-citation publication-type="book"><article-title>Gender and sex disparity in cancer trials</article-title><source>ESMO Open</source><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>Eudocia</given-names></name>
<name><surname>Wen</surname><given-names>Patrick</given-names></name>
</person-group><publisher-name>Elsevier BV</publisher-name><date><year>2020</year></date><volume>5</volume><issue>suppl 4</issue><fpage>e000773</fpage><issn>2059-7029</issn><pub-id pub-id-type="doi">10.1136/esmoopen-2020-000773</pub-id><!--<pub-id pub-id-type="pmcid">PMC7440710</pub-id>--><pub-id pub-id-type="doi">10.1136/esmoopen-2020-000773</pub-id><pub-id pub-id-type="pmid">32816862</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274992">
        <element-citation publication-type="journal"><article-title>Examining the use of real-world evidence in the regulatory process</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><person-group person-group-type="author">
<name><surname>Beaulieu-Jones</surname><given-names>Brett K.</given-names></name>
<name><surname>Finlayson</surname><given-names>Samuel G.</given-names></name>
<name><surname>Yuan</surname><given-names>William</given-names></name>
<name><surname>Altman</surname><given-names>Russ B.</given-names></name>
<name><surname>Kohane</surname><given-names>Isaac S.</given-names></name>
<name><surname>Prasad</surname><given-names>Vinay</given-names></name>
<name><surname>Yu</surname><given-names>Kun-Hsing</given-names></name>
</person-group><date><year>2020</year></date><volume>107</volume><issue>4</issue><fpage>843</fpage><lpage>852</lpage><issn>0009-9236</issn><pub-id pub-id-type="doi">10.1002/cpt.1658</pub-id><!--<pub-id pub-id-type="pmcid">PMC7093234</pub-id>--><pub-id pub-id-type="doi">10.1002/cpt.1658</pub-id><pub-id pub-id-type="pmid">31562770</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274993">
        <element-citation publication-type="book">
          <article-title>Medication adherence</article-title>
          <source>Circulation</source>
          <person-group person-group-type="author">
<name><surname>Ho</surname><given-names>P. Michael</given-names></name>
<name><surname>Bryson</surname><given-names>Chris L.</given-names></name>
<name><surname>Rumsfeld</surname><given-names>John S.</given-names></name>
</person-group>
          <publisher-name>Ovid Technologies (Wolters Kluwer Health)</publisher-name>
          <date>
            <day>16</day>
            <month>6</month>
            <year>2009</year>
          </date>
          <volume>119</volume>
          <issue>23</issue>
          <fpage>3028</fpage>
          <lpage>3035</lpage>
          <issn>0009-7322</issn>
          <pub-id pub-id-type="doi">10.1161/circulationaha.108.768986</pub-id>
          <pub-id pub-id-type="doi">10.1161/circulationaha.108.768986</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-274994">
        <element-citation publication-type="journal"><article-title>A systematic review of medication adherence thresholds dependent of clinical outcomes</article-title><source>Frontiers in Pharmacology</source><person-group person-group-type="author">
<name><surname>Baumgartner</surname><given-names>Pascal C.</given-names></name>
<name><surname>Haynes</surname><given-names>R. Brian</given-names></name>
<name><surname>Hersberger</surname><given-names>Kurt E.</given-names></name>
<name><surname>Arnet</surname><given-names>Isabelle</given-names></name>
</person-group><date><day>20</day><month>11</month><year>2018</year></date><volume>9</volume><fpage>1290</fpage><issn>1663-9812</issn><pub-id pub-id-type="doi">10.3389/fphar.2018.01290</pub-id><!--<pub-id pub-id-type="pmcid">PMC6256123</pub-id>--><pub-id pub-id-type="doi">10.3389/fphar.2018.01290</pub-id><pub-id pub-id-type="pmid">30524276</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274995">
        <element-citation publication-type="journal"><article-title>Proportion of days covered as a measure of medication adherence</article-title><source>American Journal of Health-System Pharmacy</source><person-group person-group-type="author">
<name><surname>Loucks</surname><given-names>Jennifer</given-names></name>
<name><surname>Zuckerman</surname><given-names>Autumn D</given-names></name>
<name><surname>Berni</surname><given-names>Angelica</given-names></name>
<name><surname>Saulles</surname><given-names>Adam</given-names></name>
<name><surname>Thomas</surname><given-names>Gosia</given-names></name>
<name><surname>Alonzo</surname><given-names>Amy</given-names></name>
</person-group><date><year>2022</year></date><volume>79</volume><issue>6</issue><fpage>492</fpage><lpage>496</lpage><issn>1079-2082</issn><pub-id pub-id-type="doi">10.1093/ajhp/zxab392</pub-id><pub-id pub-id-type="doi">10.1093/ajhp/zxab392</pub-id><pub-id pub-id-type="pmid">34637496</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274996">
        <element-citation publication-type="journal">
          <article-title>Medication compliance and persistence: terminology and definitions</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Cramer</surname><given-names>Joyce A.</given-names></name>
<name><surname>Roy</surname><given-names>Anuja</given-names></name>
<name><surname>Burrell</surname><given-names>Anita</given-names></name>
<name><surname>Fairchild</surname><given-names>Carol J.</given-names></name>
<name><surname>Fuldeore</surname><given-names>Mahesh J.</given-names></name>
<name><surname>Ollendorf</surname><given-names>Daniel A.</given-names></name>
<name><surname>Wong</surname><given-names>Peter K.</given-names></name>
</person-group>
          <date>
            <month>1</month>
            <year>2008</year>
          </date>
          <volume>11</volume>
          <issue>1</issue>
          <fpage>44</fpage>
          <lpage>47</lpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1111/j.1524-4733.2007.00213.x</pub-id>
          <pub-id pub-id-type="doi">10.1111/j.1524-4733.2007.00213.x</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-274997">
        <element-citation publication-type="journal"><article-title>Open-label randomized non-inferiority trial of a fixed-dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin</article-title><source>Diabetic Medicine</source><person-group person-group-type="author">
<name><surname>Ambery</surname><given-names>P.</given-names></name>
<name><surname>Stylianou</surname><given-names>A.</given-names></name>
<name><surname>Atkinson</surname><given-names>G.</given-names></name>
<name><surname>Dott</surname><given-names>C.</given-names></name>
<name><surname>Baylor Curtis</surname><given-names>L.</given-names></name>
<name><surname>Haque</surname><given-names>N.</given-names></name>
<name><surname>LaCroix</surname><given-names>K.</given-names></name>
<name><surname>Min</surname><given-names>K. W.</given-names></name>
<collab>on behalf of the Glimepiride/Atorvastatin Investigational Team</collab>
</person-group><date><year>2016</year></date><volume>33</volume><issue>8</issue><fpage>1084</fpage><lpage>1093</lpage><issn>0742-3071</issn><pub-id pub-id-type="doi">10.1111/dme.13003</pub-id><pub-id pub-id-type="doi">10.1111/dme.13003</pub-id><pub-id pub-id-type="pmid">26484794</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274998">
        <element-citation publication-type="journal"><article-title>Efficacy and safety of &#x2018;fixed dose&#x2019; versus &#x2018;loose&#x2019; drug regimens for treatment of pulmonary tuberculosis in two high TB-burden African countries: a randomized controlled trial</article-title><source>PloS One</source><person-group person-group-type="author">
<name><surname>Aseffa</surname><given-names>Abraham</given-names></name>
<name><surname>Chukwu</surname><given-names>Joseph N.</given-names></name>
<name><surname>Vahedi</surname><given-names>Mahnaz</given-names></name>
<name><surname>Aguwa</surname><given-names>Emmanuel N.</given-names></name>
<name><surname>Bedru</surname><given-names>Ahmed</given-names></name>
<name><surname>Mebrahtu</surname><given-names>Tesfamariam</given-names></name>
<name><surname>Ezechi</surname><given-names>Oliver C.</given-names></name>
<name><surname>Yimer</surname><given-names>Getnet</given-names></name>
<name><surname>Yamuah</surname><given-names>Lawrence K.</given-names></name>
<name><surname>Medhin</surname><given-names>Girmay</given-names></name>
<name><surname>Connolly</surname><given-names>Cathy</given-names></name>
<name><surname>Rida</surname><given-names>Wasima</given-names></name>
<name><surname>Aderaye</surname><given-names>Getachew</given-names></name>
<name><surname>Zumla</surname><given-names>Alimuddin I.</given-names></name>
<name><surname>Onyebujoh</surname><given-names>Philip C.</given-names></name>
<collab>4FDC Study Group</collab>
</person-group><date><day>20</day><month>6</month><year>2016</year></date><volume>11</volume><issue>6</issue><fpage>e0157434</fpage><issn>1932-6203</issn><pub-id pub-id-type="doi">10.1371/journal.pone.0157434</pub-id><!--<pub-id pub-id-type="pmcid">PMC4913909</pub-id>--><pub-id pub-id-type="doi">10.1371/journal.pone.0157434</pub-id><pub-id pub-id-type="pmid">27322164</pub-id>
</element-citation>
      </ref>
      <ref id="ref-274999">
        <element-citation publication-type="journal">
          <article-title>An open label randomized comparison of mefloquine&#x2013;artesunate as separate tablets <italic toggle="yes">vs.</italic> a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand</article-title>
          <source>Tropical Medicine &amp; International Health</source>
          <person-group person-group-type="author">
<name><surname>Ashley</surname><given-names>Elizabeth A.</given-names></name>
<name><surname>Lwin</surname><given-names>Khin Maung</given-names></name>
<name><surname>McGready</surname><given-names>Rose</given-names></name>
<name><surname>Simon</surname><given-names>Win Htay</given-names></name>
<name><surname>Phaiphun</surname><given-names>Lucy</given-names></name>
<name><surname>Proux</surname><given-names>Stephane</given-names></name>
<name><surname>Wangseang</surname><given-names>Nantawan</given-names></name>
<name><surname>Taylor</surname><given-names>Walter</given-names></name>
<name><surname>Stepniewska</surname><given-names>Kasia</given-names></name>
<name><surname>Nawamaneerat</surname><given-names>Wimon</given-names></name>
<name><surname>Thwai</surname><given-names>Kyaw Lay</given-names></name>
<name><surname>Barends</surname><given-names>Marion</given-names></name>
<name><surname>Leowattana</surname><given-names>Wattana</given-names></name>
<name><surname>Olliaro</surname><given-names>Piero</given-names></name>
<name><surname>Singhasivanon</surname><given-names>Pratap</given-names></name>
<name><surname>White</surname><given-names>Nicholas J.</given-names></name>
<name><surname>Nosten</surname><given-names>Fran&#xE7;ois</given-names></name>
</person-group>
          <date>
            <day>5</day>
            <month>10</month>
            <year>2006</year>
          </date>
          <volume>11</volume>
          <issue>11</issue>
          <fpage>1653</fpage>
          <lpage>1660</lpage>
          <issn>1360-2276</issn>
          <pub-id pub-id-type="doi">10.1111/j.1365-3156.2006.01724.x</pub-id>
          <pub-id pub-id-type="doi">10.1111/j.1365-3156.2006.01724.x</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275000">
        <element-citation publication-type="journal"><article-title>Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial</article-title><source>American Journal of Ophthalmology</source><person-group person-group-type="author">
<name><surname>Barnebey</surname><given-names>Howard S.</given-names></name>
<name><surname>Robin</surname><given-names>Alan L.</given-names></name>
</person-group><date><month>4</month><year>2017</year></date><volume>176</volume><fpage>61</fpage><lpage>69</lpage><issn>0002-9394</issn><pub-id pub-id-type="doi">10.1016/j.ajo.2016.12.002</pub-id><pub-id pub-id-type="doi">10.1016/j.ajo.2016.12.002</pub-id><pub-id pub-id-type="pmid">27993589</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275001">
        <element-citation publication-type="journal"><article-title>Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy</article-title><source>Clinical Therapeutics</source><person-group person-group-type="author">
<name><surname>Barner</surname><given-names>Jamie C.</given-names></name>
</person-group><date><month>9</month><year>2011</year></date><volume>33</volume><issue>9</issue><fpage>1281</fpage><lpage>1288</lpage><issn>0149-2918</issn><pub-id pub-id-type="doi">10.1016/j.clinthera.2011.07.016</pub-id><pub-id pub-id-type="doi">10.1016/j.clinthera.2011.07.016</pub-id><pub-id pub-id-type="pmid">21840054</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275002">
        <element-citation publication-type="journal"><article-title>Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis</article-title><source>Int J Tuberc Lung Dis</source><person-group person-group-type="author">
<name><surname>Bartacek</surname><given-names>A.</given-names></name>
<name><surname>Sch&#xFC;tt</surname><given-names>D.</given-names></name>
<name><surname>Panosch</surname><given-names>B.</given-names></name>
<name><surname>Borek</surname><given-names>M.</given-names></name>
<collab>Rimstar&#xAE; FDCSG</collab>
</person-group><date><year>2009</year></date><volume>13</volume><issue>6</issue><fpage>760</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">19460254</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275003">
        <element-citation publication-type="journal"><article-title>Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004&#x2013;2008</article-title><source>PLoS One</source><person-group person-group-type="author">
<name><surname>Beck</surname><given-names>Eduard J.</given-names></name>
<name><surname>Mandalia</surname><given-names>Sundhiya</given-names></name>
<name><surname>Sangha</surname><given-names>Roshni</given-names></name>
<name><surname>Youle</surname><given-names>Mike</given-names></name>
<name><surname>Brettle</surname><given-names>Ray</given-names></name>
<name><surname>Gompels</surname><given-names>Mark</given-names></name>
<name><surname>Johnson</surname><given-names>Margaret</given-names></name>
<name><surname>Pozniak</surname><given-names>Anton</given-names></name>
<name><surname>Schwenk</surname><given-names>Achim</given-names></name>
<name><surname>Taylor</surname><given-names>Stephen</given-names></name>
<name><surname>Walsh</surname><given-names>John</given-names></name>
<name><surname>Wilkins</surname><given-names>Ed</given-names></name>
<name><surname>Williams</surname><given-names>Ian</given-names></name>
<name><surname>Gazzard</surname><given-names>Brian</given-names></name>
<collab>for the NPMS-HHC Steering Group</collab>
</person-group><date><day>30</day><month>10</month><year>2012</year></date><volume>7</volume><issue>10</issue><fpage>e47376</fpage><issn>1932-6203</issn><pub-id pub-id-type="doi">10.1371/journal.pone.0047376</pub-id><!--<pub-id pub-id-type="pmcid">PMC3484120</pub-id>--><pub-id pub-id-type="doi">10.1371/journal.pone.0047376</pub-id><pub-id pub-id-type="pmid">23118869</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275004">
        <element-citation publication-type="journal"><article-title>Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis</article-title><source>Advances in Therapy</source><person-group person-group-type="author">
<name><surname>Belfort</surname><given-names>Rubens</given-names></name>
<name><surname>Gabriel</surname><given-names>Luis</given-names></name>
<name><surname>Martins Bispo</surname><given-names>Paulo Jos&#xE9;</given-names></name>
<name><surname>Muccioli</surname><given-names>Cristina</given-names></name>
<name><surname>Zacharias Serapicos</surname><given-names>Patricia Cabral</given-names></name>
<name><surname>Clark</surname><given-names>Linda</given-names></name>
<name><surname>Bell</surname><given-names>Belinda</given-names></name>
<name><surname>Bartell</surname><given-names>John</given-names></name>
<name><surname>Stroman</surname><given-names>David W.</given-names></name>
<name><surname>H&#xF6;fling-Lima</surname><given-names>Ana Luisa</given-names></name>
</person-group><date><month>5</month><year>2012</year></date><volume>29</volume><issue>5</issue><fpage>416</fpage><lpage>426</lpage><issn>0741-238X</issn><pub-id pub-id-type="doi">10.1007/s12325-012-0018-8</pub-id><pub-id pub-id-type="doi">10.1007/s12325-012-0018-8</pub-id><pub-id pub-id-type="pmid">22562783</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275005">
        <element-citation publication-type="journal"><article-title>Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension</article-title><source>Clinical Ophthalmology</source><person-group person-group-type="author">
<name><surname>Bhagat</surname><given-names>P</given-names></name>
<name><surname>Sodimalla</surname><given-names>K</given-names></name>
<name><surname>Paul</surname><given-names>C</given-names></name>
<etal/>
</person-group><date><month>6</month><year>2014</year></date><volume>8</volume><fpage>1241</fpage><lpage>1252</lpage><issn>1177-5483</issn><pub-id pub-id-type="doi">10.2147/opth.s64584</pub-id><!--<pub-id pub-id-type="pmcid">PMC4085316</pub-id>--><pub-id pub-id-type="doi">10.2147/opth.s64584</pub-id><pub-id pub-id-type="pmid">25061271</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275006">
        <element-citation publication-type="journal">
          <article-title>Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin</article-title>
          <source>Diabetes, Obesity and Metabolism</source>
          <person-group person-group-type="author">
<name><surname>Blonde</surname><given-names>L.</given-names></name>
<name><surname>Wogen</surname><given-names>J.</given-names></name>
<name><surname>Kreilick</surname><given-names>C.</given-names></name>
<name><surname>Seymour</surname><given-names>A. A.</given-names></name>
</person-group>
          <date>
            <month>11</month>
            <year>2003</year>
          </date>
          <volume>5</volume>
          <issue>6</issue>
          <fpage>424</fpage>
          <lpage>431</lpage>
          <issn>1462-8902</issn>
          <pub-id pub-id-type="doi">10.1046/j.1463-1326.2003.00297.x</pub-id>
          <pub-id pub-id-type="doi">10.1046/j.1463-1326.2003.00297.x</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275007">
        <element-citation publication-type="journal"><article-title>Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler</article-title><source>Respiratory Medicine</source><person-group person-group-type="author">
<name><surname>Bodzenta-Lukaszyk</surname><given-names>Anna</given-names></name>
<name><surname>Pulka</surname><given-names>Gra&#x17C;yna</given-names></name>
<name><surname>Dymek</surname><given-names>Andrzej</given-names></name>
<name><surname>Bumbacea</surname><given-names>Dragos</given-names></name>
<name><surname>McIver</surname><given-names>Tammy</given-names></name>
<name><surname>Schwab</surname><given-names>Birgit</given-names></name>
<name><surname>Mansikka</surname><given-names>Heikki</given-names></name>
</person-group><date><month>5</month><year>2011</year></date><volume>105</volume><issue>5</issue><fpage>674</fpage><lpage>682</lpage><issn>0954-6111</issn><pub-id pub-id-type="doi">10.1016/j.rmed.2010.11.011</pub-id><pub-id pub-id-type="doi">10.1016/j.rmed.2010.11.011</pub-id><pub-id pub-id-type="pmid">21196104</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275008">
        <element-citation publication-type="journal"><article-title>Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes</article-title><source>PLoS One</source><person-group person-group-type="author">
<name><surname>B&#xF6;hm</surname><given-names>Anna-Katharina</given-names></name>
<name><surname>Schneider</surname><given-names>Udo</given-names></name>
<name><surname>Aberle</surname><given-names>Jens</given-names></name>
<name><surname>Stargardt</surname><given-names>Tom</given-names></name>
</person-group><date><day>4</day><month>5</month><year>2021</year></date><volume>16</volume><issue>5</issue><fpage>e0250993</fpage><issn>1932-6203</issn><pub-id pub-id-type="doi">10.1371/journal.pone.0250993</pub-id><!--<pub-id pub-id-type="pmcid">PMC8096115</pub-id>--><pub-id pub-id-type="doi">10.1371/journal.pone.0250993</pub-id><pub-id pub-id-type="pmid">33945556</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275009">
        <element-citation publication-type="journal"><article-title>The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease</article-title><source>Clinical Nephrology</source><person-group person-group-type="author">
<name><surname>Bosworth</surname><given-names>Cortney</given-names></name>
<name><surname>de Boer</surname><given-names>Ian H.</given-names></name>
<name><surname>Targher</surname><given-names>Giovanni</given-names></name>
<name><surname>Kendrick</surname><given-names>Jessica</given-names></name>
<name><surname>Smits</surname><given-names>Gerard</given-names></name>
<name><surname>Chonchol</surname><given-names>Michel</given-names></name>
</person-group><date><day>1</day><month>5</month><year>2012</year></date><volume>77</volume><issue>5</issue><fpage>358</fpage><lpage>365</lpage><issn>0301-0430</issn><pub-id pub-id-type="doi">10.5414/cn107180</pub-id><!--<pub-id pub-id-type="pmcid">PMC4030712</pub-id>--><pub-id pub-id-type="doi">10.5414/cn107180</pub-id><pub-id pub-id-type="pmid">22551881</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275010">
        <element-citation publication-type="journal"><article-title>Fixed-dose vs free-dose combinations for the management of hypertension&#x2014;an analysis of 81&#xA0;958 patients</article-title><source>The Journal of Clinical Hypertension</source><person-group person-group-type="author">
<name><surname>Bramlage</surname><given-names>Peter</given-names></name>
<name><surname>Schmidt</surname><given-names>Stefanie</given-names></name>
<name><surname>Sims</surname><given-names>Helen</given-names></name>
</person-group><date><day>19</day><month>2</month><year>2018</year></date><volume>20</volume><issue>4</issue><fpage>705</fpage><lpage>715</lpage><issn>1524-6175</issn><pub-id pub-id-type="doi">10.1111/jch.13240</pub-id><!--<pub-id pub-id-type="pmcid">PMC8031114</pub-id>--><pub-id pub-id-type="doi">10.1111/jch.13240</pub-id><pub-id pub-id-type="pmid">29457348</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275011">
        <element-citation publication-type="journal">
          <article-title>Safety and efficacy of indapamide sustained release/amlodipine fixed-dose combination in essential hypertension</article-title>
          <source>Journal of Hypertension</source>
          <person-group person-group-type="author">
<name><surname>Bricout-Hennel</surname><given-names>S.</given-names></name>
<name><surname>Zelveian</surname><given-names>P.</given-names></name>
<name><surname>Nedogoda</surname><given-names>S.</given-names></name>
</person-group>
          <date>
            <month>6</month>
            <year>2018</year>
          </date>
          <volume>36</volume>
          <issue>suppl 1</issue>
          <fpage>e45</fpage>
          <issn>0263-6352</issn>
          <pub-id pub-id-type="doi">10.1097/01.hjh.0000539081.92227.69</pub-id>
          <pub-id pub-id-type="doi">10.1097/01.hjh.0000539081.92227.69</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275012">
        <element-citation publication-type="journal"><article-title>Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations</article-title><source>Current Medical Research and Opinion</source><person-group person-group-type="author">
<name><surname>Brixner</surname><given-names>Diana I.</given-names></name>
<name><surname>Jackson</surname><given-names>Kenneth C., II</given-names></name>
<name><surname>Sheng</surname><given-names>Xiaoming</given-names></name>
<name><surname>Nelson</surname><given-names>Richard E.</given-names></name>
<name><surname>Keskinaslan</surname><given-names>Abdulkadir</given-names></name>
</person-group><date><day>6</day><month>8</month><year>2008</year></date><volume>24</volume><issue>9</issue><fpage>2597</fpage><lpage>2607</lpage><issn>0300-7995</issn><pub-id pub-id-type="doi">10.1185/03007990802319364</pub-id><pub-id pub-id-type="doi">10.1185/03007990802319364</pub-id><pub-id pub-id-type="pmid">18812017</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275013">
        <element-citation publication-type="book"><article-title>Economic evaluation of BDP/formoterol fixed <italic toggle="yes">vs</italic> two single inhalers in asthma treatment</article-title><source>Allergy</source><person-group person-group-type="author">
<name><surname>Br&#xFC;ggenj&#xFC;rgen</surname><given-names>B.</given-names></name>
<name><surname>Ezzat</surname><given-names>N.</given-names></name>
<name><surname>Kardos</surname><given-names>P.</given-names></name>
<name><surname>Buhl</surname><given-names>R.</given-names></name>
</person-group><publisher-name>Wiley</publisher-name><date><day>4</day><month>8</month><year>2010</year></date><volume>65</volume><issue>9</issue><fpage>1108</fpage><lpage>1115</lpage><issn>0105-4538</issn><pub-id pub-id-type="doi">10.1111/j.1398-9995.2009.02317.x</pub-id><pub-id pub-id-type="doi">10.1111/j.1398-9995.2009.02317.x</pub-id><pub-id pub-id-type="pmid">20121768</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275014">
        <element-citation publication-type="journal"><article-title>Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK</article-title><source>Clinical Ophthalmology</source><person-group person-group-type="author">
<name><surname>Campos</surname><given-names>M</given-names></name>
<name><surname>Muccioli</surname><given-names>C</given-names></name>
<name><surname>Malta</surname><given-names>J B N S</given-names></name>
<name><surname>Gerade</surname><given-names>R A</given-names></name>
<name><surname>la Salame</surname><given-names>A</given-names></name>
<name><surname>Belfort</surname><given-names>R., Jr.</given-names></name>
</person-group><date><month>2</month><year>2011</year></date><volume>5</volume><issue>1</issue><fpage>209</fpage><lpage>214</lpage><issn>1177-5483</issn><pub-id pub-id-type="doi">10.2147/opth.s17059</pub-id><!--<pub-id pub-id-type="pmcid">PMC3046990</pub-id>--><pub-id pub-id-type="doi">10.2147/opth.s17059</pub-id><pub-id pub-id-type="pmid">21386913</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275015">
        <element-citation publication-type="journal">
          <article-title>A polypill strategy to improve adherence: results from the FOCUS project</article-title>
          <source>Journal of the American College of Cardiology</source>
          <person-group person-group-type="author">
<name><surname>Castellano</surname><given-names>Jos&#xE9; M.</given-names></name>
<name><surname>Sanz</surname><given-names>Gin&#xE9;s</given-names></name>
<name><surname>Pe&#xF1;alvo</surname><given-names>Jos&#xE9; L.</given-names></name>
<name><surname>Bansilal</surname><given-names>Sameer</given-names></name>
<name><surname>Fern&#xE1;ndez-Ortiz</surname><given-names>Antonio</given-names></name>
<name><surname>Alvarez</surname><given-names>Luz</given-names></name>
<name><surname>Guzm&#xE1;n</surname><given-names>Luis</given-names></name>
<name><surname>Linares</surname><given-names>Juan Carlos</given-names></name>
<name><surname>Garc&#xED;a</surname><given-names>Fernando</given-names></name>
<name><surname>D&#x2019;Aniello</surname><given-names>Fabiana</given-names></name>
<name><surname>Arn&#xE1;iz</surname><given-names>Joan Albert</given-names></name>
<name><surname>Varea</surname><given-names>Sara</given-names></name>
<name><surname>Mart&#xED;nez</surname><given-names>Felipe</given-names></name>
<name><surname>Lorenzatti</surname><given-names>Alberto</given-names></name>
<name><surname>Imaz</surname><given-names>I&#xF1;aki</given-names></name>
<name><surname>S&#xE1;nchez-G&#xF3;mez</surname><given-names>Luis M.</given-names></name>
<name><surname>Roncaglioni</surname><given-names>Maria Carla</given-names></name>
<name><surname>Baviera</surname><given-names>Marta</given-names></name>
<name><surname>Smith</surname><given-names>Sidney C. Jr.</given-names></name>
<name><surname>Taubert</surname><given-names>Kathryn</given-names></name>
<name><surname>Pocock</surname><given-names>Stuart</given-names></name>
<name><surname>Brotons</surname><given-names>Carlos</given-names></name>
<name><surname>Farkouh</surname><given-names>Michael E.</given-names></name>
<name><surname>Fuster</surname><given-names>Valentin</given-names></name>
</person-group>
          <date>
            <month>11</month>
            <year>2014</year>
          </date>
          <volume>64</volume>
          <issue>20</issue>
          <fpage>2071</fpage>
          <lpage>2082</lpage>
          <issn>0735-1097</issn>
          <pub-id pub-id-type="doi">10.1016/j.jacc.2014.08.021</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jacc.2014.08.021</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275016">
        <element-citation publication-type="journal">
          <article-title>Health care utilization and cost comparison between adherent hypertension patients treated by single exforge HCT and amlodipine/valsartan/hydrochlorothiazide free combination</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W</given-names></name>
<name><surname>Wei</surname><given-names>Z</given-names></name>
<name><surname>Ong</surname><given-names>S H</given-names></name>
<name><surname>Machnicki</surname><given-names>G</given-names></name>
<name><surname>Kristijan</surname><given-names>K</given-names></name>
</person-group>
          <date>
            <month>11</month>
            <year>2014</year>
          </date>
          <volume>17</volume>
          <issue>7</issue>
          <fpage>A723</fpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1016/j.jval.2014.08.036</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jval.2014.08.036</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275017">
        <element-citation publication-type="journal">
          <article-title>Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients</article-title>
          <source>Clinical Therapeutics</source>
          <person-group person-group-type="author">
<name><surname>Cheong</surname><given-names>Chelim</given-names></name>
<name><surname>Barner</surname><given-names>Jamie C.</given-names></name>
<name><surname>Lawson</surname><given-names>Kenneth A.</given-names></name>
<name><surname>Johnsrud</surname><given-names>Michael T.</given-names></name>
</person-group>
          <date>
            <month>10</month>
            <year>2008</year>
          </date>
          <volume>30</volume>
          <issue>10</issue>
          <fpage>1893</fpage>
          <lpage>1907</lpage>
          <issn>0149-2918</issn>
          <pub-id pub-id-type="doi">10.1016/j.clinthera.2008.10.003</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.clinthera.2008.10.003</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275018">
        <element-citation publication-type="book">
          <article-title>Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study</article-title>
          <source>Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</source>
          <person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>Calvin J.</given-names></name>
<name><surname>Kubota</surname><given-names>Marshall</given-names></name>
<name><surname>Brachman</surname><given-names>Philip S.</given-names></name>
<name><surname>Harley</surname><given-names>William B.</given-names></name>
<name><surname>Schneider</surname><given-names>Stefan</given-names></name>
<name><surname>Williams</surname><given-names>Vanessa C.</given-names></name>
<name><surname>Sutherland-Phillips</surname><given-names>Denise H.</given-names></name>
<name><surname>Lim</surname><given-names>Michael L.</given-names></name>
<name><surname>Balu</surname><given-names>Rukmini B.</given-names></name>
<name><surname>Shaefer</surname><given-names>Mark S.</given-names></name>
</person-group>
          <publisher-name>Wiley</publisher-name>
          <date>
            <month>3</month>
            <year>2008</year>
          </date>
          <volume>28</volume>
          <issue>3</issue>
          <fpage>314</fpage>
          <lpage>322</lpage>
          <issn>0277-0008</issn>
          <pub-id pub-id-type="doi">10.1592/phco.28.3.314</pub-id>
          <pub-id pub-id-type="doi">10.1592/phco.28.3.314</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275019">
        <element-citation publication-type="journal"><article-title>Benefits of a fixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients</article-title><source>Current Medical Research and Opinion</source><person-group person-group-type="author">
<name><surname>Czarnecka</surname><given-names>D.</given-names></name>
<name><surname>Koch</surname><given-names>E.M.W.</given-names></name>
<name><surname>Gottwald-Hostalek</surname><given-names>U.</given-names></name>
</person-group><date><day>8</day><month>4</month><year>2015</year></date><volume>31</volume><issue>5</issue><fpage>875</fpage><lpage>881</lpage><issn>0300-7995</issn><pub-id pub-id-type="doi">10.1185/03007995.2015.1027676</pub-id><pub-id pub-id-type="doi">10.1185/03007995.2015.1027676</pub-id><pub-id pub-id-type="pmid">25753136</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275020">
        <element-citation publication-type="book"><article-title>Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components</article-title><source>Clinics</source><person-group person-group-type="author">
<name><surname>da Cunha</surname><given-names>Patr&#xED;cia Abreu Ferreira</given-names></name>
<name><surname>Shinzato</surname><given-names>Flavio Araujo</given-names></name>
<name><surname>Tecchio</surname><given-names>Geraldine Trevisan</given-names></name>
<name><surname>La Porta Weber</surname><given-names>Sarah</given-names></name>
<name><surname>Brasil</surname><given-names>Alexandre</given-names></name>
<name><surname>Avakian</surname><given-names>Amaryllis</given-names></name>
</person-group><publisher-name>Elsevier BV</publisher-name><date><month>6</month><year>2013</year></date><volume>68</volume><issue>6</issue><fpage>834</fpage><lpage>839</lpage><issn>1807-5932</issn><pub-id pub-id-type="doi">10.6061/clinics/2013(06)18</pub-id><!--<pub-id pub-id-type="pmcid">PMC3674263</pub-id>--><pub-id pub-id-type="doi">10.6061/clinics/2013(06)18</pub-id><pub-id pub-id-type="pmid">23778476</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275021">
        <element-citation publication-type="journal"><article-title>Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study</article-title><source>Eur Resp J</source><person-group person-group-type="author">
<name><surname>Dahl</surname><given-names>Ronald</given-names></name>
<name><surname>Jadayel</surname><given-names>Dalal</given-names></name>
<name><surname>Alagappan</surname><given-names>Vijay</given-names></name>
<name><surname>Chen</surname><given-names>Hungta</given-names></name>
<name><surname>Banerji</surname><given-names>D</given-names></name>
</person-group><date><year>2013</year></date><volume>42</volume><!--<pub-id pub-id-type="pmcid">PMC3805248</pub-id>--><pub-id pub-id-type="pmid">24159259</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275022">
        <element-citation publication-type="journal"><article-title>Efficacy and safety of once-daily QVA149 compared with the free combination of its monocomponents: The Beacon Study</article-title><source>Chest</source><person-group person-group-type="author">
<name><surname>Dahl</surname><given-names>Ronald</given-names></name>
<name><surname>Jadayel</surname><given-names>Dalal</given-names></name>
<name><surname>Alagappan</surname><given-names>Vijay</given-names></name>
<name><surname>Chen</surname><given-names>Hungta</given-names></name>
<name><surname>Banerji</surname><given-names>Donald</given-names></name>
</person-group><date><month>3</month><year>2014</year></date><volume>145</volume><issue>3 MEETING ABSTRACT</issue><fpage>407A</fpage><issn>0012-3692</issn><pub-id pub-id-type="doi">10.1378/chest.1824459</pub-id><pub-id pub-id-type="doi">10.1378/chest.1824459</pub-id><pub-id pub-id-type="pmid">24493514</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275023">
        <element-citation publication-type="journal"><article-title>Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Erratum in: Int J Chron Obstruct Pulmon Dis. 2014;9:85 Note: MEDLINE/PubMed abstract corrected; Dosage error in article text.]</article-title><source>International Journal of Chronic Obstructive Pulmonary Disease</source><person-group person-group-type="author">
<name><surname>Dahl</surname><given-names>Ronald</given-names></name>
<name><surname>Jadayel</surname><given-names>Dalal</given-names></name>
<name><surname>Alagappan</surname><given-names>Vijay</given-names></name>
<name><surname>Chen</surname><given-names>Hungta</given-names></name>
<name><surname>Banerji</surname><given-names>D</given-names></name>
</person-group><date><month>10</month><year>2013</year></date><volume>8</volume><fpage>501</fpage><lpage>518</lpage><issn>1178-2005</issn><pub-id pub-id-type="doi">10.2147/copd.s49615</pub-id><!--<pub-id pub-id-type="pmcid">PMC3805248</pub-id>--><pub-id pub-id-type="doi">10.2147/copd.s49615</pub-id><pub-id pub-id-type="pmid">24159259</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275024">
        <element-citation publication-type="journal">
          <article-title>Modifications in drug adherence after switch to fixed-dose combination of perindopril/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlodipine-perindopril in real settings (AMPERES) study</article-title>
          <source>Current Medical Research and Opinion</source>
          <person-group person-group-type="author">
<name><surname>Degli Esposti</surname><given-names>Luca</given-names></name>
<name><surname>Perrone</surname><given-names>Valentina</given-names></name>
<name><surname>Veronesi</surname><given-names>Chiara</given-names></name>
<name><surname>Gambera</surname><given-names>Marco</given-names></name>
<name><surname>Nati</surname><given-names>Giulio</given-names></name>
<name><surname>Perone</surname><given-names>Francesco</given-names></name>
<name><surname>Tagliabue</surname><given-names>Paola Fausta</given-names></name>
<name><surname>Buda</surname><given-names>Stefano</given-names></name>
<name><surname>Borghi</surname><given-names>Claudio</given-names></name>
</person-group>
          <date>
            <day>22</day>
            <month>2</month>
            <year>2018</year>
          </date>
          <volume>34</volume>
          <issue>9</issue>
          <fpage>1571</fpage>
          <lpage>1577</lpage>
          <issn>0300-7995</issn>
          <pub-id pub-id-type="doi">10.1080/03007995.2018.1433648</pub-id>
          <pub-id pub-id-type="doi">10.1080/03007995.2018.1433648</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275025">
        <element-citation publication-type="journal">
          <article-title>Add-on Therapy with rosiglitazone (RSG)/metformin (MET) as a fixed-dose combination (FDC) vs RSG plus MET or RSG plus sulfonylurea (SU) as separate pills (SP): retrospective study of outcomes and costs</article-title>
          <source>Diabetes</source>
          <person-group person-group-type="author">
<name><surname>Delea</surname><given-names>T.E.</given-names></name>
<name><surname>Arondekar</surname><given-names>B.</given-names></name>
<name><surname>Kartashov</surname><given-names>A.</given-names></name>
</person-group>
          <date>
            <year>2007</year>
          </date>
          <volume>56</volume>
          <issue>suppl 1</issue>
          <fpage>2200</fpage>
          <lpage>P0</lpage>
        </element-citation>
      </ref>
      <ref id="ref-275026">
        <element-citation publication-type="journal"><article-title>Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson&#x2019;s disease</article-title><source>Current Medical Research and Opinion</source><person-group person-group-type="author">
<name><surname>Delea</surname><given-names>Thomas E.</given-names></name>
<name><surname>Thomas</surname><given-names>Simu K.</given-names></name>
<name><surname>Hagiwara</surname><given-names>May</given-names></name>
<name><surname>Mancione</surname><given-names>L.</given-names></name>
</person-group><date><day>30</day><month>4</month><year>2010</year></date><volume>26</volume><issue>7</issue><fpage>1543</fpage><lpage>1552</lpage><issn>0300-7995</issn><pub-id pub-id-type="doi">10.1185/03007991003780628</pub-id><pub-id pub-id-type="doi">10.1185/03007991003780628</pub-id><pub-id pub-id-type="pmid">20429819</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275027">
        <element-citation publication-type="journal">
          <article-title>A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components</article-title>
          <source>Ophthalmology</source>
          <person-group person-group-type="author">
<name><surname>Diestelhorst</surname><given-names>Michael</given-names></name>
<name><surname>Larsson</surname><given-names>Lill-Inger</given-names></name>
<collab>European-Canadian Latanoprost Fixed Combination Study Group</collab>
</person-group>
          <date>
            <month>1</month>
            <year>2006</year>
          </date>
          <volume>113</volume>
          <issue>1</issue>
          <fpage>70</fpage>
          <lpage>76</lpage>
          <issn>0161-6420</issn>
          <pub-id pub-id-type="doi">10.1016/j.ophtha.2005.06.027</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.ophtha.2005.06.027</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275028">
        <element-citation publication-type="journal"><article-title>Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets</article-title><source>Journal of Managed Care Pharmacy</source><person-group person-group-type="author">
<name><surname>Duckworth</surname><given-names>Wiliam</given-names></name>
</person-group><date><month>5</month><year>2003</year></date><volume>9</volume><issue>3</issue><fpage>256</fpage><lpage>262</lpage><issn>1083-4087</issn><pub-id pub-id-type="doi">10.18553/jmcp.2003.9.3.256</pub-id><!--<pub-id pub-id-type="pmcid">PMC10437279</pub-id>--><pub-id pub-id-type="doi">10.18553/jmcp.2003.9.3.256</pub-id><pub-id pub-id-type="pmid">14613469</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275029">
        <element-citation publication-type="journal">
          <article-title>PCV104 persistence in hypertension treatment with olmesartan medoxomil versus valsartan - analysis of real-life prescription data in Germany</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Ehlken</surname><given-names>B.</given-names></name>
<name><surname>Kostev</surname><given-names>K.</given-names></name>
<name><surname>Breitscheidel</surname><given-names>L.</given-names></name>
<name><surname>Sandberg</surname><given-names>A.</given-names></name>
<name><surname>Holz</surname><given-names>B.</given-names></name>
<name><surname>Oberdiek</surname><given-names>A.M.</given-names></name>
</person-group>
          <date>
            <month>11</month>
            <year>2011</year>
          </date>
          <volume>14</volume>
          <issue>7</issue>
          <fpage>A383</fpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1016/j.jval.2011.08.824</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jval.2011.08.824</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275030">
        <element-citation publication-type="journal">
          <article-title>Calcium channel blocker and angiotensin-converting enzyme (ACE) inhibitor antihypertensive regimen: comparing fixed vs. free combination therapy</article-title>
          <source>High Blood Pressure &amp; Cardiovascular Prevention</source>
          <person-group person-group-type="author">
<name><surname>Finelli</surname><given-names>R</given-names></name>
<name><surname>Pascale</surname><given-names>A V</given-names></name>
<name><surname>Battimelli</surname><given-names>A</given-names></name>
<etal/>
</person-group>
          <date>
            <day>9</day>
            <month>10</month>
            <year>2014</year>
          </date>
          <volume>21</volume>
          <issue>4</issue>
          <fpage>333</fpage>
          <lpage>334</lpage>
          <issn>1120-9879</issn>
          <pub-id pub-id-type="doi">10.1007/s40292-014-0066-z</pub-id>
          <pub-id pub-id-type="doi">10.1007/s40292-014-0066-z</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275031">
        <element-citation publication-type="journal"><article-title>Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol -- a randomized controlled trial and a replacement study</article-title><source>Journal of Clinical Pharmacy and Therapeutics</source><person-group person-group-type="author">
<name><surname>Francis</surname><given-names>B. A.</given-names></name>
<name><surname>Du</surname><given-names>L. T.</given-names></name>
<name><surname>Berke</surname><given-names>S.</given-names></name>
<name><surname>Ehrenhaus</surname><given-names>M.</given-names></name>
<name><surname>Minckler</surname><given-names>D. S.</given-names></name>
<collab>Cosopt Study G</collab>
</person-group><date><month>8</month><year>2004</year></date><volume>29</volume><issue>4</issue><fpage>375</fpage><lpage>380</lpage><issn>0269-4727</issn><pub-id pub-id-type="doi">10.1111/j.1365-2710.2004.00574.x</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2710.2004.00574.x</pub-id><pub-id pub-id-type="pmid">15271105</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275032">
        <element-citation publication-type="journal">
          <article-title>Cost-effectiveness analysis and budget impact of concor&#xAE; am versus bisoprolol plus amlodipine in systemic arterial hypertension treatment, from the perspective of the Brazilian public health system</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Fujii</surname><given-names>R.K.</given-names></name>
<name><surname>Restrepo</surname><given-names>M.</given-names></name>
<name><surname>Fernandes</surname><given-names>R.A.</given-names></name>
<name><surname>Haas</surname><given-names>L.</given-names></name>
<name><surname>Pepe</surname><given-names>C.</given-names></name>
<name><surname>Junqueira</surname><given-names>M.</given-names></name>
</person-group>
          <date>
            <month>5</month>
            <year>2015</year>
          </date>
          <volume>18</volume>
          <issue>3</issue>
          <fpage>A138</fpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1016/j.jval.2015.03.801</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jval.2015.03.801</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275033">
        <element-citation publication-type="journal">
          <article-title>Compliance and acceptance of fixed-dose combination of bisoprolol and aspirin. Open-label multicenter study</article-title>
          <source>Journal of Hypertension</source>
          <person-group person-group-type="author">
<name><surname>Gaciong</surname><given-names>Z.</given-names></name>
<name><surname>Hostalek</surname><given-names>U.</given-names></name>
<name><surname>Kurzeja</surname><given-names>A.</given-names></name>
</person-group>
          <date>
            <month>9</month>
            <year>2017</year>
          </date>
          <volume>35</volume>
          <issue>[LB.03.16]</issue>
          <fpage>e340</fpage>
          <lpage>e341</lpage>
          <issn>0263-6352</issn>
          <pub-id pub-id-type="doi">10.1097/01.hjh.0000524012.97940.f0</pub-id>
          <pub-id pub-id-type="doi">10.1097/01.hjh.0000524012.97940.f0</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275034">
        <element-citation publication-type="journal">
          <article-title>Approaches to increase efficacy of antihypertensive treatment: results of the Russian observational program forsage</article-title>
          <source>Journal of Hypertension</source>
          <person-group person-group-type="author">
<name><surname>Glezer</surname><given-names>M.</given-names></name>
</person-group>
          <date>
            <year>2016</year>
          </date>
          <volume>34</volume>
          <issue>suppl 2</issue>
          <fpage>e297</fpage>
          <lpage>e298</lpage>
          <issn>0263-6352</issn>
          <pub-id pub-id-type="doi">10.1097/01.hjh.0000523870.41484.74</pub-id>
          <pub-id pub-id-type="doi">10.1097/01.hjh.0000523870.41484.74</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275035">
        <element-citation publication-type="journal"><article-title>Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD</article-title><source>Respiratory Medicine</source><person-group person-group-type="author">
<name><surname>Hagedorn</surname><given-names>Cordula</given-names></name>
<name><surname>K&#xE4;ssner</surname><given-names>Frank</given-names></name>
<name><surname>Banik</surname><given-names>Norbert</given-names></name>
<name><surname>Ntampakas</surname><given-names>Paris</given-names></name>
<name><surname>Fielder</surname><given-names>Karin</given-names></name>
</person-group><date><month>4</month><year>2013</year></date><volume>107</volume><issue>4</issue><fpage>542</fpage><lpage>549</lpage><issn>0954-6111</issn><pub-id pub-id-type="doi">10.1016/j.rmed.2012.12.020</pub-id><pub-id pub-id-type="doi">10.1016/j.rmed.2012.12.020</pub-id><pub-id pub-id-type="pmid">23337300</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275036">
        <element-citation publication-type="journal">
          <article-title>Preservative-free tafluprost 00015%/timolol 05% fixed dose combination: a 6-month double-masked, randomized multicenter P-III comparison to concomitant use of the individual preservative-free components in patients with glaucoma or ocular hypertension</article-title>
          <source>2013 Annual Meeting of the Association for Research in Vision and Ophthalmology</source>
          <person-group person-group-type="author">
<name><surname>Hollo</surname><given-names>G.</given-names></name>
<name><surname>Hommer</surname><given-names>A.</given-names></name>
<name><surname>Anton</surname><given-names>A.</given-names></name>
<name><surname>Ropo</surname><given-names>A.</given-names></name>
</person-group>
          <date>
            <year>2014</year>
          </date>
          <volume>54</volume>
          <issue>15</issue>
        </element-citation>
      </ref>
      <ref id="ref-275037">
        <element-citation publication-type="journal"><article-title>Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients</article-title><source>Journal of Ocular Pharmacology and Therapeutics</source><person-group person-group-type="author">
<name><surname>Holl&#xF3;</surname><given-names>G&#xE1;bor</given-names></name>
<name><surname>Hommer</surname><given-names>Anton</given-names></name>
<name><surname>Ant&#xF3;n L&#xF3;pez</surname><given-names>Alfonso</given-names></name>
<name><surname>Ropo</surname><given-names>Auli</given-names></name>
</person-group><date><month>8</month><year>2014</year></date><volume>30</volume><issue>6</issue><fpage>468</fpage><lpage>475</lpage><issn>1080-7683</issn><pub-id pub-id-type="doi">10.1089/jop.2013.0229</pub-id><pub-id pub-id-type="doi">10.1089/jop.2013.0229</pub-id><pub-id pub-id-type="pmid">24738883</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275038">
        <element-citation publication-type="journal"><article-title>Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma</article-title><source>Current Medical Research and Opinion</source><person-group person-group-type="author">
<name><surname>Holl&#xF3;</surname><given-names>G&#xE1;bor</given-names></name>
<name><surname>Ropo</surname><given-names>Auli</given-names></name>
</person-group><date><year>2015</year></date><volume>31</volume><issue>1</issue><fpage>13</fpage><lpage>16</lpage><issn>0300-7995</issn><pub-id pub-id-type="doi">10.1185/03007995.2014.972500</pub-id><pub-id pub-id-type="doi">10.1185/03007995.2014.972500</pub-id><pub-id pub-id-type="pmid">25275411</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275039">
        <element-citation publication-type="journal">
          <article-title>A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension</article-title>
          <source>European Journal of Ophthalmology</source>
          <person-group person-group-type="author">
<name><surname>Hommer</surname><given-names>A.</given-names></name>
<collab>Ganfort Investigators Group</collab>
</person-group>
          <date>
            <month>1</month>
            <year>2007</year>
          </date>
          <volume>17</volume>
          <issue>1</issue>
          <fpage>53</fpage>
          <lpage>62</lpage>
          <issn>1120-6721</issn>
          <pub-id pub-id-type="doi">10.1177/112067210701700108</pub-id>
          <pub-id pub-id-type="doi">10.1177/112067210701700108</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275040">
        <element-citation publication-type="journal">
          <article-title>Dynamic view on affordability of fixed-dose combination antihypertensive drug therapy</article-title>
          <source>American Journal of Hypertension</source>
          <person-group person-group-type="author">
<name><surname>Hong</surname><given-names>S. H.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
</person-group>
          <date>
            <day>18</day>
            <month>3</month>
            <year>2013</year>
          </date>
          <volume>26</volume>
          <issue>7</issue>
          <fpage>879</fpage>
          <lpage>887</lpage>
          <issn>0895-7061</issn>
          <pub-id pub-id-type="doi">10.1093/ajh/hpt035</pub-id>
          <pub-id pub-id-type="doi">10.1093/ajh/hpt035</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275041">
        <element-citation publication-type="book"><article-title>Treatment of hypertensive patients with a fixed-dose combination of bisoprolol and amlodipine: results of a cohort study with more than 10,000 patients</article-title><source>Cardiology and Therapy</source><person-group person-group-type="author">
<name><surname>Hostalek</surname><given-names>Ulrike</given-names></name>
<name><surname>Czarnecka</surname><given-names>Danuta</given-names></name>
<name><surname>Koch</surname><given-names>Ernst M. W.</given-names></name>
</person-group><publisher-name>Springer Science and Business Media LLC</publisher-name><date><day>8</day><month>8</month><year>2015</year></date><volume>4</volume><issue>2</issue><fpage>179</fpage><lpage>190</lpage><issn>2193-8261</issn><pub-id pub-id-type="doi">10.1007/s40119-015-0045-z</pub-id><!--<pub-id pub-id-type="pmcid">PMC4675749</pub-id>--><pub-id pub-id-type="doi">10.1007/s40119-015-0045-z</pub-id><pub-id pub-id-type="pmid">26253777</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275042">
        <element-citation publication-type="journal"><article-title>Lung function and asthma control with beclomethasone and formoterol in a single inhaler [Comment in: Respir Med. 2009;103(12):1969-70; author reply 1971-1972]</article-title><source>Respiratory Medicine</source><person-group person-group-type="author">
<name><surname>Huchon</surname><given-names>G.</given-names></name>
<name><surname>Magnussen</surname><given-names>H.</given-names></name>
<name><surname>Chuchalin</surname><given-names>A.</given-names></name>
<name><surname>Dymek</surname><given-names>L.</given-names></name>
<name><surname>Gonod</surname><given-names>F. Bonnet</given-names></name>
<name><surname>Bousquet</surname><given-names>J.</given-names></name>
</person-group><date><month>1</month><year>2009</year></date><volume>103</volume><issue>1</issue><fpage>41</fpage><lpage>49</lpage><issn>0954-6111</issn><pub-id pub-id-type="doi">10.1016/j.rmed.2008.09.002</pub-id><pub-id pub-id-type="doi">10.1016/j.rmed.2008.09.002</pub-id><pub-id pub-id-type="pmid">18977646</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275043">
        <element-citation publication-type="book">
          <article-title>Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs</article-title>
          <source>Japanese Journal of Ophthalmology</source>
          <person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>Kenji</given-names></name>
<name><surname>Shiokawa</surname><given-names>Minako</given-names></name>
<name><surname>Sugahara</surname><given-names>Michitaka</given-names></name>
<name><surname>Wakakura</surname><given-names>Masato</given-names></name>
<name><surname>Soeda</surname><given-names>Shoichi</given-names></name>
<name><surname>Tomita</surname><given-names>Goji</given-names></name>
</person-group>
          <publisher-name>Springer Science and Business Media LLC</publisher-name>
          <date>
            <day>22</day>
            <month>9</month>
            <year>2012</year>
          </date>
          <volume>56</volume>
          <issue>6</issue>
          <fpage>559</fpage>
          <lpage>563</lpage>
          <issn>0021-5155</issn>
          <pub-id pub-id-type="doi">10.1007/s10384-012-0186-8</pub-id>
          <pub-id pub-id-type="doi">10.1007/s10384-012-0186-8</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275044">
        <element-citation publication-type="journal">
          <article-title>Compliance and persistence of fixed dose versus free dose combination therapy with valsartan and HCTZ for patients with hypertension</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Jackson</surname><given-names>KC</given-names></name>
<name><surname>Brixner</surname><given-names>D</given-names></name>
<name><surname>Oderda</surname><given-names>GM</given-names></name>
<name><surname>Oberg</surname><given-names>B</given-names></name>
<name><surname>Sheng</surname><given-names>X</given-names></name>
<name><surname>Keskinaslan</surname><given-names>A</given-names></name>
</person-group>
          <date>
            <month>11</month>
            <year>2006</year>
          </date>
          <volume>9</volume>
          <issue>6</issue>
          <fpage>A363</fpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1016/s1098-3015(10)63700-x</pub-id>
          <pub-id pub-id-type="doi">10.1016/s1098-3015(10)63700-x</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275045">
        <element-citation publication-type="book">
          <article-title>Efficacy and safety of high-dose budesonide/formoterol (Symbicort<sup>&#xAE;</sup>) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma</article-title>
          <source>Respirology</source>
          <person-group person-group-type="author">
<name><surname>Jenkins</surname><given-names>Christine</given-names></name>
<name><surname>Kolarikova</surname><given-names>Renata</given-names></name>
<name><surname>Kuna</surname><given-names>Piotr</given-names></name>
<name><surname>CAILLAUD</surname><given-names>Denis</given-names></name>
<name><surname>SANCHIS</surname><given-names>Joaquin</given-names></name>
<name><surname>POPP</surname><given-names>Wolfgang</given-names></name>
<name><surname>PETTERSSON</surname><given-names>Eva</given-names></name>
</person-group>
          <publisher-name>Wiley</publisher-name>
          <date>
            <day>19</day>
            <month>4</month>
            <year>2006</year>
          </date>
          <volume>11</volume>
          <issue>3</issue>
          <fpage>276</fpage>
          <lpage>286</lpage>
          <issn>1323-7799</issn>
          <pub-id pub-id-type="doi">10.1111/j.1440-1843.2006.00856.x</pub-id>
          <pub-id pub-id-type="doi">10.1111/j.1440-1843.2006.00856.x</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275046">
        <element-citation publication-type="journal"><article-title>Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population</article-title><source>Current Medical Research and Opinion</source><person-group person-group-type="author">
<name><surname>Kamat</surname><given-names>Siddhesh A.</given-names></name>
<name><surname>Bullano</surname><given-names>Michael F.</given-names></name>
<name><surname>Chang</surname><given-names>Chun-Lan</given-names></name>
<name><surname>Gandhi</surname><given-names>Sanjay K.</given-names></name>
<name><surname>Cziraky</surname><given-names>Mark J.</given-names></name>
</person-group><date><day>7</day><month>3</month><year>2011</year></date><volume>27</volume><issue>5</issue><fpage>961</fpage><lpage>968</lpage><issn>0300-7995</issn><pub-id pub-id-type="doi">10.1185/03007995.2011.562494</pub-id><pub-id pub-id-type="doi">10.1185/03007995.2011.562494</pub-id><pub-id pub-id-type="pmid">21381893</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275047">
        <element-citation publication-type="book">
          <article-title>Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting</article-title>
          <source>Kardiologia Polska</source>
          <person-group person-group-type="author">
<name><surname>Kawalec</surname><given-names>Pawe&#x142;</given-names></name>
<name><surname>Holko</surname><given-names>Przemys&#x142;aw</given-names></name>
<name><surname>Stawowczyk</surname><given-names>Ewa</given-names></name>
<name><surname>Borowiec</surname><given-names>&#x141;ukasz</given-names></name>
<name><surname>Filipiak</surname><given-names>Krzysztof J.</given-names></name>
</person-group>
          <publisher-name>Polskie Towarzystwo Kardiologiczne</publisher-name>
          <date>
            <day>16</day>
            <month>9</month>
            <year>2015</year>
          </date>
          <volume>73</volume>
          <issue>9</issue>
          <fpage>768</fpage>
          <lpage>780</lpage>
          <issn>1897-4279</issn>
          <pub-id pub-id-type="doi">10.5603/kp.a2015.0089</pub-id>
          <pub-id pub-id-type="doi">10.5603/kp.a2015.0089</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275048">
        <element-citation publication-type="journal">
          <article-title>Budget impact analysis of hypertensive treatment with indapamide and amlodipine single-pill combination in the Polish setting</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Kawalec</surname><given-names>P.</given-names></name>
<name><surname>Stawowczyk</surname><given-names>E.</given-names></name>
<name><surname>Holko</surname><given-names>P.</given-names></name>
<name><surname>Borowiec</surname><given-names>L.</given-names></name>
<name><surname>Filipiak</surname><given-names>K.J.</given-names></name>
</person-group>
          <date>
            <month>11</month>
            <year>2014</year>
          </date>
          <volume>17</volume>
          <issue>7</issue>
          <fpage>A479</fpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1016/j.jval.2014.08.1381</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jval.2014.08.1381</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275049">
        <element-citation publication-type="book">
          <article-title>Comparison of sputum conversion time in tuberculosis treatment with fix-dose combination drugs and separate drug regimens</article-title>
          <source>The Egyptian Journal of Chest Diseases and Tuberculosis</source>
          <person-group person-group-type="author">
<name><surname>Fallah</surname><given-names>Saeid</given-names></name>
<name><surname>Khodakarim</surname><given-names>Soheila</given-names></name>
<name><surname>Bazmi</surname><given-names>Elham</given-names></name>
<name><surname>Lak</surname><given-names>ShakerSalari</given-names></name>
<name><surname>Raeisi</surname><given-names>Vahideh</given-names></name>
<name><surname>Behnoush</surname><given-names>Behnam</given-names></name>
</person-group>
          <publisher-name>Medknow</publisher-name>
          <date>
            <year>2020</year>
          </date>
          <volume>69</volume>
          <issue>3</issue>
          <fpage>468</fpage>
          <issn>0422-7638</issn>
          <pub-id pub-id-type="doi">10.4103/ejcdt.ejcdt_80_19</pub-id>
          <pub-id pub-id-type="doi">10.4103/ejcdt.ejcdt_80_19</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275050">
        <element-citation publication-type="journal"><article-title>Pharmacodynamic effects of a new fixed-dose clopidogrel&#x2013;aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: the ACCEL-COMBO trial</article-title><source>Platelets</source><person-group person-group-type="author">
<name><surname>Koh</surname><given-names>Jin-Sin</given-names></name>
<name><surname>Park</surname><given-names>Yongwhi</given-names></name>
<name><surname>Tantry</surname><given-names>Udaya S.</given-names></name>
<name><surname>Ahn</surname><given-names>Jong-Hwa</given-names></name>
<name><surname>Kang</surname><given-names>Min Gyu</given-names></name>
<name><surname>Kim</surname><given-names>Kyehwan</given-names></name>
<name><surname>Jang</surname><given-names>Jeong Yoon</given-names></name>
<name><surname>Park</surname><given-names>Hyun Woong</given-names></name>
<name><surname>Park</surname><given-names>Jeong Rang</given-names></name>
<name><surname>Hwang</surname><given-names>Seok-Jae</given-names></name>
<name><surname>Kwak</surname><given-names>Choong Hwan</given-names></name>
<name><surname>Hwang</surname><given-names>Jin-Yong</given-names></name>
<name><surname>Gurbel</surname><given-names>Paul A.</given-names></name>
<name><surname>Jeong</surname><given-names>Young-Hoon</given-names></name>
</person-group><date><year>2017</year></date><volume>28</volume><issue>2</issue><fpage>187</fpage><lpage>193</lpage><issn>0953-7104</issn><pub-id pub-id-type="doi">10.1080/09537104.2016.1206197</pub-id><pub-id pub-id-type="doi">10.1080/09537104.2016.1206197</pub-id><pub-id pub-id-type="pmid">27560946</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275051">
        <element-citation publication-type="journal"><article-title>Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components</article-title><source>Eye</source><person-group person-group-type="author">
<name><surname>Konstas</surname><given-names>A G P</given-names></name>
<name><surname>Katsimpris</surname><given-names>I E</given-names></name>
<name><surname>Kaltsos</surname><given-names>K</given-names></name>
<name><surname>Georgiadou</surname><given-names>I</given-names></name>
<name><surname>Kordelou</surname><given-names>A</given-names></name>
<name><surname>Nelson</surname><given-names>L A</given-names></name>
<name><surname>Stewart</surname><given-names>W C</given-names></name>
</person-group><date><year>2008</year></date><volume>22</volume><issue>11</issue><fpage>1391</fpage><lpage>1397</lpage><issn>0950-222X</issn><pub-id pub-id-type="doi">10.1038/sj.eye.6702906</pub-id><pub-id pub-id-type="doi">10.1038/sj.eye.6702906</pub-id><pub-id pub-id-type="pmid">17571086</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275052">
        <element-citation publication-type="journal"><article-title>The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD</article-title><source>American Journal of Kidney Diseases</source><person-group person-group-type="author">
<name><surname>Kooienga</surname><given-names>Laura</given-names></name>
<name><surname>Fried</surname><given-names>Linda</given-names></name>
<name><surname>Scragg</surname><given-names>Robert</given-names></name>
<name><surname>Kendrick</surname><given-names>Jessica</given-names></name>
<name><surname>Smits</surname><given-names>Gerard</given-names></name>
<name><surname>Chonchol</surname><given-names>Michel</given-names></name>
</person-group><date><month>3</month><year>2009</year></date><volume>53</volume><issue>3</issue><fpage>408</fpage><lpage>416</lpage><issn>0272-6386</issn><pub-id pub-id-type="doi">10.1053/j.ajkd.2008.09.020</pub-id><pub-id pub-id-type="doi">10.1053/j.ajkd.2008.09.020</pub-id><pub-id pub-id-type="pmid">19185400</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275053">
        <element-citation publication-type="book">
          <article-title>Efficacy of fixed dose of triple combination of perindopril-indapamide-amlodipine in obese patients with moderate-to-severe arterial hypertension: an open-label 6-month study</article-title>
          <source>Biomedical Research and Therapy</source>
          <person-group person-group-type="author">
<name><surname>Koval</surname><given-names>Sergiy M.</given-names></name>
<name><surname>Snihurska</surname><given-names>Iryna O.</given-names></name>
<name><surname>Starchenko</surname><given-names>Tetyana G.</given-names></name>
<name><surname>Penkova</surname><given-names>Marina Yu.</given-names></name>
<name><surname>Mysnychenko</surname><given-names>Olga V.</given-names></name>
<name><surname>Yushko</surname><given-names>Kostyantin O.</given-names></name>
<name><surname>Lytvynova</surname><given-names>Olga M.</given-names></name>
<name><surname>Vysotska</surname><given-names>Olena</given-names></name>
<name><surname>Berezin</surname><given-names>Alexander E.</given-names></name>
</person-group>
          <publisher-name>Biomedical Research and Therapy</publisher-name>
          <date>
            <day>30</day>
            <month>11</month>
            <year>2019</year>
          </date>
          <volume>6</volume>
          <issue>11</issue>
          <fpage>3501</fpage>
          <lpage>3512</lpage>
          <issn>2198-4093</issn>
          <pub-id pub-id-type="doi">10.15419/bmrat.v6i11.578</pub-id>
          <pub-id pub-id-type="doi">10.15419/bmrat.v6i11.578</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275054">
        <element-citation publication-type="journal"><article-title>Topical glaucoma therapy cost in Mexico</article-title><source>International Ophthalmology</source><person-group person-group-type="author">
<name><surname>Lazcano-Gomez</surname><given-names>Gabriel</given-names></name>
<name><surname>Hernandez-Oteyza</surname><given-names>Alejandra</given-names></name>
<name><surname>Iriarte-Barbosa</surname><given-names>Mar&#xED;a Jos&#xE9;</given-names></name>
<name><surname>Hernandez-Garciadiego</surname><given-names>Carlos</given-names></name>
</person-group><date><year>2014</year></date><volume>34</volume><issue>2</issue><fpage>241</fpage><lpage>249</lpage><issn>0165-5701</issn><pub-id pub-id-type="doi">10.1007/s10792-013-9823-6</pub-id><pub-id pub-id-type="doi">10.1007/s10792-013-9823-6</pub-id><pub-id pub-id-type="pmid">23846765</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275055">
        <element-citation publication-type="book">
          <article-title>Adherence to combined Lamivudine+Zidovudine versus individual components: a community-based retrospective medicaid claims analysis</article-title>
          <source>AIDS Care</source>
          <person-group person-group-type="author">
<name><surname>Legorreta</surname><given-names>A.</given-names></name>
<name><surname>Yu</surname><given-names>A.</given-names></name>
<name><surname>Chernicoff</surname><given-names>H.</given-names></name>
<name><surname>Gilmore</surname><given-names>A.</given-names></name>
<name><surname>Jordan</surname><given-names>J.</given-names></name>
<name><surname>Rosenzweig</surname><given-names>J. C.</given-names></name>
</person-group>
          <publisher-name>Informa UK Limited</publisher-name>
          <date>
            <month>11</month>
            <year>2005</year>
          </date>
          <volume>17</volume>
          <issue>8</issue>
          <fpage>938</fpage>
          <lpage>948</lpage>
          <issn>0954-0121</issn>
          <pub-id pub-id-type="doi">10.1080/09540120500100692</pub-id>
          <pub-id pub-id-type="doi">10.1080/09540120500100692</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275056">
        <element-citation publication-type="journal"><article-title>Patient adherence to olmesartan/amlodipine combinations: fixed versus extemporaneous combinations</article-title><source>Journal of Managed Care &amp; Specialty Pharmacy</source><person-group person-group-type="author">
<name><surname>Levi</surname><given-names>Miriam</given-names></name>
<name><surname>Pasqua</surname><given-names>Alessandro</given-names></name>
<name><surname>Cricelli</surname><given-names>Iacopo</given-names></name>
<name><surname>Cricelli</surname><given-names>Claudio</given-names></name>
<name><surname>Piccinni</surname><given-names>Carlo</given-names></name>
<name><surname>Parretti</surname><given-names>Damiano</given-names></name>
<name><surname>Lapi</surname><given-names>Francesco</given-names></name>
</person-group><date><month>3</month><year>2016</year></date><volume>22</volume><issue>3</issue><fpage>255</fpage><lpage>262</lpage><issn>2376-0540</issn><pub-id pub-id-type="doi">10.18553/jmcp.2016.22.3.255</pub-id><!--<pub-id pub-id-type="pmcid">PMC10398216</pub-id>--><pub-id pub-id-type="doi">10.18553/jmcp.2016.22.3.255</pub-id><pub-id pub-id-type="pmid">27003555</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275057">
        <element-citation publication-type="journal">
          <article-title>Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs</article-title>
          <source>Current Medical Research and Opinion</source>
          <person-group person-group-type="author">
<name><surname>Machnicki</surname><given-names>G.</given-names></name>
<name><surname>Ong</surname><given-names>S.H.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Wei</surname><given-names>Z.J.</given-names></name>
<name><surname>Kahler</surname><given-names>K.H.</given-names></name>
</person-group>
          <date>
            <day>11</day>
            <month>11</month>
            <year>2015</year>
          </date>
          <volume>31</volume>
          <issue>12</issue>
          <fpage>2287</fpage>
          <lpage>2296</lpage>
          <issn>0300-7995</issn>
          <pub-id pub-id-type="doi">10.1185/03007995.2015.1098598</pub-id>
          <pub-id pub-id-type="doi">10.1185/03007995.2015.1098598</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275058">
        <element-citation publication-type="journal"><article-title>The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects</article-title><source>European Heart Journal: Acute Cardiovascular Care</source><person-group person-group-type="author">
<name><surname>Maggioni</surname><given-names>Aldo P</given-names></name>
<name><surname>Dondi</surname><given-names>Letizia</given-names></name>
<name><surname>Pedrini</surname><given-names>Antonella</given-names></name>
<name><surname>Ronconi</surname><given-names>Giulia</given-names></name>
<name><surname>Calabria</surname><given-names>Silvia</given-names></name>
<name><surname>Cimminiello</surname><given-names>Claudio</given-names></name>
<name><surname>Martini</surname><given-names>Nello</given-names></name>
</person-group><date><year>2019</year></date><volume>8</volume><issue>6</issue><fpage>527</fpage><lpage>535</lpage><issn>2048-8726</issn><pub-id pub-id-type="doi">10.1177/2048872618801252</pub-id><pub-id pub-id-type="doi">10.1177/2048872618801252</pub-id><pub-id pub-id-type="pmid">30209955</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275059">
        <element-citation publication-type="journal"><article-title>Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial</article-title><source>Therapeutic Advances in Cardiovascular Disease</source><person-group person-group-type="author">
<name><surname>Mariani</surname><given-names>Javier</given-names></name>
<name><surname>Rosende</surname><given-names>Andr&#xE9;s</given-names></name>
<name><surname>De Abreu</surname><given-names>Maximiliano</given-names></name>
<name><surname>Gonzalez Villa Monte</surname><given-names>Gabriel</given-names></name>
<name><surname>D&#x2019;Imperio</surname><given-names>Heraldo</given-names></name>
<name><surname>Antonietti</surname><given-names>Laura</given-names></name>
<name><surname>Lemonnier</surname><given-names>Gabriela</given-names></name>
<name><surname>de Bonis</surname><given-names>Alejandra</given-names></name>
<name><surname>Tajer</surname><given-names>Carlos</given-names></name>
</person-group><date><month>1</month><year>2020</year></date><volume>14</volume><issn>1753-9447</issn><pub-id pub-id-type="doi">10.1177/1753944720912071</pub-id><!--<pub-id pub-id-type="pmcid">PMC7081461</pub-id>--><pub-id pub-id-type="doi">10.1177/1753944720912071</pub-id><pub-id pub-id-type="pmid">32186246</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275060">
        <element-citation publication-type="journal">
          <article-title>Updated medication costs from a real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma maintenance and reliever therapy in asthma [abstract]</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Medin</surname><given-names>E</given-names></name>
<name><surname>Safioti</surname><given-names>G</given-names></name>
<name><surname>Lindqvist</surname><given-names>F</given-names></name>
<name><surname>Torvinen</surname><given-names>S</given-names></name>
</person-group>
          <date>
            <month>11</month>
            <year>2015</year>
          </date>
          <volume>18</volume>
          <issue>7</issue>
          <fpage>A500</fpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1016/j.jval.2015.09.1413</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jval.2015.09.1413</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275061">
        <element-citation publication-type="journal">
          <article-title>Treatment outcome in smear-positive pulmonary tuberculosis patients treated with a fixed-dose drug combination regimen in comparison with a separate regimen: a randomized clinical trial</article-title>
          <source>The Egyptian Journal of Chest Diseases and Tuberculosis</source>
          <person-group person-group-type="author">
<name><surname>Fallah</surname><given-names>Saeid</given-names></name>
<name><surname>Nazari</surname><given-names>Seyed SaeedHashemi</given-names></name>
<name><surname>Raeisi</surname><given-names>Vahideh</given-names></name>
</person-group>
          <date>
            <year>2021</year>
          </date>
          <volume>70</volume>
          <issue>1</issue>
          <fpage>26</fpage>
          <lpage>30</lpage>
          <issn>0422-7638</issn>
          <pub-id pub-id-type="doi">10.4103/ejcdt.ejcdt_110_19</pub-id>
          <pub-id pub-id-type="doi">10.4103/ejcdt.ejcdt_110_19</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275062">
        <element-citation publication-type="book"><article-title>Single-pill combination of perindopril/indapamide/amlodipine in patients with uncontrolled hypertension: a randomized controlled trial</article-title><source>Cardiology and Therapy</source><person-group person-group-type="author">
<name><surname>Nedogoda</surname><given-names>Sergey V.</given-names></name>
<name><surname>Stojanov</surname><given-names>Vesna J.</given-names></name>
</person-group><publisher-name>Springer Science and Business Media LLC</publisher-name><date><day>8</day><month>2</month><year>2017</year></date><volume>6</volume><issue>1</issue><fpage>91</fpage><lpage>104</lpage><issn>2193-8261</issn><pub-id pub-id-type="doi">10.1007/s40119-017-0085-7</pub-id><!--<pub-id pub-id-type="pmcid">PMC5446818</pub-id>--><pub-id pub-id-type="doi">10.1007/s40119-017-0085-7</pub-id><pub-id pub-id-type="pmid">28181192</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275063">
        <element-citation publication-type="journal">
          <article-title>The efficacy of the fixed combination of mometasone furoate and azelastine hydrochloride as a nasal spray in adult patients with perennial rhinitis</article-title>
          <source>Allergy</source>
          <person-group person-group-type="author">
<name><surname>Nenasheva</surname><given-names>N</given-names></name>
<name><surname>Nosulya</surname><given-names>E</given-names></name>
<name><surname>Kim</surname><given-names>I</given-names></name>
<name><surname>Ryazantsev</surname><given-names>S</given-names></name>
<name><surname>Ovchinnikov</surname><given-names>A</given-names></name>
<name><surname>Berdnikova</surname><given-names>N</given-names></name>
</person-group>
          <date>
            <month>8</month>
            <year>2019</year>
          </date>
          <volume>74</volume>
          <issue>suppl 106</issue>
          <fpage>400</fpage>
          <lpage>401</lpage>
          <issn>0105-4538</issn>
          <pub-id pub-id-type="doi">10.1111/all.13961</pub-id>
          <!--<pub-id pub-id-type="pmcid">PMC7463038</pub-id>-->
          <pub-id pub-id-type="doi">10.1111/all.13961</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275064">
        <element-citation publication-type="book"><article-title>Fixed-dose versus off-label combination of isosorbide dinitrate plus hydralazine hydrochloride: retrospective propensity-matched analysis in black Medicare patients with heart failure</article-title><source>Advances in Therapy</source><person-group person-group-type="author">
<name><surname>Ofili</surname><given-names>Elizabeth</given-names></name>
<name><surname>Anand</surname><given-names>Inder</given-names></name>
<name><surname>Williams</surname><given-names>Richard Allen</given-names></name>
<name><surname>Akinboboye</surname><given-names>Ola</given-names></name>
<name><surname>Xu</surname><given-names>Liou</given-names></name>
<name><surname>Puckrein</surname><given-names>Gary</given-names></name>
</person-group><publisher-name>Springer Science and Business Media LLC</publisher-name><date><day>13</day><month>7</month><year>2017</year></date><volume>34</volume><issue>8</issue><fpage>1976</fpage><lpage>1988</lpage><issn>0741-238X</issn><pub-id pub-id-type="doi">10.1007/s12325-017-0584-x</pub-id><!--<pub-id pub-id-type="pmcid">PMC5565652</pub-id>--><pub-id pub-id-type="doi">10.1007/s12325-017-0584-x</pub-id><pub-id pub-id-type="pmid">28707284</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275065">
        <element-citation publication-type="journal">
          <article-title>Ramipril/amlodipine single pill &#x2013; effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status</article-title>
          <source>Pharmacological Reports</source>
          <person-group person-group-type="author">
<name><surname>Olszanecka-Glinianowicz</surname><given-names>Magdalena</given-names></name>
<name><surname>Smertka</surname><given-names>Mike</given-names></name>
<name><surname>Almgren-Rachtan</surname><given-names>Agnieszka</given-names></name>
<name><surname>Chudek</surname><given-names>Jerzy</given-names></name>
</person-group>
          <date>
            <month>12</month>
            <year>2014</year>
          </date>
          <volume>66</volume>
          <issue>6</issue>
          <fpage>1043</fpage>
          <lpage>1049</lpage>
          <issn>1734-1140</issn>
          <pub-id pub-id-type="doi">10.1016/j.pharep.2014.06.020</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.pharep.2014.06.020</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275066">
        <element-citation publication-type="journal">
          <article-title>Persistence and adherence with exforge HCT single pill combination versus amlodipine/valsartan/hydrochlorothiazide free combination: a comparison controlling for demographic and clinical factors</article-title>
          <source>European Heart Journal</source>
          <person-group person-group-type="author">
<name><surname>Ong</surname><given-names>S</given-names></name>
<name><surname>Machnicki</surname><given-names>G</given-names></name>
<name><surname>Chen</surname><given-names>W</given-names></name>
<name><surname>Wei</surname><given-names>Z J</given-names></name>
<name><surname>Kahler</surname><given-names>K H</given-names></name>
</person-group>
          <date>
            <day>2</day>
            <month>9</month>
            <year>2014</year>
          </date>
          <volume>35</volume>
          <issue>suppl_1</issue>
          <fpage>1</fpage>
          <lpage>172</lpage>
          <issn>0195-668X</issn>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehu322</pub-id>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehu322</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275067">
        <element-citation publication-type="journal"><article-title>Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen</article-title><source>Vasc Health Risk Manag</source><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>B.</given-names></name>
<name><surname>Leslie</surname><given-names>R.</given-names></name>
<name><surname>Thiebaud</surname><given-names>P..</given-names></name>
<etal/>
</person-group><date><year>2008</year></date><volume>4</volume><issue>3</issue><fpage>673</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">18827917</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275068">
        <element-citation publication-type="journal"><article-title>Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting &#x3B2;-agonist inhaler therapy in asthma</article-title><source>Journal of Allergy and Clinical Immunology</source><person-group person-group-type="author">
<name><surname>Perrin</surname><given-names>Kyle</given-names></name>
<name><surname>Williams</surname><given-names>Mathew</given-names></name>
<name><surname>Wijesinghe</surname><given-names>Meme</given-names></name>
<name><surname>James</surname><given-names>Kate</given-names></name>
<name><surname>Weatherall</surname><given-names>Mark</given-names></name>
<name><surname>Beasley</surname><given-names>Richard</given-names></name>
</person-group><date><month>9</month><year>2010</year></date><volume>126</volume><issue>3</issue><fpage>505</fpage><lpage>510</lpage><issn>0091-6749</issn><pub-id pub-id-type="doi">10.1016/j.jaci.2010.06.033</pub-id><pub-id pub-id-type="doi">10.1016/j.jaci.2010.06.033</pub-id><pub-id pub-id-type="pmid">20816187</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275069">
        <element-citation publication-type="journal">
          <article-title>The single pill concept leads to improved persistence of medication, clinical outomes and reduced all-cause mortaility in hypertensive patients - results from the START project</article-title>
          <source>Journal of Hypertension</source>
          <person-group person-group-type="author">
<name><surname>Predel</surname><given-names>Hans-Georg</given-names></name>
<name><surname>Weisser</surname><given-names>Burkhard</given-names></name>
<name><surname>Wassmann</surname><given-names>Sven</given-names></name>
<name><surname>Gillessen</surname><given-names>Anton</given-names></name>
<name><surname>Blettenberg</surname><given-names>J&#xF6;rg</given-names></name>
<name><surname>Fournier</surname><given-names>Val&#xE9;rie</given-names></name>
<name><surname>Noetel</surname><given-names>Andrea</given-names></name>
<name><surname>Randerath</surname><given-names>Olaf</given-names></name>
<name><surname>B&#xF6;hm</surname><given-names>Michael</given-names></name>
<name><surname>Schmieder</surname><given-names>Roland E.</given-names></name>
</person-group>
          <date>
            <month>4</month>
            <year>2021</year>
          </date>
          <volume>39</volume>
          <issue>suppl 1</issue>
          <fpage>e378</fpage>
          <issn>0263-6352</issn>
          <pub-id pub-id-type="doi">10.1097/01.hjh.0000748928.45804.cf</pub-id>
          <pub-id pub-id-type="doi">10.1097/01.hjh.0000748928.45804.cf</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275070">
        <element-citation publication-type="journal">
          <article-title>Persistence and cardiovascular outcomes with ramipril, atorvastatin, ASA as a single pill compared to the multi pill combination. A subanalysis of the START study, a claims data analysis</article-title>
          <source>European Heart Journal</source>
          <person-group person-group-type="author">
<name><surname>Predel</surname><given-names>H.G</given-names></name>
<name><surname>Weisser</surname><given-names>B</given-names></name>
<name><surname>Wassmann</surname><given-names>S</given-names></name>
<name><surname>Schmieder</surname><given-names>R.E</given-names></name>
<name><surname>Blettenberg</surname><given-names>J</given-names></name>
<name><surname>Gillessen</surname><given-names>A</given-names></name>
<name><surname>Fournier</surname><given-names>V</given-names></name>
<name><surname>Noetel</surname><given-names>A</given-names></name>
<name><surname>Randerath</surname><given-names>O</given-names></name>
<name><surname>Boehm</surname><given-names>M</given-names></name>
</person-group>
          <date>
            <day>1</day>
            <month>11</month>
            <year>2020</year>
          </date>
          <volume>41</volume>
          <issue>suppl_2</issue>
          <fpage>ehaa946.2964</fpage>
          <issn>0195-668X</issn>
          <pub-id pub-id-type="doi">10.1093/ehjci/ehaa946.2964</pub-id>
          <pub-id pub-id-type="doi">10.1093/ehjci/ehaa946.2964</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275071">
        <element-citation publication-type="journal">
          <article-title>Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting</article-title>
          <source>Resp Med</source>
          <person-group person-group-type="author">
<name><surname>Price</surname><given-names>D.</given-names></name>
<name><surname>Keininger</surname><given-names>D.</given-names></name>
<name><surname>Costa-Scharplatz</surname><given-names>M..</given-names></name>
<etal/>
</person-group>
          <date>
            <year>2014</year>
          </date>
          <volume>108</volume>
          <issue>12</issue>
          <fpage>1786</fpage>
          <lpage>1793</lpage>
          <pub-id pub-id-type="doi">10.1016/j.rmed.2014.09.015</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.rmed.2014.09.015</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275072">
        <element-citation publication-type="journal">
          <article-title>Economic evaluation of olmesartan/amlodipine fixed-dose combination for hypertension treatment in China</article-title>
          <source>Journal of Medical Economics</source>
          <person-group person-group-type="author">
<name><surname>Ren</surname><given-names>Maodong</given-names></name>
<name><surname>Xuan</surname><given-names>Dennis</given-names></name>
<name><surname>Lu</surname><given-names>Yongji</given-names></name>
<name><surname>Fu</surname><given-names>YuYan</given-names></name>
<name><surname>Xuan</surname><given-names>Jianwei</given-names></name>
</person-group>
          <date>
            <day>25</day>
            <month>1</month>
            <year>2020</year>
          </date>
          <volume>23</volume>
          <issue>4</issue>
          <fpage>394</fpage>
          <lpage>400</lpage>
          <issn>1369-6998</issn>
          <pub-id pub-id-type="doi">10.1080/13696998.2019.1699799</pub-id>
          <pub-id pub-id-type="doi">10.1080/13696998.2019.1699799</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275073">
        <element-citation publication-type="journal"><article-title>Treatment compliance with fixed-dose combination of vildagliptin/metformin in patients with Type 2 diabetes mellitus inadequately controlled with metformin monotherapy: a 24-week observational study</article-title><source>International Journal of Endocrinology</source><person-group person-group-type="author">
<name><surname>Rombopoulos</surname><given-names>Grigorios</given-names></name>
<name><surname>Hatzikou</surname><given-names>Magdalini</given-names></name>
<name><surname>Athanasiadis</surname><given-names>Athanasios</given-names></name>
<name><surname>Elisaf</surname><given-names>Moyses</given-names></name>
</person-group><date><year>2015</year></date><volume>2015</volume><issue>251485</issue><fpage>1</fpage><lpage>5</lpage><issn>1687-8337</issn><pub-id pub-id-type="doi">10.1155/2015/251485</pub-id><!--<pub-id pub-id-type="pmcid">PMC4452314</pub-id>--><pub-id pub-id-type="doi">10.1155/2015/251485</pub-id><pub-id pub-id-type="pmid">26089879</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275074">
        <element-citation publication-type="journal">
          <article-title>Preliminary results of a multicenter observational study of treatment compliance with free-combination versus fixed combination treatment in Type II diabetes mellitus patients in Greece (Less Study)</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Rombopoulos</surname><given-names>G.</given-names></name>
<name><surname>Hatzikou</surname><given-names>M.</given-names></name>
<name><surname>Kossiva</surname><given-names>E.</given-names></name>
<name><surname>Athanasiadis</surname><given-names>A.</given-names></name>
<name><surname>Elisaf</surname><given-names>M.</given-names></name>
</person-group>
          <date>
            <month>11</month>
            <year>2012</year>
          </date>
          <volume>15</volume>
          <issue>7)(PDB53</issue>
          <fpage>A503</fpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1016/j.jval.2012.08.1696</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jval.2012.08.1696</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275075">
        <element-citation publication-type="journal">
          <article-title>Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months</article-title>
          <source>International Journal of Clinical Practice</source>
          <person-group person-group-type="author">
<name><surname>Rosenhall</surname><given-names>L</given-names></name>
<name><surname>Borg</surname><given-names>S</given-names></name>
<name><surname>Andersson</surname><given-names>F</given-names></name>
<name><surname>Ericsson</surname><given-names>K</given-names></name>
</person-group>
          <date>
            <month>10</month>
            <year>2003</year>
          </date>
          <volume>57</volume>
          <issue>8</issue>
          <fpage>662</fpage>
          <lpage>667</lpage>
          <issn>1368-5031</issn>
          <pub-id pub-id-type="doi">10.1111/j.1742-1241.2003.tb10584.x</pub-id>
          <pub-id pub-id-type="doi">10.1111/j.1742-1241.2003.tb10584.x</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275076">
        <element-citation publication-type="journal"><article-title>One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort&#xAE; Turbuhaler&#xAE;) for the treatment of asthma</article-title><source>Respiratory Medicine</source><person-group person-group-type="author">
<name><surname>Rosenhall</surname><given-names>L.</given-names></name>
<name><surname>Elvstrand</surname><given-names>A.</given-names></name>
<name><surname>Tilling</surname><given-names>B.</given-names></name>
<name><surname>VINGE</surname><given-names>I.</given-names></name>
<name><surname>JEMSBY</surname><given-names>P.</given-names></name>
<name><surname>STAHL</surname><given-names>E.</given-names></name>
<name><surname>JERRE</surname><given-names>F.</given-names></name>
<name><surname>BERGQVIST</surname><given-names>P.B.F.</given-names></name>
</person-group><date><month>6</month><year>2003</year></date><volume>97</volume><issue>6</issue><fpage>702</fpage><lpage>708</lpage><issn>0954-6111</issn><pub-id pub-id-type="doi">10.1053/rmed.2003.1504</pub-id><pub-id pub-id-type="doi">10.1053/rmed.2003.1504</pub-id><pub-id pub-id-type="pmid">12814158</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275077">
        <element-citation publication-type="journal"><article-title>Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma</article-title><source>International Journal of Clinical Practice</source><person-group person-group-type="author">
<name><surname>Rosenhall</surname><given-names>L</given-names></name>
<name><surname>Heinig</surname><given-names>JH</given-names></name>
<name><surname>Lindqvist</surname><given-names>A</given-names></name>
<name><surname>Leegaard</surname><given-names>J</given-names></name>
<name><surname>St&#xE5;hl</surname><given-names>E</given-names></name>
<name><surname>Bergqvist</surname><given-names>PBF</given-names></name>
</person-group><date><month>7</month><year>2002</year></date><volume>56</volume><issue>6</issue><fpage>427</fpage><lpage>433</lpage><issn>1368-5031</issn><pub-id pub-id-type="doi">10.1111/j.1742-1241.2002.tb11292.x</pub-id><pub-id pub-id-type="doi">10.1111/j.1742-1241.2002.tb11292.x</pub-id><pub-id pub-id-type="pmid">12166540</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275078">
        <element-citation publication-type="journal"><article-title>Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen</article-title><source>AIDS Care</source><person-group person-group-type="author">
<name><surname>Rosso</surname><given-names>Raffaella</given-names></name>
<name><surname>Di Biagio</surname><given-names>Antonio</given-names></name>
<name><surname>Maggiolo</surname><given-names>Franco</given-names></name>
<name><surname>Nulvesu</surname><given-names>Loredana</given-names></name>
<name><surname>Callegaro</surname><given-names>Anna Paola</given-names></name>
<name><surname>Taramasso</surname><given-names>Lucia</given-names></name>
<name><surname>Bruzzone</surname><given-names>Bianca</given-names></name>
<name><surname>Viscoli</surname><given-names>Claudio</given-names></name>
</person-group><date><year>2012</year></date><volume>24</volume><issue>1</issue><fpage>54</fpage><lpage>58</lpage><issn>0954-0121</issn><pub-id pub-id-type="doi">10.1080/09540121.2011.596511</pub-id><pub-id pub-id-type="doi">10.1080/09540121.2011.596511</pub-id><pub-id pub-id-type="pmid">21800951</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275079">
        <element-citation publication-type="journal">
          <article-title>Pharmacoeconomic evaluation: cost effectiveness analysis of oral antidiabetic therapy in a tertiary care hospital</article-title>
          <source>International Journal of Pharmaceutical Sciences Review and Research</source>
          <person-group person-group-type="author">
<name><surname>Saju</surname><given-names>Sereena</given-names></name>
<name><surname>Varghese</surname><given-names>Fedrin</given-names></name>
<name><surname>R S</surname><given-names>Deena</given-names></name>
<name><surname>N R</surname><given-names>Nivetha</given-names></name>
<name><surname>Chetty</surname><given-names>Samhitha</given-names></name>
<name><surname>Mahesh</surname><given-names>K. Uma</given-names></name>
</person-group>
          <date>
            <day>15</day>
            <month>1</month>
            <year>2021</year>
          </date>
          <volume>66</volume>
          <issue>1</issue>
          <fpage>31</fpage>
          <lpage>37</lpage>
          <issn>0976-044X</issn>
          <pub-id pub-id-type="doi">10.47583/ijpsrr.2021.v66i01.008</pub-id>
          <pub-id pub-id-type="doi">10.47583/ijpsrr.2021.v66i01.008</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275080">
        <element-citation publication-type="journal">
          <article-title>PCV62 Persistence and compliance in hypertension treatment with olmesartan medoxomil analysis of real-life prescription data</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Sandberg</surname><given-names>A.</given-names></name>
<name><surname>Kostev</surname><given-names>K.</given-names></name>
<name><surname>Ehlken</surname><given-names>B.</given-names></name>
<name><surname>Holz</surname><given-names>B.</given-names></name>
<name><surname>Oberdiek</surname><given-names>A.</given-names></name>
</person-group>
          <date>
            <month>5</month>
            <year>2011</year>
          </date>
          <volume>14</volume>
          <issue>3</issue>
          <fpage>A43</fpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1016/j.jval.2011.02.249</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jval.2011.02.249</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275081">
        <element-citation publication-type="journal">
          <article-title>Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience</article-title>
          <source>Current Medical Research and Opinion</source>
          <person-group person-group-type="author">
<name><surname>Simons</surname><given-names>Leon A.</given-names></name>
<name><surname>Chung</surname><given-names>Eric</given-names></name>
<name><surname>Ortiz</surname><given-names>Michael</given-names></name>
</person-group>
          <date>
            <day>24</day>
            <month>8</month>
            <year>2017</year>
          </date>
          <volume>33</volume>
          <issue>10</issue>
          <fpage>1783</fpage>
          <lpage>1787</lpage>
          <issn>0300-7995</issn>
          <pub-id pub-id-type="doi">10.1080/03007995.2017.1367275</pub-id>
          <pub-id pub-id-type="doi">10.1080/03007995.2017.1367275</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275082">
        <element-citation publication-type="journal">
          <article-title>Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006&#x2013;2010</article-title>
          <source>Medical Journal of Australia</source>
          <person-group person-group-type="author">
<name><surname>Simons</surname><given-names>Leon A</given-names></name>
<name><surname>Ortiz</surname><given-names>Michael</given-names></name>
<name><surname>Calcino</surname><given-names>Gordon</given-names></name>
</person-group>
          <date>
            <month>8</month>
            <year>2011</year>
          </date>
          <volume>195</volume>
          <issue>3</issue>
          <fpage>134</fpage>
          <lpage>137</lpage>
          <issn>0025-729X</issn>
          <pub-id pub-id-type="doi">10.5694/j.1326-5377.2011.tb03240.x</pub-id>
          <pub-id pub-id-type="doi">10.5694/j.1326-5377.2011.tb03240.x</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275083">
        <element-citation publication-type="journal"><article-title>Persistence of fixed and free combination of ramipril and amlodipine in hypertension</article-title><source>Eur Heart J</source><person-group person-group-type="author">
<name><surname>Simonyi</surname><given-names>G.</given-names></name>
<name><surname>Ferenci</surname><given-names>T.</given-names></name>
</person-group><date><year>2015</year></date><volume>36</volume><fpage>326</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">25811057</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275084">
        <element-citation publication-type="journal">
          <article-title>Persistence of fixed and free combination of perindopril and amlodipine in hypertension</article-title>
          <source>European Heart Journal</source>
          <person-group person-group-type="author">
<name><surname>Simonyi</surname><given-names>G</given-names></name>
<name><surname>Ferenci</surname><given-names>T</given-names></name>
<name><surname>Medvegy</surname><given-names>M</given-names></name>
</person-group>
          <date>
            <day>1</day>
            <month>8</month>
            <year>2016</year>
          </date>
          <volume>37</volume>
          <issue>suppl_1</issue>
          <fpage>191</fpage>
          <lpage>598</lpage>
          <issn>0195-668X</issn>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehw432</pub-id>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehw432</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275085">
        <element-citation publication-type="journal">
          <article-title>Which is the best choice? One year persistence of ramipril, ramipril/amlodipin free and fixed dose combination therapy in hypertension</article-title>
          <source>European Heart Journal</source>
          <person-group person-group-type="author">
<name><surname>Simonyi</surname><given-names>G.</given-names></name>
<name><surname>Ferenczi</surname><given-names>T.</given-names></name>
<name><surname>Medvegy</surname><given-names>M.</given-names></name>
<name><surname>Finta</surname><given-names>E.</given-names></name>
</person-group>
          <date>
            <day>1</day>
            <month>8</month>
            <year>2017</year>
          </date>
          <volume>38</volume>
          <issue>suppl_1)(P1654</issue>
          <fpage>ehx502</fpage>
          <issn>0195-668X</issn>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehx502.p1654</pub-id>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehx502.p1654</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275086">
        <element-citation publication-type="journal"><article-title>Efficacy and safety of a fixed combination of intramuscular diclofenac 75 mg + thiocolchicoside 4 mg in the treatment of acute low back pain: a phase III, randomized, double blind, controlled trial</article-title><source>European Journal of Physical and Rehabilitation Medicine</source><person-group person-group-type="author">
<name><surname>Sproviero</surname><given-names>Egidio</given-names></name>
<name><surname>Albamonte</surname><given-names>Emilio</given-names></name>
<name><surname>Costantino</surname><given-names>Cosimo</given-names></name>
<name><surname>Giossi</surname><given-names>Attilio</given-names></name>
<name><surname>Mancuso</surname><given-names>Maurizio</given-names></name>
<name><surname>Rigamonti</surname><given-names>Alberto</given-names></name>
<name><surname>Tornari</surname><given-names>Paolo</given-names></name>
<name><surname>Caggiano</surname><given-names>Giuseppe</given-names></name>
</person-group><date><month>9</month><year>2018</year></date><volume>54</volume><issue>5</issue><fpage>654</fpage><issn>1973-9087</issn><pub-id pub-id-type="doi">10.23736/s1973-9087.17.04923-1</pub-id><pub-id pub-id-type="doi">10.23736/s1973-9087.17.04923-1</pub-id><pub-id pub-id-type="pmid">29265793</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275087">
        <element-citation publication-type="journal">
          <article-title>Budget impact analysis of the introduction of a single-pill combination of atorvastatin, perindopril and amlodipine in the Greek setting</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Stafylas</surname><given-names>P.</given-names></name>
<name><surname>Karaiskou</surname><given-names>M.</given-names></name>
<name><surname>Zouka</surname><given-names>M.</given-names></name>
</person-group>
          <date>
            <month>10</month>
            <year>2018</year>
          </date>
          <volume>21</volume>
          <issue>PCV43</issue>
          <fpage>S99</fpage>
          <lpage>S100</lpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1016/j.jval.2018.09.590</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jval.2018.09.590</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275088">
        <element-citation publication-type="journal">
          <article-title>Cost analysis of the introduction of a single-pill combination of rosuvastatin and ezetimibe in the Greek setting</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Stafylas</surname><given-names>P.</given-names></name>
<name><surname>Stamuli</surname><given-names>E.</given-names></name>
<name><surname>Karaiskou</surname><given-names>M.</given-names></name>
<name><surname>Panteris</surname><given-names>E.</given-names></name>
<name><surname>Chotzagiannoglou</surname><given-names>V.</given-names></name>
<name><surname>Beletsi</surname><given-names>A.</given-names></name>
</person-group>
          <date>
            <month>11</month>
            <year>2019</year>
          </date>
          <volume>22</volume>
          <issue>PCV44</issue>
          <fpage>S548</fpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1016/j.jval.2019.09.769</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jval.2019.09.769</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275089">
        <element-citation publication-type="journal">
          <article-title>A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma</article-title>
          <source>Respiratory Medicine</source>
          <person-group person-group-type="author">
<name><surname>St&#xE4;llberg</surname><given-names>B.</given-names></name>
<name><surname>Ekstr&#xF6;m</surname><given-names>T.</given-names></name>
<name><surname>Neij</surname><given-names>F.</given-names></name>
<name><surname>Olsson</surname><given-names>P.</given-names></name>
<name><surname>Skoogh</surname><given-names>B.-E.</given-names></name>
<name><surname>Wennergren</surname><given-names>G.</given-names></name>
<name><surname>L&#xF6;fdahl</surname><given-names>C.-G.</given-names></name>
</person-group>
          <date>
            <month>10</month>
            <year>2008</year>
          </date>
          <volume>102</volume>
          <issue>10</issue>
          <fpage>1360</fpage>
          <lpage>1370</lpage>
          <issn>0954-6111</issn>
          <pub-id pub-id-type="doi">10.1016/j.rmed.2008.06.017</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.rmed.2008.06.017</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275090">
        <element-citation publication-type="journal">
          <article-title>Cost-utility analysis of hypertensive treatment with indapamide and amlodipine single-pill combination in the Polish setting</article-title>
          <source>Value in Health</source>
          <person-group person-group-type="author">
<name><surname>Stawowczyk</surname><given-names>E.</given-names></name>
<name><surname>Holko</surname><given-names>P.</given-names></name>
<name><surname>Kawalec</surname><given-names>P.</given-names></name>
<name><surname>Borowiec</surname><given-names>L.</given-names></name>
<name><surname>Filipiak</surname><given-names>K.J.</given-names></name>
</person-group>
          <date>
            <month>11</month>
            <year>2014</year>
          </date>
          <volume>17</volume>
          <issue>7</issue>
          <fpage>A491</fpage>
          <issn>1098-3015</issn>
          <pub-id pub-id-type="doi">10.1016/j.jval.2014.08.1450</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jval.2014.08.1450</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275091">
        <element-citation publication-type="journal">
          <article-title>Adherence to asthma controller medication regimens</article-title>
          <source>Respiratory Medicine</source>
          <person-group person-group-type="author">
<name><surname>Stempel</surname><given-names>D.A.</given-names></name>
<name><surname>Stoloff</surname><given-names>S.W.</given-names></name>
<name><surname>Carranza Rosenzweig</surname><given-names>J.R.</given-names></name>
<name><surname>Stanford</surname><given-names>R.H.</given-names></name>
<name><surname>Ryskina</surname><given-names>K.L.</given-names></name>
<name><surname>Legorreta</surname><given-names>A.P.</given-names></name>
</person-group>
          <date>
            <month>10</month>
            <year>2005</year>
          </date>
          <volume>99</volume>
          <issue>10</issue>
          <fpage>1263</fpage>
          <lpage>1267</lpage>
          <issn>0954-6111</issn>
          <pub-id pub-id-type="doi">10.1016/j.rmed.2005.03.002</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.rmed.2005.03.002</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275092">
        <element-citation publication-type="journal">
          <article-title>Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies</article-title>
          <source>Journal of Allergy and Clinical Immunology</source>
          <person-group person-group-type="author">
<name><surname>Stoloff</surname><given-names>Stuart W</given-names></name>
<name><surname>Stempel</surname><given-names>David A</given-names></name>
<name><surname>Meyer</surname><given-names>Jay</given-names></name>
<name><surname>Stanford</surname><given-names>Richard H</given-names></name>
<name><surname>Carranza Rosenzweig</surname><given-names>Jacqueline R</given-names></name>
</person-group>
          <date>
            <month>2</month>
            <year>2004</year>
          </date>
          <volume>113</volume>
          <issue>2</issue>
          <fpage>245</fpage>
          <lpage>251</lpage>
          <issn>0091-6749</issn>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2003.10.011</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2003.10.011</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275093">
        <element-citation publication-type="journal"><article-title>Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up</article-title><source>Int J Tuberc Lung Dis</source><person-group person-group-type="author">
<name><surname>Su</surname><given-names>W.J.</given-names></name>
<name><surname>Perng</surname><given-names>R.P.</given-names></name>
</person-group><date><year>2002</year></date><volume>6</volume><issue>11</issue><fpage>1029</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">12475151</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275094">
        <element-citation publication-type="journal"><article-title>Adherence to triple-component antihypertensive regimens is higher with single-pill than equivalent two-pill regimens: a randomized controlled trial</article-title><source>Clinical and Translational Science</source><person-group person-group-type="author">
<name><surname>Sung</surname><given-names>Jidong</given-names></name>
<name><surname>Ahn</surname><given-names>Kye Taek</given-names></name>
<name><surname>Cho</surname><given-names>Byung-Ryul</given-names></name>
<name><surname>Lee</surname><given-names>Sung Yun</given-names></name>
<name><surname>Kim</surname><given-names>Byung Jin</given-names></name>
<name><surname>Kim</surname><given-names>Dae Kyeong</given-names></name>
<name><surname>Park</surname><given-names>Joong-il</given-names></name>
<name><surname>Lee</surname><given-names>Wang-Soo</given-names></name>
</person-group><date><day>13</day><month>2</month><year>2021</year></date><volume>14</volume><issue>3</issue><fpage>1185</fpage><lpage>1192</lpage><issn>1752-8054</issn><pub-id pub-id-type="doi">10.1111/cts.12979</pub-id><!--<pub-id pub-id-type="pmcid">PMC8212718</pub-id>--><pub-id pub-id-type="doi">10.1111/cts.12979</pub-id><pub-id pub-id-type="pmid">33503302</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275095">
        <element-citation publication-type="journal"><article-title>Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia?</article-title><source>Int J Tuberc Lung Dis</source><person-group person-group-type="author">
<name><surname>Suryanto</surname><given-names>A.A.</given-names></name>
<name><surname>van denBroek</surname><given-names>J.</given-names></name>
<name><surname>Hatta</surname><given-names>M.</given-names></name>
<name><surname>de Soldenhoff</surname><given-names>R.</given-names></name>
<name><surname>van der Werf</surname><given-names>M.J.</given-names></name>
</person-group><date><year>2008</year></date><volume>12</volume><issue>2</issue><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">18230250</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275096">
        <element-citation publication-type="book"><article-title>Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea</article-title><source>Annals of Pharmacotherapy</source><person-group person-group-type="author">
<name><surname>Thayer</surname><given-names>Sarah</given-names></name>
<name><surname>Arondekar</surname><given-names>Bhakti</given-names></name>
<name><surname>Harley</surname><given-names>Carolyn</given-names></name>
<name><surname>Darkow</surname><given-names>Theodore E</given-names></name>
</person-group><publisher-name>SAGE Publications</publisher-name><date><month>5</month><year>2010</year></date><volume>44</volume><issue>5</issue><fpage>791</fpage><lpage>799</lpage><issn>1060-0280</issn><pub-id pub-id-type="doi">10.1345/aph.1m426</pub-id><pub-id pub-id-type="doi">10.1345/aph.1m426</pub-id><pub-id pub-id-type="pmid">20371759</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275097">
        <element-citation publication-type="journal">
          <article-title>Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis</article-title>
          <source>Clinical Therapeutics</source>
          <person-group person-group-type="author">
<name><surname>Vanderpoel</surname><given-names>Daniel R.</given-names></name>
<name><surname>Hussein</surname><given-names>Mohamed A.</given-names></name>
<name><surname>Watson-Heidari</surname><given-names>Teresa</given-names></name>
<name><surname>Perry</surname><given-names>Andrew</given-names></name>
</person-group>
          <date>
            <month>12</month>
            <year>2004</year>
          </date>
          <volume>26</volume>
          <issue>12</issue>
          <fpage>2066</fpage>
          <lpage>2075</lpage>
          <issn>0149-2918</issn>
          <pub-id pub-id-type="doi">10.1016/j.clinthera.2004.12.018</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.clinthera.2004.12.018</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275098">
        <element-citation publication-type="journal"><article-title>Simplification of HAART therapy on ambulatory HIV patients in Malaysia: a randomized controlled trial</article-title><source>Pharmacy Practice</source><person-group person-group-type="author">
<name><surname>Velvanathan</surname><given-names>Tineshwaran</given-names></name>
<name><surname>Islahudin</surname><given-names>Farida</given-names></name>
<name><surname>Sim</surname><given-names>Benedict L.</given-names></name>
<name><surname>Taha</surname><given-names>Nur A.</given-names></name>
</person-group><date><day>31</day><month>12</month><year>2016</year></date><volume>14</volume><issue>4</issue><fpage>830</fpage><issn>1885-642X</issn><pub-id pub-id-type="doi">10.18549/pharmpract.2016.04.830</pub-id><!--<pub-id pub-id-type="pmcid">PMC5184376</pub-id>--><pub-id pub-id-type="doi">10.18549/pharmpract.2016.04.830</pub-id><pub-id pub-id-type="pmid">28042354</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275099">
        <element-citation publication-type="journal">
          <article-title>Benefits of ART simplification on adherence, clinical and economic outcomes</article-title>
          <source>Journal of the International AIDS Society</source>
          <person-group person-group-type="author">
<name><surname>Vera</surname><given-names>J</given-names></name>
<name><surname>Arag&#xE3;o</surname><given-names>F</given-names></name>
<name><surname>Guimaraes</surname><given-names>M</given-names></name>
<name><surname>Vaz Pinto</surname><given-names>I</given-names></name>
</person-group>
          <date>
            <month>11</month>
            <year>2012</year>
          </date>
          <volume>15</volume>
          <issue>S4</issue>
          <fpage>18064</fpage>
          <issn>1758-2652</issn>
          <pub-id pub-id-type="doi">10.7448/ias.15.6.18064</pub-id>
          <!--<pub-id pub-id-type="pmcid">PMC3512537</pub-id>-->
          <pub-id pub-id-type="doi">10.7448/ias.15.6.18064</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-275100">
        <element-citation publication-type="journal">
          <article-title>Comparison of the cost of topical therapy for glaucoma between generic and brand medicines in Mexico</article-title>
          <source>Invest Ophthalmol Visual Sci</source>
          <person-group person-group-type="author">
<name><surname>Vidaurre Mora</surname><given-names>E.V.</given-names></name>
<name><surname>Moreno</surname><given-names>U</given-names></name>
<name><surname>Lazcano</surname><given-names>G</given-names></name>
<name><surname>Jim&#xE9;nez Rom&#xE1;n</surname><given-names>J</given-names></name>
</person-group>
          <date>
            <year>2019</year>
          </date>
          <volume>60</volume>
          <issue>9</issue>
          <fpage>5472</fpage>
          <lpage>5472</lpage>
        </element-citation>
      </ref>
      <ref id="ref-275101">
        <element-citation publication-type="journal"><article-title>Larger blood pressure reduction by fixed-dose compared to free dose combination therapy of ACE inhibitor and calcium antagonist in hypertensive patients</article-title><source>Transl Med UniSa</source><person-group person-group-type="author">
<name><surname>Visco</surname><given-names>V.</given-names></name>
<name><surname>Finelli</surname><given-names>R.</given-names></name>
<name><surname>Pascale</surname><given-names>A.V..</given-names></name>
<etal/>
</person-group><date><year>2017</year></date><volume>16</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">28775965</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275102">
        <element-citation publication-type="journal"><article-title>Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients</article-title><source>Pak J Pharm Sci</source><person-group person-group-type="author">
<name><surname>Zaka-Ur-Rehman</surname><given-names>Z.</given-names></name>
<name><surname>Jamshaid</surname><given-names>M.</given-names></name>
<name><surname>Chaudhry</surname><given-names>A.</given-names></name>
</person-group><date><year>2008</year></date><volume>21</volume><issue>2</issue><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">18390450</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275103">
        <element-citation publication-type="journal"><article-title>Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone</article-title><source>European Respiratory Journal</source><person-group person-group-type="author">
<name><surname>Zetterstr&#xF6;m</surname><given-names>O.</given-names></name>
<name><surname>Buhl</surname><given-names>R.</given-names></name>
<name><surname>Mellem</surname><given-names>H.</given-names></name>
<name><surname>Perpi&#xF1;&#xE1;</surname><given-names>M.</given-names></name>
<name><surname>Hedman</surname><given-names>J.</given-names></name>
<name><surname>O'Neill</surname><given-names>S.</given-names></name>
<name><surname>Ekstr&#xF6;m</surname><given-names>T.</given-names></name>
</person-group><date><month>8</month><year>2001</year></date><volume>18</volume><issue>2</issue><fpage>262</fpage><lpage>268</lpage><issn>0903-1936</issn><pub-id pub-id-type="doi">10.1183/09031936.01.00065801</pub-id><pub-id pub-id-type="doi">10.1183/09031936.01.00065801</pub-id><pub-id pub-id-type="pmid">11529282</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275104">
        <element-citation publication-type="journal"><article-title>Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension</article-title><source>BMC Ophthalmology</source><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Jia-Liang</given-names></name>
<name><surname>Ge</surname><given-names>Jian</given-names></name>
<name><surname>Li</surname><given-names>Xiao-Xin</given-names></name>
<name><surname>Li</surname><given-names>Yu-Min</given-names></name>
<name><surname>Sheng</surname><given-names>Yao-Hua</given-names></name>
<name><surname>Sun</surname><given-names>Nai-Xue</given-names></name>
<name><surname>Sun</surname><given-names>Xing-Huai</given-names></name>
<name><surname>Yao</surname><given-names>Ke</given-names></name>
<name><surname>Zhong</surname><given-names>Zheng</given-names></name>
</person-group><date><day>19</day><month>8</month><year>2011</year></date><volume>11</volume><issue>1</issue><fpage>23</fpage><issn>1471-2415</issn><pub-id pub-id-type="doi">10.1186/1471-2415-11-23</pub-id><!--<pub-id pub-id-type="pmcid">PMC3175210</pub-id>--><pub-id pub-id-type="doi">10.1186/1471-2415-11-23</pub-id><pub-id pub-id-type="pmid">21851642</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275105">
        <element-citation publication-type="journal"><article-title>Medication adherence in inflammatory bowel disease</article-title><source>Intestinal Research</source><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>Webber</given-names></name>
<name><surname>Chen</surname><given-names>Andy</given-names></name>
<name><surname>Tiao</surname><given-names>Darren</given-names></name>
<name><surname>Selinger</surname><given-names>Christian</given-names></name>
<name><surname>Leong</surname><given-names>Rupert</given-names></name>
</person-group><date><year>2017</year></date><volume>15</volume><issue>4</issue><fpage>434</fpage><lpage>445</lpage><issn>1598-9100</issn><pub-id pub-id-type="doi">10.5217/ir.2017.15.4.434</pub-id><!--<pub-id pub-id-type="pmcid">PMC5683974</pub-id>--><pub-id pub-id-type="doi">10.5217/ir.2017.15.4.434</pub-id><pub-id pub-id-type="pmid">29142511</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275106">
        <element-citation publication-type="journal">
          <article-title>Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review</article-title>
          <source>J Neurol</source>
          <person-group person-group-type="author">
<name><surname>Washington</surname><given-names>F.A.-O.</given-names></name>
<name><surname>Langdon</surname><given-names>D.</given-names></name>
</person-group>
          <date>
            <year>2021</year>
          </date>
          <volume>269</volume>
          <fpage>1432</fpage>
          <lpage>1459</lpage>
        </element-citation>
      </ref>
      <ref id="ref-275107">
        <element-citation publication-type="journal"><article-title>Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease</article-title><source>Health and Quality of Life Outcomes</source><person-group person-group-type="author">
<name><surname>Atkinson</surname><given-names>Mark J</given-names></name>
<name><surname>Sinha</surname><given-names>Anusha</given-names></name>
<name><surname>Hass</surname><given-names>Steven L</given-names></name>
<name><surname>Colman</surname><given-names>Shoshana S</given-names></name>
<name><surname>Kumar</surname><given-names>Ritesh N</given-names></name>
<name><surname>Brod</surname><given-names>Meryl</given-names></name>
<name><surname>Rowland</surname><given-names>Clayton R</given-names></name>
</person-group><date><year>2004</year></date><volume>2</volume><issue>1</issue><fpage>12</fpage><issn>1477-7525</issn><pub-id pub-id-type="doi">10.1186/1477-7525-2-12</pub-id><!--<pub-id pub-id-type="pmcid">PMC398419</pub-id>--><pub-id pub-id-type="doi">10.1186/1477-7525-2-12</pub-id><pub-id pub-id-type="pmid">14987333</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275108">
        <element-citation publication-type="article-journal">
          <article-title>Validation of a tool to assess medication treatment satisfaction in patients with Type 2 diabetes: the Diabetes Medication System Rating Questionnaire (DMSRQ)</article-title>
          <person-group person-group-type="author">
<name><surname>Peyrot</surname><given-names>M</given-names></name>
<name><surname>Harshaw Q Fau - Shillington</surname><given-names>A C</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Rubin</surname><given-names>R R</given-names></name>
</person-group>
          <issn>1464-5491</issn>
        </element-citation>
      </ref>
      <ref id="ref-275109">
        <element-citation publication-type="journal"><article-title>Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature</article-title><source>Journal of Hypertension</source><person-group person-group-type="author">
<name><surname>Tsioufis</surname><given-names>Konstantinos</given-names></name>
<name><surname>Kreutz</surname><given-names>Reinhold</given-names></name>
<name><surname>Sykara</surname><given-names>Georgia</given-names></name>
<name><surname>van Vugt</surname><given-names>Joris</given-names></name>
<name><surname>Hassan</surname><given-names>Tarek</given-names></name>
</person-group><date><month>6</month><year>2020</year></date><volume>38</volume><issue>6</issue><fpage>1016</fpage><lpage>1028</lpage><issn>0263-6352</issn><pub-id pub-id-type="doi">10.1097/hjh.0000000000002381</pub-id><!--<pub-id pub-id-type="pmcid">PMC7253190</pub-id>--><pub-id pub-id-type="doi">10.1097/hjh.0000000000002381</pub-id><pub-id pub-id-type="pmid">32371789</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275110">
        <element-citation publication-type="journal"><article-title>The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis</article-title><source>The Journal of Clinical Hypertension</source><person-group person-group-type="author">
<name><surname>Du</surname><given-names>Li-Ping</given-names></name>
<name><surname>Cheng</surname><given-names>Zhong-Wei</given-names></name>
<name><surname>Zhang</surname><given-names>Yu-Xuan</given-names></name>
<name><surname>Li</surname><given-names>Ying</given-names></name>
<name><surname>Mei</surname><given-names>Dan</given-names></name>
</person-group><date><day>27</day><month>4</month><year>2018</year></date><volume>20</volume><issue>5</issue><fpage>902</fpage><lpage>907</lpage><issn>1524-6175</issn><pub-id pub-id-type="doi">10.1111/jch.13272</pub-id><!--<pub-id pub-id-type="pmcid">PMC8030969</pub-id>--><pub-id pub-id-type="doi">10.1111/jch.13272</pub-id><pub-id pub-id-type="pmid">29700923</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275111">
        <element-citation publication-type="book"><article-title>Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens</article-title><source>Medicine</source><person-group person-group-type="author">
<name><surname>Clay</surname><given-names>P.G.</given-names></name>
<name><surname>Nag</surname><given-names>S.</given-names></name>
<name><surname>Graham</surname><given-names>C.M.</given-names></name>
<name><surname>Narayanan</surname><given-names>S.</given-names></name>
</person-group><publisher-name>Ovid Technologies (Wolters Kluwer Health)</publisher-name><date><month>10</month><year>2015</year></date><volume>94</volume><issue>42</issue><fpage>e1677</fpage><issn>0025-7974</issn><pub-id pub-id-type="doi">10.1097/md.0000000000001677</pub-id><!--<pub-id pub-id-type="pmcid">PMC4620781</pub-id>--><pub-id pub-id-type="doi">10.1097/md.0000000000001677</pub-id><pub-id pub-id-type="pmid">26496277</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275112">
        <element-citation publication-type="journal"><article-title>Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence</article-title><source>The Journal of Clinical Hypertension</source><person-group person-group-type="author">
<name><surname>Sherrill</surname><given-names>Beth</given-names></name>
<name><surname>Halpern</surname><given-names>Michael</given-names></name>
<name><surname>Khan</surname><given-names>Shahnaz</given-names></name>
<name><surname>Zhang</surname><given-names>Jie</given-names></name>
<name><surname>Panjabi</surname><given-names>Sumeet</given-names></name>
</person-group><date><day>7</day><month>11</month><year>2011</year></date><volume>13</volume><issue>12</issue><fpage>898</fpage><lpage>909</lpage><issn>1524-6175</issn><pub-id pub-id-type="doi">10.1111/j.1751-7176.2011.00550.x</pub-id><!--<pub-id pub-id-type="pmcid">PMC8108883</pub-id>--><pub-id pub-id-type="doi">10.1111/j.1751-7176.2011.00550.x</pub-id><pub-id pub-id-type="pmid">22142349</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275113">
        <element-citation publication-type="journal"><article-title>Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson&#x2019;s disease</article-title><source>Current Medical Research and Opinion</source><person-group person-group-type="author">
<name><surname>Delea</surname><given-names>Thomas E.</given-names></name>
<name><surname>Thomas</surname><given-names>Simu K.</given-names></name>
<name><surname>Hagiwara</surname><given-names>May</given-names></name>
<name><surname>Mancione</surname><given-names>L.</given-names></name>
</person-group><date><day>30</day><month>4</month><year>2010</year></date><volume>26</volume><issue>7</issue><fpage>1543</fpage><lpage>1552</lpage><issn>0300-7995</issn><pub-id pub-id-type="doi">10.1185/03007991003780628</pub-id><pub-id pub-id-type="doi">10.1185/03007991003780628</pub-id><pub-id pub-id-type="pmid">20429819</pub-id>
</element-citation>
      </ref>
      <ref id="ref-275114">
        <element-citation publication-type="article-newspaper">
          <article-title>Help patients safely handle medications to improve adherence</article-title>
          <source>Pharmacy Times</source>
          <person-group person-group-type="author">
<name><surname>Maxik</surname><given-names>K.</given-names></name>
<name><surname>Kimble</surname><given-names>C.</given-names></name>
<name><surname>Coustasse</surname><given-names>A.</given-names></name>
</person-group>
          <date>
            <year>2021</year>
          </date>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>